AU2016331955A1 - Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors - Google Patents
Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors Download PDFInfo
- Publication number
- AU2016331955A1 AU2016331955A1 AU2016331955A AU2016331955A AU2016331955A1 AU 2016331955 A1 AU2016331955 A1 AU 2016331955A1 AU 2016331955 A AU2016331955 A AU 2016331955A AU 2016331955 A AU2016331955 A AU 2016331955A AU 2016331955 A1 AU2016331955 A1 AU 2016331955A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- group
- ring
- 4aliphatic
- occurrences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 227
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 188
- 239000012623 DNA damaging agent Substances 0.000 title claims abstract description 152
- 239000003112 inhibitor Substances 0.000 title claims abstract description 139
- 201000011510 cancer Diseases 0.000 title claims abstract description 91
- 150000001875 compounds Chemical class 0.000 claims abstract description 479
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 98
- 150000003839 salts Chemical class 0.000 claims abstract description 88
- 230000002062 proliferating effect Effects 0.000 claims abstract description 78
- 102000001253 Protein Kinase Human genes 0.000 claims abstract description 34
- 108060006633 protein kinase Proteins 0.000 claims abstract description 34
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 305
- 229910052717 sulfur Inorganic materials 0.000 claims description 165
- 229910052757 nitrogen Inorganic materials 0.000 claims description 160
- 238000011282 treatment Methods 0.000 claims description 155
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 150
- 239000011593 sulfur Substances 0.000 claims description 150
- 125000005842 heteroatom Chemical group 0.000 claims description 149
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 142
- 229910052760 oxygen Inorganic materials 0.000 claims description 142
- 239000001301 oxygen Substances 0.000 claims description 142
- 125000005843 halogen group Chemical group 0.000 claims description 112
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 100
- 229960004562 carboplatin Drugs 0.000 claims description 100
- 229960005277 gemcitabine Drugs 0.000 claims description 100
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 100
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 81
- 229920006395 saturated elastomer Polymers 0.000 claims description 77
- 229960004316 cisplatin Drugs 0.000 claims description 75
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 74
- 208000035475 disorder Diseases 0.000 claims description 74
- 125000001931 aliphatic group Chemical group 0.000 claims description 66
- 125000004429 atom Chemical group 0.000 claims description 61
- 239000003795 chemical substances by application Substances 0.000 claims description 56
- -1 ProLindac Chemical compound 0.000 claims description 52
- 210000004027 cell Anatomy 0.000 claims description 46
- 230000004044 response Effects 0.000 claims description 46
- 230000000340 anti-metabolite Effects 0.000 claims description 43
- 229940100197 antimetabolite Drugs 0.000 claims description 43
- 239000002256 antimetabolite Substances 0.000 claims description 43
- 125000001072 heteroaryl group Chemical group 0.000 claims description 38
- 206010033128 Ovarian cancer Diseases 0.000 claims description 35
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 35
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 34
- 125000000623 heterocyclic group Chemical group 0.000 claims description 34
- 229910052799 carbon Inorganic materials 0.000 claims description 31
- 125000004122 cyclic group Chemical group 0.000 claims description 31
- 125000001153 fluoro group Chemical group F* 0.000 claims description 30
- 238000009097 single-agent therapy Methods 0.000 claims description 29
- 206010009944 Colon cancer Diseases 0.000 claims description 28
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 26
- 206010025323 Lymphomas Diseases 0.000 claims description 25
- 230000003442 weekly effect Effects 0.000 claims description 25
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 23
- 125000002619 bicyclic group Chemical group 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 206010006187 Breast cancer Diseases 0.000 claims description 20
- 208000026310 Breast neoplasm Diseases 0.000 claims description 20
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 19
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 claims description 18
- 206010039491 Sarcoma Diseases 0.000 claims description 18
- 208000020816 lung neoplasm Diseases 0.000 claims description 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 15
- 206010027406 Mesothelioma Diseases 0.000 claims description 15
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 15
- 201000005202 lung cancer Diseases 0.000 claims description 15
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 14
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 14
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 14
- 125000002950 monocyclic group Chemical group 0.000 claims description 14
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 13
- 230000007547 defect Effects 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 13
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 13
- 238000002512 chemotherapy Methods 0.000 claims description 12
- 229960002949 fluorouracil Drugs 0.000 claims description 12
- 230000004083 survival effect Effects 0.000 claims description 12
- 206010024612 Lipoma Diseases 0.000 claims description 11
- 239000003242 anti bacterial agent Substances 0.000 claims description 11
- 229910052801 chlorine Inorganic materials 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 11
- 230000005855 radiation Effects 0.000 claims description 11
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 9
- 229960001428 mercaptopurine Drugs 0.000 claims description 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 9
- 201000002528 pancreatic cancer Diseases 0.000 claims description 9
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 9
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 206010043276 Teratoma Diseases 0.000 claims description 8
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 8
- 210000000481 breast Anatomy 0.000 claims description 8
- 238000001990 intravenous administration Methods 0.000 claims description 8
- 201000003076 Angiosarcoma Diseases 0.000 claims description 7
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 7
- OLBVUFHMDRJKTK-UHFFFAOYSA-N [N].[O] Chemical group [N].[O] OLBVUFHMDRJKTK-UHFFFAOYSA-N 0.000 claims description 7
- 229940100198 alkylating agent Drugs 0.000 claims description 7
- 239000002168 alkylating agent Substances 0.000 claims description 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 229960004679 doxorubicin Drugs 0.000 claims description 7
- 206010016629 fibroma Diseases 0.000 claims description 7
- 201000011066 hemangioma Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 238000005457 optimization Methods 0.000 claims description 7
- 229960001756 oxaliplatin Drugs 0.000 claims description 7
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 7
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 7
- 229960000624 procarbazine Drugs 0.000 claims description 7
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 7
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 6
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 6
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 claims description 6
- 229940088710 antibiotic agent Drugs 0.000 claims description 6
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 claims description 6
- PZAQDVNYNJBUTM-UHFFFAOYSA-L cyclohexane-1,2-diamine;7,7-dimethyloctanoate;platinum(2+) Chemical compound [Pt+2].NC1CCCCC1N.CC(C)(C)CCCCCC([O-])=O.CC(C)(C)CCCCCC([O-])=O PZAQDVNYNJBUTM-UHFFFAOYSA-L 0.000 claims description 6
- 201000004101 esophageal cancer Diseases 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 208000005017 glioblastoma Diseases 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 229950008991 lobaplatin Drugs 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 229950007221 nedaplatin Drugs 0.000 claims description 6
- 201000008968 osteosarcoma Diseases 0.000 claims description 6
- 229950005566 picoplatin Drugs 0.000 claims description 6
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims description 6
- 229960005399 satraplatin Drugs 0.000 claims description 6
- 190014017285 satraplatin Chemical compound 0.000 claims description 6
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 5
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 5
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 5
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 claims description 5
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 5
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 5
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 5
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 5
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 5
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 claims description 5
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 5
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 5
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 5
- 208000002927 Hamartoma Diseases 0.000 claims description 5
- 206010023347 Keratoacanthoma Diseases 0.000 claims description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 5
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 5
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 claims description 5
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 229960003896 aminopterin Drugs 0.000 claims description 5
- 229960002756 azacitidine Drugs 0.000 claims description 5
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 5
- 229960004117 capecitabine Drugs 0.000 claims description 5
- 125000002837 carbocyclic group Chemical group 0.000 claims description 5
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 5
- 229960003261 carmofur Drugs 0.000 claims description 5
- 229960002436 cladribine Drugs 0.000 claims description 5
- 229960000928 clofarabine Drugs 0.000 claims description 5
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 claims description 5
- 229960004397 cyclophosphamide Drugs 0.000 claims description 5
- 229960000684 cytarabine Drugs 0.000 claims description 5
- 229960000975 daunorubicin Drugs 0.000 claims description 5
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 5
- 229960001904 epirubicin Drugs 0.000 claims description 5
- 229960000961 floxuridine Drugs 0.000 claims description 5
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 5
- 229960000390 fludarabine Drugs 0.000 claims description 5
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 5
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims description 5
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 5
- 201000010536 head and neck cancer Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 229960004768 irinotecan Drugs 0.000 claims description 5
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 229960004961 mechlorethamine Drugs 0.000 claims description 5
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 5
- 229960000485 methotrexate Drugs 0.000 claims description 5
- 229960004857 mitomycin Drugs 0.000 claims description 5
- 125000003566 oxetanyl group Chemical group 0.000 claims description 5
- 229960005079 pemetrexed Drugs 0.000 claims description 5
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 5
- 229960002340 pentostatin Drugs 0.000 claims description 5
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- 229960004432 raltitrexed Drugs 0.000 claims description 5
- 230000019491 signal transduction Effects 0.000 claims description 5
- 229960001674 tegafur Drugs 0.000 claims description 5
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 claims description 5
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 5
- 201000002510 thyroid cancer Diseases 0.000 claims description 5
- 229960003087 tioguanine Drugs 0.000 claims description 5
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims description 5
- 229950002860 triplatin tetranitrate Drugs 0.000 claims description 5
- 190014017283 triplatin tetranitrate Chemical compound 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 4
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 claims description 4
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 4
- 108010006654 Bleomycin Proteins 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 4
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 claims description 4
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 4
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 claims description 4
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 4
- 201000005262 Chondroma Diseases 0.000 claims description 4
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 4
- 201000009047 Chordoma Diseases 0.000 claims description 4
- 108010092160 Dactinomycin Proteins 0.000 claims description 4
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 4
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims description 4
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 4
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 4
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 claims description 4
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 4
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 claims description 4
- 229930192392 Mitomycin Natural products 0.000 claims description 4
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 claims description 4
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 claims description 4
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 241000187747 Streptomyces Species 0.000 claims description 4
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 4
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 4
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 claims description 4
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 4
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 claims description 4
- 229960004176 aclarubicin Drugs 0.000 claims description 4
- 229930183665 actinomycin Natural products 0.000 claims description 4
- 208000002517 adenoid cystic carcinoma Diseases 0.000 claims description 4
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 4
- 150000008052 alkyl sulfonates Chemical class 0.000 claims description 4
- 229960000473 altretamine Drugs 0.000 claims description 4
- 229960002550 amrubicin Drugs 0.000 claims description 4
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 claims description 4
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 claims description 4
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 4
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 claims description 4
- 150000001541 aziridines Chemical class 0.000 claims description 4
- LNHWXBUNXOXMRL-VWLOTQADSA-N belotecan Chemical compound C1=CC=C2C(CCNC(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 LNHWXBUNXOXMRL-VWLOTQADSA-N 0.000 claims description 4
- 229950011276 belotecan Drugs 0.000 claims description 4
- 229960002707 bendamustine Drugs 0.000 claims description 4
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims description 4
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 4
- 229960001561 bleomycin Drugs 0.000 claims description 4
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 4
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims description 4
- 229960002092 busulfan Drugs 0.000 claims description 4
- 229940127093 camptothecin Drugs 0.000 claims description 4
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 4
- 229960002115 carboquone Drugs 0.000 claims description 4
- 229960005243 carmustine Drugs 0.000 claims description 4
- 229960004630 chlorambucil Drugs 0.000 claims description 4
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 210000001072 colon Anatomy 0.000 claims description 4
- 229960003901 dacarbazine Drugs 0.000 claims description 4
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 4
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims description 4
- 229960001842 estramustine Drugs 0.000 claims description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 4
- 229960004783 fotemustine Drugs 0.000 claims description 4
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 claims description 4
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims description 4
- 229960001330 hydroxycarbamide Drugs 0.000 claims description 4
- 229960000908 idarubicin Drugs 0.000 claims description 4
- 229960001101 ifosfamide Drugs 0.000 claims description 4
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 4
- 230000005865 ionizing radiation Effects 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 229960002247 lomustine Drugs 0.000 claims description 4
- 229960000733 mannosulfan Drugs 0.000 claims description 4
- UUVIQYKKKBJYJT-ZYUZMQFOSA-N mannosulfan Chemical compound CS(=O)(=O)OC[C@@H](OS(C)(=O)=O)[C@@H](O)[C@H](O)[C@H](OS(C)(=O)=O)COS(C)(=O)=O UUVIQYKKKBJYJT-ZYUZMQFOSA-N 0.000 claims description 4
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 4
- 229960001924 melphalan Drugs 0.000 claims description 4
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 4
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 4
- 229960005485 mitobronitol Drugs 0.000 claims description 4
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 4
- 229960001420 nimustine Drugs 0.000 claims description 4
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 claims description 4
- 229960001221 pirarubicin Drugs 0.000 claims description 4
- 229960003171 plicamycin Drugs 0.000 claims description 4
- 229960004694 prednimustine Drugs 0.000 claims description 4
- 229960002185 ranimustine Drugs 0.000 claims description 4
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 claims description 4
- 229950009213 rubitecan Drugs 0.000 claims description 4
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims description 4
- 229960003440 semustine Drugs 0.000 claims description 4
- 229960001052 streptozocin Drugs 0.000 claims description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 4
- 229960004964 temozolomide Drugs 0.000 claims description 4
- 229960001278 teniposide Drugs 0.000 claims description 4
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- 229960001196 thiotepa Drugs 0.000 claims description 4
- 229960000303 topotecan Drugs 0.000 claims description 4
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 4
- 229960003181 treosulfan Drugs 0.000 claims description 4
- 150000004654 triazenes Chemical class 0.000 claims description 4
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 claims description 4
- 229960004560 triaziquone Drugs 0.000 claims description 4
- 229960000875 trofosfamide Drugs 0.000 claims description 4
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 claims description 4
- 229960001055 uracil mustard Drugs 0.000 claims description 4
- 229960000653 valrubicin Drugs 0.000 claims description 4
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 claims description 4
- 229960000641 zorubicin Drugs 0.000 claims description 4
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 claims description 4
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 claims description 3
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 claims description 3
- 206010073153 Familial medullary thyroid cancer Diseases 0.000 claims description 3
- 206010053717 Fibrous histiocytoma Diseases 0.000 claims description 3
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 claims description 3
- 208000007569 Giant Cell Tumors Diseases 0.000 claims description 3
- 206010019629 Hepatic adenoma Diseases 0.000 claims description 3
- 208000002404 Liver Cell Adenoma Diseases 0.000 claims description 3
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 claims description 3
- 208000006876 Multiple Endocrine Neoplasia Type 2b Diseases 0.000 claims description 3
- 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 claims description 3
- 101710204212 Neocarzinostatin Proteins 0.000 claims description 3
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims description 3
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 3
- 208000005678 Rhabdomyoma Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 206010046431 Urethral cancer Diseases 0.000 claims description 3
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 3
- 210000004100 adrenal gland Anatomy 0.000 claims description 3
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 3
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 claims description 3
- 208000001119 benign fibrous histiocytoma Diseases 0.000 claims description 3
- 201000009036 biliary tract cancer Diseases 0.000 claims description 3
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 201000002143 bronchus adenoma Diseases 0.000 claims description 3
- 210000003679 cervix uteri Anatomy 0.000 claims description 3
- 201000005217 chondroblastoma Diseases 0.000 claims description 3
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 claims description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 3
- 229960005420 etoposide Drugs 0.000 claims description 3
- 208000006359 hepatoblastoma Diseases 0.000 claims description 3
- 201000002735 hepatocellular adenoma Diseases 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 201000004593 malignant giant cell tumor Diseases 0.000 claims description 3
- 208000009091 myxoma Diseases 0.000 claims description 3
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 claims description 3
- 210000000653 nervous system Anatomy 0.000 claims description 3
- 201000011682 nervous system cancer Diseases 0.000 claims description 3
- 230000000955 neuroendocrine Effects 0.000 claims description 3
- 208000004649 neutrophil actin dysfunction Diseases 0.000 claims description 3
- 229960005419 nitrogen Drugs 0.000 claims description 3
- 208000003388 osteoid osteoma Diseases 0.000 claims description 3
- 208000007312 paraganglioma Diseases 0.000 claims description 3
- 208000028591 pheochromocytoma Diseases 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 230000000113 radiomimetic effect Effects 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 210000001685 thyroid gland Anatomy 0.000 claims description 3
- 208000013066 thyroid gland cancer Diseases 0.000 claims description 3
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims description 3
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 claims description 3
- 229950001353 tretamine Drugs 0.000 claims description 3
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 claims description 3
- 229950009268 zinostatin Drugs 0.000 claims description 3
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 2
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 2
- 208000024348 heart neoplasm Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 210000002418 meninge Anatomy 0.000 claims description 2
- 201000002575 ocular melanoma Diseases 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 201000008006 pharynx cancer Diseases 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000003625 skull Anatomy 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 201000006134 tongue cancer Diseases 0.000 claims description 2
- 210000003708 urethra Anatomy 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- 210000003905 vulva Anatomy 0.000 claims description 2
- 102000002804 Ataxia Telangiectasia Mutated Proteins Human genes 0.000 claims 5
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims 3
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 claims 1
- 206010062038 Lip neoplasm Diseases 0.000 claims 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 1
- 229960004853 betadex Drugs 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 201000006721 lip cancer Diseases 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 201000000360 urethra cancer Diseases 0.000 claims 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 24
- 201000010099 disease Diseases 0.000 description 22
- 102000000872 ATM Human genes 0.000 description 20
- 125000004093 cyano group Chemical group *C#N 0.000 description 19
- 208000009956 adenocarcinoma Diseases 0.000 description 18
- 230000036961 partial effect Effects 0.000 description 18
- 238000002648 combination therapy Methods 0.000 description 16
- 238000001574 biopsy Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 230000003902 lesion Effects 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 12
- 201000009030 Carcinoma Diseases 0.000 description 11
- 230000018199 S phase Effects 0.000 description 11
- 125000001424 substituent group Chemical group 0.000 description 11
- 230000002411 adverse Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 208000004235 neutropenia Diseases 0.000 description 10
- 229940002612 prodrug Drugs 0.000 description 10
- 239000000651 prodrug Substances 0.000 description 10
- 208000037821 progressive disease Diseases 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 239000002585 base Substances 0.000 description 9
- 230000033115 angiogenesis Effects 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 231100000517 death Toxicity 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- 101000785063 Homo sapiens Serine-protein kinase ATM Proteins 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 208000037844 advanced solid tumor Diseases 0.000 description 7
- 239000000090 biomarker Substances 0.000 description 7
- OHUHVTCQTUDPIJ-JYCIKRDWSA-N ceralasertib Chemical group C[C@@H]1COCCN1C1=CC(C2(CC2)[S@](C)(=N)=O)=NC(C=2C=3C=CNC=3N=CC=2)=N1 OHUHVTCQTUDPIJ-JYCIKRDWSA-N 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 206010043554 thrombocytopenia Diseases 0.000 description 7
- 208000018142 Leiomyosarcoma Diseases 0.000 description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 6
- 208000008383 Wilms tumor Diseases 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 208000002458 carcinoid tumor Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 208000027866 inflammatory disease Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000002611 ovarian Effects 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 5
- 208000003174 Brain Neoplasms Diseases 0.000 description 5
- 101150006084 CHKB gene Proteins 0.000 description 5
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 5
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 5
- 230000005778 DNA damage Effects 0.000 description 5
- 231100000277 DNA damage Toxicity 0.000 description 5
- 230000005971 DNA damage repair Effects 0.000 description 5
- 230000033616 DNA repair Effects 0.000 description 5
- 208000032612 Glial tumor Diseases 0.000 description 5
- 206010018338 Glioma Diseases 0.000 description 5
- 208000017604 Hodgkin disease Diseases 0.000 description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 5
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 5
- 229930012538 Paclitaxel Natural products 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 206010027191 meningioma Diseases 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 229960001592 paclitaxel Drugs 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- 206010060999 Benign neoplasm Diseases 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- 206010014733 Endometrial cancer Diseases 0.000 description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
- 201000004404 Neurofibroma Diseases 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 101100352419 Pithecopus hypochondrialis psn1 gene Proteins 0.000 description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 201000010260 leiomyoma Diseases 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 201000005962 mycosis fungoides Diseases 0.000 description 4
- 206010028537 myelofibrosis Diseases 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- 206010038038 rectal cancer Diseases 0.000 description 4
- 201000001275 rectum cancer Diseases 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010069754 Acquired gene mutation Diseases 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 102000052609 BRCA2 Human genes 0.000 description 3
- 108700020462 BRCA2 Proteins 0.000 description 3
- 208000009458 Carcinoma in Situ Diseases 0.000 description 3
- 208000006332 Choriocarcinoma Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010014967 Ependymoma Diseases 0.000 description 3
- 208000007465 Giant cell arteritis Diseases 0.000 description 3
- 208000024869 Goodpasture syndrome Diseases 0.000 description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000029523 Interstitial Lung disease Diseases 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 208000000172 Medulloblastoma Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000014767 Myeloproliferative disease Diseases 0.000 description 3
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 201000010133 Oligodendroglioma Diseases 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 208000007641 Pinealoma Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 201000000582 Retinoblastoma Diseases 0.000 description 3
- 201000010208 Seminoma Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 208000035269 cancer or benign tumor Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000001981 dermatomyositis Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 201000003914 endometrial carcinoma Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 201000003115 germ cell cancer Diseases 0.000 description 3
- 208000025750 heavy chain disease Diseases 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 201000002313 intestinal cancer Diseases 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 208000022013 kidney Wilms tumor Diseases 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 206010024627 liposarcoma Diseases 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 201000008026 nephroblastoma Diseases 0.000 description 3
- 238000007481 next generation sequencing Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 208000024724 pineal body neoplasm Diseases 0.000 description 3
- 201000004123 pineal gland cancer Diseases 0.000 description 3
- 208000003476 primary myelofibrosis Diseases 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000028617 response to DNA damage stimulus Effects 0.000 description 3
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000037439 somatic mutation Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 206010043207 temporal arteritis Diseases 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 206010044412 transitional cell carcinoma Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- 206010073485 Abdominal lymphadenopathy Diseases 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 206010001233 Adenoma benign Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 206010073360 Appendix cancer Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 101150008921 Brca2 gene Proteins 0.000 description 2
- JZCWLJDSIRUGIN-UHFFFAOYSA-N CC(C)S(c(cc1)ccc1-c(nc1-c2cc(-c3ccc(CNC)cc3)n[o]2)cnc1N)(=O)=O Chemical compound CC(C)S(c(cc1)ccc1-c(nc1-c2cc(-c3ccc(CNC)cc3)n[o]2)cnc1N)(=O)=O JZCWLJDSIRUGIN-UHFFFAOYSA-N 0.000 description 2
- 201000004085 CLL/SLL Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 206010007275 Carcinoid tumour Diseases 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- 206010008263 Cervical dysplasia Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010048832 Colon adenoma Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010013700 Drug hypersensitivity Diseases 0.000 description 2
- 208000007033 Dysgerminoma Diseases 0.000 description 2
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 201000001342 Fallopian tube cancer Diseases 0.000 description 2
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 2
- 208000002633 Febrile Neutropenia Diseases 0.000 description 2
- 208000007659 Fibroadenoma Diseases 0.000 description 2
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 2
- 208000000527 Germinoma Diseases 0.000 description 2
- 201000005409 Gliomatosis cerebri Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 206010018404 Glucagonoma Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 208000005045 Interdigitating dendritic cell sarcoma Diseases 0.000 description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
- 206010070999 Intraductal papillary mucinous neoplasm Diseases 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 208000002260 Keloid Diseases 0.000 description 2
- 238000000719 MTS assay Methods 0.000 description 2
- 231100000070 MTS assay Toxicity 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 208000032818 Microsatellite Instability Diseases 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 208000009905 Neurofibromatoses Diseases 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 208000000035 Osteochondroma Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000027067 Paget disease of bone Diseases 0.000 description 2
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 2
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 2
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 description 2
- 208000012896 Peritoneal disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 208000009311 VIPoma Diseases 0.000 description 2
- 206010047741 Vulval cancer Diseases 0.000 description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 2
- 206010048214 Xanthoma Diseases 0.000 description 2
- 206010048215 Xanthomatosis Diseases 0.000 description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 description 2
- 208000002718 adenomatoid tumor Diseases 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 208000021780 appendiceal neoplasm Diseases 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 208000016738 bone Paget disease Diseases 0.000 description 2
- 201000009480 botryoid rhabdomyosarcoma Diseases 0.000 description 2
- 201000003149 breast fibroadenoma Diseases 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 description 2
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 description 2
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 2
- 201000000052 gastrinoma Diseases 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 201000004933 in situ carcinoma Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 206010022498 insulinoma Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 210000002570 interstitial cell Anatomy 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000001117 keloid Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 238000009092 lines of therapy Methods 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 2
- 201000000289 malignant teratoma Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 208000007538 neurilemmoma Diseases 0.000 description 2
- 201000004931 neurofibromatosis Diseases 0.000 description 2
- 208000029974 neurofibrosarcoma Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 2
- 229960000572 olaparib Drugs 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 208000008798 osteoma Diseases 0.000 description 2
- 208000021255 pancreatic insulinoma Diseases 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 description 2
- 208000037244 polycythemia vera Diseases 0.000 description 2
- 208000005987 polymyositis Diseases 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 206010039667 schwannoma Diseases 0.000 description 2
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 208000001608 teratocarcinoma Diseases 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 125000004001 thioalkyl group Chemical group 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 208000022271 tubular adenoma Diseases 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 206010046885 vaginal cancer Diseases 0.000 description 2
- 208000013139 vaginal neoplasm Diseases 0.000 description 2
- 230000004862 vasculogenesis Effects 0.000 description 2
- 208000009540 villous adenoma Diseases 0.000 description 2
- 201000005102 vulva cancer Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- YJUFGFXVASPYFQ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene Chemical compound C1=CC=C2SCCC2=C1 YJUFGFXVASPYFQ-UHFFFAOYSA-N 0.000 description 1
- BLDFSDCBQJUWFG-UHFFFAOYSA-N 2-(methylamino)-1,2-diphenylethanol Chemical compound C=1C=CC=CC=1C(NC)C(O)C1=CC=CC=C1 BLDFSDCBQJUWFG-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- FSUYMKXZLQOFQY-UHFFFAOYSA-N 3,4-dihydro-1,2-benzodithiine Chemical compound C1=CC=C2SSCCC2=C1 FSUYMKXZLQOFQY-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- JDUBGYFRJFOXQC-KRWDZBQOSA-N 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide Chemical compound C1([C@H](CCO)NC(=O)C2(CCN(CC2)C=2C=3C=CNC=3N=CN=2)N)=CC=C(Cl)C=C1 JDUBGYFRJFOXQC-KRWDZBQOSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000591 Acrochordon Diseases 0.000 description 1
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 description 1
- 229940126638 Akt inhibitor Drugs 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000012791 Alpha-heavy chain disease Diseases 0.000 description 1
- 208000035939 Alveolitis allergic Diseases 0.000 description 1
- 206010060937 Amniotic cavity infection Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000000058 Anaplasia Diseases 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 102000008076 Angiogenic Proteins Human genes 0.000 description 1
- 108010074415 Angiogenic Proteins Proteins 0.000 description 1
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000033116 Asbestos intoxication Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 208000029862 Barrett adenocarcinoma Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 206010004485 Berylliosis Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- DUIHHZKTCSNTGM-UHFFFAOYSA-N CS(c(cc1)ccc1-c(nc1C(Nc2ccccc2)=O)cnc1N)(=O)=O Chemical compound CS(c(cc1)ccc1-c(nc1C(Nc2ccccc2)=O)cnc1N)(=O)=O DUIHHZKTCSNTGM-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 102100028914 Catenin beta-1 Human genes 0.000 description 1
- NCCPTBXDQPTHTK-UHFFFAOYSA-N Cc1cncc(NC(c2c3ncc(F)c[n]3nc2N)=O)c1-c1cnc[n]1C Chemical compound Cc1cncc(NC(c2c3ncc(F)c[n]3nc2N)=O)c1-c1cnc[n]1C NCCPTBXDQPTHTK-UHFFFAOYSA-N 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 108010019244 Checkpoint Kinase 1 Proteins 0.000 description 1
- 102000006459 Checkpoint Kinase 1 Human genes 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010008617 Cholecystitis chronic Diseases 0.000 description 1
- 208000008158 Chorioamnionitis Diseases 0.000 description 1
- 208000023355 Chronic beryllium disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 description 1
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010011841 Dacryoadenitis acquired Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 201000011275 Epicondylitis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 description 1
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 description 1
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000003623 Hypoalbuminemia Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000007866 Immunoproliferative Small Intestinal Disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 description 1
- 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229910015837 MSH2 Inorganic materials 0.000 description 1
- 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 208000015021 Meningeal Neoplasms Diseases 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- 206010051696 Metastases to meninges Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 102000008071 Mismatch Repair Endonuclease PMS2 Human genes 0.000 description 1
- 108010074346 Mismatch Repair Endonuclease PMS2 Proteins 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 1
- 208000012799 Mu-heavy chain disease Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000002231 Muscle Neoplasms Diseases 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 150000007945 N-acyl ureas Chemical class 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 206010028885 Necrotising fasciitis Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 1
- 229910004679 ONO2 Inorganic materials 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 206010031149 Osteitis Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 208000017459 Paget disease of the penis Diseases 0.000 description 1
- 208000025610 Paget disease of the vulva Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 description 1
- 208000032758 Precursor T-lymphoblastic lymphoma/leukaemia Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010068956 Respiratory tract inflammation Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 101100294404 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CDC36 gene Proteins 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 208000006938 Schwannomatosis Diseases 0.000 description 1
- 206010048810 Sebaceous hyperplasia Diseases 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 201000008736 Systemic mastocytosis Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
- 101150080074 TP53 gene Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047124 Vasculitis necrotising Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000025751 alpha chain disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 206010003441 asbestosis Diseases 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 208000018339 bone inflammation disease Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 201000000135 breast papillary carcinoma Diseases 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 201000005200 bronchus cancer Diseases 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 1
- 229960001573 cabazitaxel Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000009636 cerebral lymphoma Diseases 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 208000010575 cherry hemangioma Diseases 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 201000010903 chronic neutrophilic leukemia Diseases 0.000 description 1
- 201000010918 connective tissue cancer Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- KDUIUFJBNGTBMD-VXMYFEMYSA-N cyclooctatetraene Chemical compound C1=C\C=C/C=C\C=C1 KDUIUFJBNGTBMD-VXMYFEMYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 201000004400 dacryoadenitis Diseases 0.000 description 1
- 238000011334 debulking surgery Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 201000009803 desquamative interstitial pneumonia Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 201000011025 embryonal testis carcinoma Diseases 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 206010024217 lentigo Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 208000005158 lymphoid interstitial pneumonia Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 208000022006 malignant tumor of meninges Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000030163 medullary breast carcinoma Diseases 0.000 description 1
- 210000001704 mesoblast Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 206010063344 microscopic polyangiitis Diseases 0.000 description 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 208000026114 mu chain disease Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000002077 muscle cancer Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 201000007970 necrotizing fasciitis Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 201000009494 neurilemmomatosis Diseases 0.000 description 1
- 201000004662 neurofibroma of spinal cord Diseases 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 206010030306 omphalitis Diseases 0.000 description 1
- 208000005963 oophoritis Diseases 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
- 201000011029 ovarian embryonal carcinoma Diseases 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000007271 pre-malignant neoplasm Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 239000003197 protein kinase B inhibitor Substances 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000002661 proton therapy Methods 0.000 description 1
- 239000000649 purine antagonist Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 102200106583 rs121912666 Human genes 0.000 description 1
- 102220041065 rs200979664 Human genes 0.000 description 1
- 102220018750 rs80358450 Human genes 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 208000014956 scrotum Paget disease Diseases 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 201000003385 seborrheic keratosis Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 201000005574 senile angioma Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 201000000195 skin tag Diseases 0.000 description 1
- 201000001839 skull cancer Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 201000011096 spinal cancer Diseases 0.000 description 1
- 208000014618 spinal cord cancer Diseases 0.000 description 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 229950004550 talazoparib Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 206010062123 testicular embryonal carcinoma Diseases 0.000 description 1
- 201000002814 testicular lymphoma Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 208000007617 thrombocytopenia 1 Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 208000002419 toxicodendron dermatitis Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000023747 urothelial carcinoma Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 208000028010 vulval Paget disease Diseases 0.000 description 1
- 208000002003 vulvitis Diseases 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Described herein are methods of treating a proliferative disorder (e.g., cancer) in a patient by administering a DNA damaging agent and between about 12 and about 48 hours later administering to the subject a compound that inhibits ATR protein kinase. Methods of treating a proliferative disorder (e.g., cancer) in a patient by administering a compound that inhibits ATR protein kinase are also described. Exemplary ATR inhibitors are represented by Formulae A-I and A-II or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein.
Description
BACKGROUND OF THE INVENTION [0001] Cancers as a group account for approximately 13% of all deaths each year with the most common being: lung cancer (1.4 million deaths), stomach cancer (740,000 deaths), liver cancer (700,000 deaths), colorectal cancer (610,000 deaths), and breast cancer (460,000 deaths). The three most common childhood cancers are leukemia (34%), brain tumors (23%), and lymphomas (12%). Rates of childhood cancer have increased by 0.6% per year between 1975 to 2002 in the United States and by 1.1% per year between 1978 and 1997 in Europe. This makes invasive cancer the leading cause of death in the developed world and the second leading cause of death in the developing world. Accordingly, there is a need to identify novel and efficacious therapeutic strategies that mitigate the limitations of current anti-cancer drugs.
SUMMARY OF THE INVENTION [0002] The present disclosure is based, at least in part, on the unexpected discovery that ATR inhibitors administered about 12-48 hours after DNA damaging agents are particularly effective at treating proliferative diseases. Accordingly, aspects of the disclosure relate to a method of treating a proliferative disorder, such as cancer, in a subject, the method comprising administering to a subject in need thereof a DNA damaging agent and between about 12-48 hours later administering to the subject a compound that inhibits ATR protein kinase.
[0003] In some embodiments, said DNA-damaging agent is selected from the group consisting of chemotherapy and radiation treatment. In some embodiments, said DNAdamaging agent is independently selected from the group consisting of ionizing radiation, radiomimetic neocarzinostatin, a platinating agent, a Topo I inhibitor, a Topo II inhibitor, an antimetabolite, an alkylating agent (e.g., alkyl sulphonate), and an antibiotic.
[0004] In some embodiments, said DNA-damaging agent is a platinating agent selected from the group consisting of Cisplatin, Oxaliplatin, Carboplatin, Nedaplatin, Lobaplatin, Triplatin Tetranitrate, Picoplatin, Satraplatin, ProLindac, and Aroplatin.
[0005] In some embodiments, said DNA-damaging agent is a Topo I inhibitor selected from the group consisting of Camptothecin, Topotecan, Irinotecan/SN38, Rubitecan, and Belotecan. In some embodiments, said DNA-damaging agent is a Topo II inhibitor selected
WO 2017/059357
PCT/US2016/054996 from the group consisting of Etoposide, Daunorubicin, Doxorubicin, Aclarubicin, Epirubicin, Idarubicin, Amrubicin, Pirarubicin, Valrubicin, Zorubicin, and Teniposide.
[0006] In some embodiments, said DNA-damaging agent is an antimetabolite selected from the group consisting of Aminopterin, Methotrexate, Pemetrexed, Raltitrexed, Pentostatin, Cladribine, Clofarabine, Fludarabine, Thioguanine, Mercaptopurine, Fluorouracil, Capecitabine, Tegafur, Carmofur, Floxuridine, Cytarabine, Gemcitabine, 6-Mercaptopurine, 5-Fluorouracil, Azacitidine, and Hydroxyurea.
[0007] In some embodiments, said DNA-damaging agent is an alkylating agent selected from the group consisting of Mechlorethamine, Cyclophosphamide, Ifosfamide, Trofosfamide, Chlorambucil, Melphalan, Prednimustine, Bendamustine, Uramustine, Estramustine, Carmustine, Lomustine, Semustine, Fotemustine, Nimustine, Ranimustine, Streptozocin, Busulfan, Mannosulfan, Treosulfan, Carboquone, ThioTEPA, Triaziquone,
Triethylenemelamine, Procarbazine, Dacarbazine, Temozolomide, Altretamine,
Mitobronitol, Actinomycin, Bleomycin, Mitomycin, nitrogen mustards, nitrosoureas, triazenes, alkyl sulfonates, Procarbazine, aziridines, and Plicamycin.
[0008] In some embodiments, said DNA-damaging agent is an antibiotic selected from the group consisting of Hydroxyurea, Anthracyclines, Anthracenediones, and antibiotics from the Streptomyces family.
[0009] In some embodiments, the proliferative disorder may be cancer, such as a solid tumor cancer. In some such embodiments, said cancer is a solid tumor cancer selected from the group consisting of lung cancer, gastrointestinal cancer, genitourinary tract cancer, liver cancer, bone cancer, nervous system cancer, gynecological cancer, skin cancer, thyroid gland cancer, and adrenal gland cancer.
[0010] In some embodiments, said cancer is a solid tumor cancer selected from the following cancers: Oral: buccal cavity, lip, tongue, mouth, pharynx; Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell or epidermoid, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinakesophagus (squamous cell carcinoma, larynx, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel or small intestines (adenocarcinoma, lymphoma, carcinoid tumors, Karposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel or large
WO 2017/059357
PCT/US2016/054996 intestines (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), colon, colon-rectum, colorectal; rectum, Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor [nephroblastoma], lymphoma), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma, biliary passages; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma [pinealoma], glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], granulosathecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma), breast; Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, keratoacanthoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis, Thyroid gland: papillary thyroid carcinoma, follicular thyroid carcinoma; medullary thyroid carcinoma, multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type 2B, familial medullary thyroid cancer, pheochromocytoma, paraganglioma; Adenoid cystic carcinoma; and Adrenal glands: neuroblastoma.
[0011] In some embodiments, said cancer is non-small cell lung cancer, small cell lung cancer, pancreatic cancer, biliary tract cancer, head and neck cancer, bladder cancer, colorectal cancer, glioblastoma, esophageal cancer, breast cancer, hepatocellular carcinoma, or ovarian cancer.
WO 2017/059357
PCT/US2016/054996 [0012] In some embodiments, said cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, and triple negative breast cancer.
[0013] In some embodiments, the compound that inhibits ATR is a compound represented by Formula A-I:
(L)n—R1
R2 A-I or a pharmaceutically acceptable salt thereof, wherein:
R1 is a 5-6 membered monocyclic aryl or heteroaryl ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein said monocyclic aryl or heteroaryl ring is optionally fused to another ring to form an 8-10 membered bicyclic aryl or heteroaryl ring having 0-6 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; each R1 is optionally substituted with 1-5 J1 groups;
R is a 5-6 membered monocyclic aryl or heteroaryl ring having 0-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein said monocyclic aryl or heteroaryl ring is optionally fused to another ring to form an 8-10 membered bicyclic aryl or heteroaryl ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; each R is optionally substituted with 1-5 J groups;
L is -C(O)NH- or -C(O)N(Ci_6alkyl)-;
n is 0 or 1;
each J1 and J2 is independently halo, -CN, -NO2, -V^R, or -(V2)m-Q;
V1 is a Ci-ioaliphatic chain, wherein 0-3 methylene units are optionally and independently replaced with O, NR”, S, C(O), S(O), or S(O)2; V1 is optionally substituted with 1-6 occurrences of Jvl;
V is a Ci_ioaliphatic chain, wherein 0-3 methylene units are optionally and independently replaced with O, NR”, S, C(O), S(O), or S(O)2; V2 is optionally substituted with 1-6 occurrences of Jv2;
m is 0 or 1;
WO 2017/059357
PCT/US2016/054996
Q is a 3-8 membered saturated or unsaturated monocyclic ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, or a 910 membered saturated or unsaturated bicyclic ring having 0-6 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; each Q is optionally substituted with 0-5 JQ;
each JV1 or Jv2 is independently halogen, CN, NH2, NO2, C^aliphatic, NH(C ^aliphatic), N(Ci_4aliphatic)2, OH, O(Ci_4aliphatic), CO2H, CO2(Ci_4aliphatic), C(O)NH2, C(O)NH(Ci_4aliphatic), C(O)N(Ci_4ahphatic)2iNHCO(Ci_4aliphatic), N(Ci_4aliphatic)CO(Ci_4aliphatic), SO2(CMaliphatic), NHSO2(Ci_4aliphatic), or N(Ci_4aliphatic)SO2(Ci_4aliphatic), wherein said Ci_4aliphatic is optionally substituted with halo;
R is H or Ci_6aliphatic, wherein said C^aliphatic is optionally substituted with 1-4 occurrences of NH2, NH(Ci_4aliphatic), N(C|_4aliphatic)2, halogen, C^aliphatic, OH, O(Ci_4aliphatic), NO2, CN, CO2H, CO2(Ci_4aliphatic), CO(Ci_4aliphatic), O(haloCi_4aliphatic), or haloCi^aliphatic;
each JQ is independently halo, oxo, CN, NO2, X-R, or -(X)p-Q4;
p is 0 or 1;
X is Ci-ioaliphatic, wherein 1-3 methylene units of said Ci_6aliphatic are optionally replaced with -NR, -O-, -S-, C(O), S(O)2, or S(O); wherein X is optionally and independently substituted with 1-4 occurrences of NH2, NH(Ci_4aliphatic), N(Ci_4aliphatic)2, halogen, Ci_4aliphatic, OH, O(Ci_4aliphatic), NO2, CN, CO(Ci_4aliphatic), CO2H,
CO2(Ci_4aliphatic), C(O)NH2, C(O)NH(Ci_4aliphatic), C(O)N(Ci_4aliphatic)2, SO(Ci_4aliphatic), SO2(Ci_4aliphatic), SO2NH(Ci_4aliphatic), SO2N(Ci_4aliphatic)2, NHC(O)(Ci_4aliphatic), N(Ci_4aliphatic)C(O)(Ci_4aliphatic), wherein said Ci_4aliphatic is optionally substituted with 1-3 occurrences of halo;
Q4 is a 3-8 membered saturated or unsaturated monocyclic ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, or a 810 membered saturated or unsaturated bicyclic ring having 0-6 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; each Q4 is optionally substituted with 1-5 JQ4;
J^4 is halo, CN, or Ci-4alkyl, wherein up to 2 methylene units are optionally replaced with O, NR*, S, C(O), S(O), or S(O)2;
R is H or Ci_4alkyl wherein said Ci^alkyl is optionally substituted with 1-4 halo;
WO 2017/059357
PCT/US2016/054996
R” and R* are each independently H, (Malkyl, or is absent, wherein said Ci_4alkyl is optionally substituted with 1-4 halo;
wherein the proliferative disorder has one or more defects in the ATM signaling pathway. [0014] In some embodiments, the compound that inhibits ATR is a compound represented by Formula A-l:
A-l or a pharmaceutically acceptable salt thereof.
[0015] In some embodiments, the compound that inhibits ATR is a compound represented by Formula A-I-a:
or a pharmaceutically acceptable salt thereof, wherein:
N-N 0'N
RingAi.MN„VVy,
J5o is H, F, Cl, Ci_4aliphatic, O(Ci_3aliphatic), or OH;
—(s
J5p is J P2 ;
J5p 1 is H, Ci_4aliphatic, oxetanyl, tetrahydrofuranyl, tetrahydropyrany, wherein J5p 1 is optionally substituted with 1-2 occurrences of OH or halo;
J5p2 is H, methyl, ethyl, CH2F, CF3, or CH2OH;
J2o is H, CN, or SO2CH3;
J2m is H, F, Cl, or methyl;
WO 2017/059357
PCT/US2016/054996
J p is -SO2(Ci_6alkyl), -SO2(C3_6cycloalkyl), -SO2(4-6 membered heterocyclyl), -SO2(Ci_4alkyl)N(Ci_4alkyl)2, or -SO2(CMalkyl)-(4-6 membered heterocyclyl), wherein said heterocyclyl contains 1 heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, and wherein said J p is optionally substituted with 1-3 occurrences halo, OH, or O(Ci_4alkyl).
N'N .__ [0016] In some embodiments, Ring A is ’ O A In some embodiments, Ring A is O'N yAAv [0017] In some embodiments, the compound that inhibits ATR is a compound represented by Formula A-2:
A-2 or a pharmaceutically acceptable salt thereof.
[0018] In some embodiments, the compound that inhibits ATR is a compound represented by Formula A-II:
or a pharmaceutically salt thereof, wherein:
R10 is fluoro, chloro, or -C(J10)2CN;
J10 is independently H or Ci_2alkyl; or two occurrences of J10, together with the carbon atom to which they are attached, form a 3-4 membered optionally substituted carbocyclic ring;
R is H, halo, -CN, NH2, a Ci_2alkyl optionally substituted with 0-3 occurrences of fluoro, or
WO 2017/059357
PCT/US2016/054996 a Ci_3aliphatic chain, wherein up to two methylene units of the aliphatic chain are optionally replaced with -0-, -NRa-, -C(O)-, or -S(O)Z;
a
R is H, halo, Ci-4alkyl optionally substituted with 1-3 occurrences of halo, C3_4cycloalkyl, CN, or a Ci_3aliphatic chain, wherein up to two methylene units of the aliphatic chain are optionally replaced with -0-, -NRa-, -C(O)-, or -S(O)Z;
R4 is Q1 or a C iio^il iphatic chain, wherein up to four methylene units of the aliphatic chain are optionally replaced with -0-, -NRa-, -C(O)-, or -S(O)Z-; each R4 is optionally substituted with 0-5 occurrences of JQ1; or
R3 and R4, taken together with the atoms to which they are bound, form a 5-6 membered aromatic or non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; the ring formed by R3 and R4 is optionally substituted with 0-3 occurrences of J ;
Q1 is a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring, the
3-7 membered ring having 0-3 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or an 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;
J is independently C^aliphatic, =0, halo, or ->0;
O1 2
I is independently-CN; halo; =0; Q ; or a Ci-saliphatic chain, wherein up to three methylene units of the aliphatic chain are optionally replaced with -0-, -NRa-, -C(O)-, or S(O)Z-; each occurrence of I is optionally substituted by 0-3 occurrences of J ; or two occurrences of JQ1 on the same atom, taken together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein the ring formed by two occurrences of I is optionally substituted with 0-3 occurrences of J ; or two occurrences of JQ1, together with Q1, form a 6-10 membered saturated or partially unsaturated bridged ring system;
Q is independently a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring having 0-3 heteroatoms selected from the group consisting of oxygen, nitrogen, a sulfur; or an 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;
J is independently -CN; halo; =0; ->O; Q ; or a Ci_6aliphatic chain, wherein up to three methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or 8
WO 2017/059357
PCT/US2016/054996
R T
S(O)Z-; each J is optionally substituted with 0-3 occurrences of J ; or
D two occurrences of J on the same atom, together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from the group consisting of
D oxygen, nitrogen, and sulfur; wherein the ring formed by two occurrences of J is optionally substituted with 0-3 occurrences of J ; or R 2 two occurrences of J , together with Q , form a 6-10 membered saturated or partially unsaturated bridged ring system;
a
Q is a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring having 0-3 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or an 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;
J is independently -CN; =0; halo; or a Ci_4aliphatic chain, wherein up to two methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or -S(O)Z-;
J is independently halo, -CN; ->O; =0; -OH; a Ci_6aliphatic chain, wherein up to two methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or S(O)Z-; or a 3-6 membered non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; each occurrence of J is optionally substituted with 0-3 occurrences of JM; or two occurrences of J on the same atom, together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or two occurrences of J , together with Q , form a 6-10 membered saturated or partially unsaturated bridged ring system;
JM is independently halo or Ci_6aliphatic;
z is 0, 1 or 2; and
Ra is independently H or Ci ^aliphatic.
[0019] In some embodiments, R1 and R3 are fluoro. In some embodiments, R4 is Q1. In some embodiments, Q1 is independently piperidinyl and imidazolyl.
[0020] In some embodiments, the compound that inhibits ATR is a compound represented by Formula A-3:
WO 2017/059357
PCT/US2016/054996
or a pharmaceutically acceptable salt thereof.
[0021] In some embodiments, the compound that inhibits ATR is a compound represented by Formula
A-II-a:
or a pharmaceutically acceptable salt thereof, wherein:
R10 is fluoro, chloro, or -C(J10)2CN;
J10 is independently H or Ci_2alkyl; or two occurrences of J1 ,together with the carbon atom to which they are attached, form an optionally substituted 3-4 membered carbocyclic ring;
a
R is independently H, chloro, fluoro, Ci_4alkyl optionally substituted with 1-3 occurrences of halo, C3_4cycloalkyl, -CN, or a Ci_3aliphatic chain, wherein up to two methylene units of the aliphatic chain are optionally replaced with -0-, -NRa-, -C(O)-, or -S(O)Z;
L1 is H; a 3-7 membered aromatic or non-aromatic ring having 0-2 heteroatoms selected from selected from the group consisting of oxygen, nitrogen, and sulfur; or a C ^aliphatic chain, wherein up to two methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or -S(O)Z; each L1 is optionally substituted with Ci ^aliphatic, CN, halo, -OH, or a 3-6 membered non-aromatic ring having 0-2 heteroatoms selected from the group consisting oxygen, nitrogen, and sulfur;
L is H; a 3-7 membered aromatic or non-aromatic ring having 0-2 heteroatoms selected from the group consisting oxygen, nitrogen, and sulfur; or a Ci_6aliphatic chain, wherein up to two methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O), or -S(O)Z; each L is optionally substituted with C^aliphatic, -CN, halo, -OH, or a 3-6 membered non-aromatic ring having 0-2 heteroatoms selected from the group consisting
WO 2017/059357
PCT/US2016/054996 oxygen, nitrogen, and sulfur; or 1 2
L and L , together with the nitrogen to which they are attached, form a Ring D; Ring D is optionally substituted with 0-5 occurrences of J ;
L3 is H, Ci_3aliphatic, or CN;
Ring D is independently a 3-7 membered heterocyclyl ring having 1-2 heteroatoms selected from the group consisting oxygen, nitrogen, and sulfur; or an 7-12 membered fully saturated or partially unsaturated bicyclic ring having 1-5 heteroatoms selected from the group consisting oxygen, nitrogen, and sulfur;
J is independently halo, -CN, -N(R°)2; ->O; a 3-6 membered carbocycyl, a 3-6 membered heterocyclyl having 1-2 heteroatoms selected from the group consisting oxygen nitrogen, and sulfur, or a Ci-4alkyl chain, wherein up to two methylene units of the alkyl chain are optionally replaced with -0-, -NRa-, -C(O)-, or -S(O)Z; each JG is optionally substituted
LZ with 0-2 occurrences of J .
two occurrences of J on the same atom, together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or two occurrences of J , together with Ring D, form a 6-10 membered saturated or partially unsaturated bridged ring system;
LZ
J is a 3-7 membered aromatic or non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;
z is 0, 1, or 2; and
Ra and R° independently are H or Ci_4alkyl.
3 [0022] In some embodiments, R and R are fluoro.
[0023] In some embodiments, the compound that inhibits ATR is a compound represented by Formula A-4:
AO A-4 or a pharmaceutically acceptable salt thereof.
[0024] In some embodiments, the compound that inhibits ATR is:
WO 2017/059357
PCT/US2016/054996
\-0 A-4, or a pharmaceutically acceptable salt thereof.
[0025] In some embodiments, a method of treating a proliferative disorder (e.g., cancer) in a subject comprises administering to the subject in need thereof a first dose of an antimetabolite and between about 12-48 hours later administering to the subject a compound that inhibits ATR protein kinase; and administering to the subject in need thereof a second dose of the antimetabolite and between about 12-48 hours later administering to the subject the compound that inhibits ATR protein kinase, wherein the second dose of the antimetabolite is administered between about 6-9 days after the first dose. In some such embodiments, the
WO 2017/059357
PCT/US2016/054996 antimetabolite is selected from the group consisting of Aminopterin, Methotrexate, Pemetrexed, Raltitrexed, Pentostatin, Cladribine, Clofarabine, Fludarabine, Thioguanine, Mercaptopurine, Fluorouracil, Capecitabine, Tegafur, Carmofur, Floxuridine, Cytarabine, Gemcitabine, 6-Mercaptopurine, 5-Fluorouracil, Azacitidine and Hydroxyurea. For example, the antimetabolite may be Gemcitabine.
[0026] In some embodiments, a method of treating a proliferative disorder in a subject comprises administering to the subject in need thereof carboplatin and between about 12-24 hours later administering to the subject a compound that inhibits ATR protein kinase.
[0027] In some embodiments, a method for achieving complete response in a subject having colorectal cancer comprises administering to the subject in need thereof a compound that inhibits ATR protein kinase as a monotherapy, wherein the colorectal cancer comprises cells having a defect in ATM.
[0028] In some embodiments, a method of treating a proliferative disorder in a subject comprises administering to the subject in need thereof carboplatin and between about 12-48 hours later administering to the subject a compound represented by Formula A-2:
or a pharmaceutically acceptable salt thereof, wherein the target AUC of carboplatin is 4 mg/mL*min or 5 mg/mL*min and wherein the dosage of a compound of Formula A-2 is 120 mg/m2.
[0029] In some embodiments, a method of treating a proliferative disorder in a subject comprises administering to the subject in need thereof carboplatin and between about 12-48 hours later administering to the subject a compound represented by Formula A-2:
WO 2017/059357
PCT/US2016/054996
or a pharmaceutically acceptable salt thereof, wherein the target AUC of carboplatin is 5 mg/mL*min and wherein the dosage of a compound of Formula A-2 is 90 mg/m .
[0030] In some embodiments, a method of treating a proliferative disorder in a subject comprises administering to the subject in need thereof a platinating agent on day 1 and between about 12-48 hours later administering to the subject a first dose of a compound that inhibits ATR protein kinase; and administering to the subject in need thereof a second dose of the compound that inhibits ATR protein kinase on day 9.
[0031] In some embodiments, a method of treating a proliferative disorder in a subject comprises administering to the subject in need thereof a DNA damaging agent and between about 12-24 hours later administering to the subject a first dose of a compound that inhibits ATR protein kinase; and administering to the subject in need thereof a second dose of the compound that inhibits ATR protein kinase between about 6 to about 9 days after administering the first dose of the compound.
[0032] In some embodiments, a method of treating a proliferative disorder in a subject comprises administering to the subject in need thereof a platinating agent and between about 12-48 hours later administering to the subject a compound that inhibits ATR protein kinase, wherein the subject is refractory to a treatment with the platinating agent.
[0033] In some embodiments, a method of treating a proliferative disorder in a subject comprises administering to the subject in need thereof a platinating agent and between about 12-48 hours later administering to the subject a compound that inhibits ATR protein kinase, wherein the subject is resistant to a treatment with the platinating agent.
[0034] In some embodiments, a method of treating a proliferative disorder in a subject comprises administering to the subject in need thereof carboplatin and a compound of Formula A-2, wherein the target AUC of carboplatin is between about 3 mg/mL*min and about 6 mg/mL*min and wherein the dosage of a compound of Formula A-2 is between about 60 mg/m2 and about 240 mg/m2.
[0035] In some embodiments, a method of treating a proliferative disorder in a subject
WO 2017/059357
PCT/US2016/054996 comprises administering to the subject in need thereof a compound of Formula A-2, wherein the dosage of a compound of Formula A-2 is between about 120 mg/m and about 480 mg/m2.
[0036] In some embodiments, the compound that inhibits ATR is administered about 18-42 hours after administration of the DNA damaging agent. In some embodiments, the compound that inhibits ATR is administered about 20-40 hours after administration of the DNA damaging agent. In some embodiments, the compound that inhibits ATR is administered about 12-36 hours after administration of the DNA damaging agent. In some embodiments, the compound that inhibits ATR is administered about 18-36 hours after administration of the DNA damaging agent. In some embodiments, the compound that inhibits ATR is administered about 20-28 hours after administration of the DNA damaging agent. In some embodiments, the compound that inhibits ATR is administered about 24 hours after administration of the DNA damaging agent.
BRIEF DESCRIPTION OF THE DRAWINGS [0037] FIG. 1 shows the optimization of Compound A-2 dose schedule in vitro. PSN1 cancer cells were treated with gemcitabine for 24 hours starting at 0 hours and with Compound A-2 for 2 hours starting at 1, 17, 27, 41, 51 and 65°hours. Cell viability was measured by MTS assay at 96 hours and the data subjected to a statistical Bliss analysis using MacSynergy II software to quantitate synergy as a log volume.
[0038] FIG. 2 shows the optimization of intravenous Compound A-2 dose schedule in combination with gemcitabine in vivo. Nude mice bearing PSN 1 human pancreatic cancer xenografts were dosed with Compound A-2 or gemcitabine alone or in combination on different schedules, and tumor volumes were monitored for 49 days.
[0039] FIG. 3 shows the optimization of intravenous Compound A-2 dose schedule in combination with cisplatin in vivo. SCID mice bearing OD26749 primary human non-small cell lung cancer xenografts were dosed with Compound A-2 or cisplatin alone or in combination on different schedules, and tumor volumes were monitored for 40 days.
[0040] FIG. 4 shows radiographs of the left common iliac lymph node before treatment (left) and after 15 months of treatment (right) with 60 mg/m of Compound A-2 weekly monotherapy.
[0041] FIG. 5A shows a graph of plasma concentration versus time for Compound A-2 monotherapy.
[0042] FIG. 5B shows a graph of plasma concentration versus time for combination therapy
WO 2017/059357
PCT/US2016/054996 with carboplatin and Compound A-2.
[0043] FIG. 6 shows a graph of percentage of pChkl in the nuclei of cancer cells/mm tumor before exposure to Compound A-2 (pre-dose) and after exposure to Compound A-2 (postdose) for various subjects.
[0044] FIG. 7 shows radiographs of left peritoneal disease before treatment (left) and after 5 months of treatment (right) after combination treatment with a target AUC of 5 mg/mL*min of carboplatin on day 1 and 90 mg/m of Compound A-2 on day 2, 24 hours after treatment with carboplatin, and 90 mg/m of Compound A-2 on day 9.
[0045] FIG. 8 shows a tumor response showing changes from baseline in cancer subjects who received treatment of Compound A-2 and cisplatin.
[0046] FIG. 9 shows duration of progression-free survival (PFS) from start of treatments of Compound A-2 and cisplatin in subjects having cancer.
[0047] FIG. 10 shows radiographs of ovarian cancer before treatment (top) and after 4 cycles of treatment (bottom) with cisplatin and Compound A-2.
[0048] FIG. 11 shows radiographs of breast cancer before treatment (top) and after 4 cycles of treatment (bottom) with cisplatin and Compound A-2.
[0049] FIG. 12 shows tumor response showing changes from baseline in cancer subjects who received treatment of Compound A-2 as a monotherapy.
[0050] FIG. 13 shows duration of progression-free survival (PFS) from start of treatments of Compound A-2 as a monotherapy in subjects having cancer.
[0051] FIG. 14 shows tumor response showing changes from baseline in cancer subjects who received treatment of Compound A-2 and carboplatin.
[0052] FIG. 15 shows duration of progression-free survival (PFS) from start of treatments of Compound A-2 and carboplatin in subjects having cancer.
[0053] FIG. 16 shows tumor response showing changes from baseline in cancer subjects who received treatment of Compound A-2 and gemcitabine, and treatment of Compound A-2, gemcitabine, and cisplatin.
[0054] FIG. 17 shows duration of progression-free survival (PFS) from start of treatments of Compound A-2 and gemcitabine in subjects having cancer.
DETAILED DESCRIPTION OF THE INVENTION [0055] The present disclosure is based, at least in part, on the unexpected discovery that ATR inhibitors administered about 12-48 hours after DNA damaging agents are particularly effective at treating proliferative diseases, such as cancer. As demonstrated in the Examples
WO 2017/059357
PCT/US2016/054996 described below, it has been found that a compound of Formula A-2 (Compound A-2), an ATR inhibitor, synergized with gemcitabine and this synergistic effect markedly increased as Compound A-2 was administered progressively later through the 24 hour gemcitabine dosing period. Synergy was maximal when Compound A-2 was administered about 24 hours after starting gemcitabine treatment; later administration of Compound A-2 was less effective. No synergy was seen when Compound A-2 was administered 48 hours or later, after gemcitabine treatment was started. The strong schedule dependence is attributed to an accumulation of cells in S phase, and concomitant increase in ATR activity that occurs in response to gemcitabine treatment alone. Thus, maximal impact of Compound A-2 is expected at a time when most cells are in S phase as a result of gemcitabine treatment. Extended intervals (>48 hours) between gemcitabine therapy and Compound A-2 exposure allows DNA damage to be repaired, permitting cells to exit S phase and dramatically reducing the impact of ATR inhibition.
[0056] Without being bound by theory, it is believed that exposure of cancer cells to certain DNA-damaging agent results in sufficient DNA damage to trigger the DNA damage response and temporary S phase arrest to allow for DNA repair. The DNA damage response is believed to be regulated by two homologous protein kinases, ataxia telangiectasia (ATM) and ataxia telangiectasia Rad3-related (ATR). ATR signals to regulate DNA replication, cell cycle transitions, and DNA repair through the phosphorylation of hundreds of substrates, including checkpoint kinase 1 (Chkl). ATR inhibition during the S phase can thus block effectively the DNA damage repair in cancer cells. It is believed that offsetting treatment with a DNA damaging agent and an ATR inhibitor allows for accumulation of cells in the S phase and the concomitant increase in ATR activity due to the DNA damage response. However, a relatively long offset allows for DNA damage repair, limiting the efficacy of the ATR inhibitor. Accordingly, it is believed that effective treatment of certain cancers may be achieved by administering an ATR inhibitor between about 12 hours and about 48 hours (e.g., between about 12 hours and about 36 hours, between about 20 hours and about 28 hours, about 24 hours, or 24 hours + 2 hours) after administration of a DNA-damaging agent. Moreover, administering the ATR inhibitor within the window of highest efficacy can allow efficacy and possible toxicity to be efficiently balanced.
[0057] Accordingly, aspects of the disclosure provide a method of treating a proliferative disorder in a subject, the method comprising administering to a subject in need thereof a DNA damaging agent and between about 12-48 hours later administering to the subject a compound that inhibits ATR protein kinase. In some embodiments, the compound that
WO 2017/059357
PCT/US2016/054996 inhibits ATR is administered about 18-42 hours after administration of the DNA damaging agent. In some embodiments, the compound that inhibits ATR is administered about 20-40 hours after administration of the DNA damaging agent. In some embodiments, the compound that inhibits ATR is administered about 12-36 hours after administration of the DNA damaging agent. In some embodiments, the compound that inhibits ATR is administered about 18-36 hours after administration of the DNA damaging agent. In some embodiments, the compound that inhibits ATR is administered about 20-28 hours after administration of the DNA damaging agent. In some embodiments, the compound that inhibits ATR is administered about 24 hours, or 24 hours + 2 hours, after administration of the DNA damaging agent. In some embodiments, said DNA-damaging agent is chemotherapy or radiation treatment.
[0058] In some embodiments in which the DNA damaging agent is given once per treatment cycle (e.g., 3 week treatment cycle, 4 week treatment cycle), the ATR inhibitor may be administered at least about 12 hours (e.g., at least about 24 hours) after the DNA damaging agent, and optionally a second dose of the ATR inhibitor may be administered at least about 5 days (e.g., at least about 6 days) after a prior (e.g., the immediately prior) administration of the ATR inhibitor. In certain embodiments in which the DNA damaging agent is given once per treatment cycle (e.g., 3 week treatment cycle, 4 week treatment cycle), the ATR inhibitor may be administered between about 12 hours and about 48 hours (e.g., between about 12 hours and about 36 hours, between about 20 hours and about 28 hours) after the DNA damaging agent, and optionally a second dose of the ATR inhibitor may be administered between about 5 days to about 9 days after a prior (e.g., the immediately prior) administration of the ATR inhibitor. For instance, in some embodiments, a DNAdamaging agent (e.g., platinating agent) may be administered on day 1 and an ATR inhibitor (e.g., a compound of Formula A-2) may be administered between about 12 hours and about 48 hours (e.g., between about 12 hours and about 36 hours, between about 20 hours and about 28 hours) later. In some such embodiments, a second dose of the ATR inhibitor (e.g., a compound of Formula A-2) may be administered between about 5 days to about 9 days after a prior (e.g., the immediately prior) administration of the ATR inhibitor.
[0059] For instance, the second dose of the ATR inhibitor may be administered after about between about 5 days and about 9 days, between about 5 days and about 8 days, between about 5 days and about 7 days, between about 6 days and about 9 days, between about 6 days and about 8 days, or between about 6 days and about 7 days. In some instances, the second dose of the ATR inhibitor may be administered after between about 6 days and about 8 days
WO 2017/059357
PCT/US2016/054996 or after about 7 days. In one example, a method of treating a proliferative disorder may comprise administering a platinating agent (e.g., carboplatin, cisplatin) on day 1, a first dose of an ATR inhibitor on day 2 (e.g., a compound of Formula A-2) between about 20 hours and about 28 hours (e.g., 24 hours or 24 hours + 2 hours) after administration of the platinating agent, and a second dose of the ATR inhibitor about 6 days and about 8 days (e.g., on day 9) after administration of the ATR inhibitor. The method may be part of a 3 week or 4 week treatment cycle. In some such embodiments, a DNA-damaging agent or ATR inhibitor may not be administered after the second dose of the ATR inhibitor for the remaining portion of the treatment cycle. For instance, a method of treating a proliferative disorder using a three week treatment cycle may comprise administering a platinating agent (e.g., carboplatin, cisplatin) on day 1, a first dose of an ATR inhibitor (e.g., a compound of Formula A-2) on day 2 (e.g., about 24 hours, or 24 hours + 2 hours, after administration of the platinating agent) and a second dose of the ATR inhibitor on day 9. In some such embodiments, a DNAdamaging agent or ATR inhibitor may not be administered after the second dose of the ATR inhibitor for the remaining portion of the treatment cycle. In certain embodiments, a method of treating a proliferative disorder using a four week treatment cycle may comprise administering a platinating agent (e.g., carboplatin, cisplatin) on day 1, a first dose of an ATR inhibitor (e.g., a compound of Formula A-2) on day 2 (e.g., about 24 hours, or 24 hours + 2 hours, after administration of the platinating agent) and a second dose of the ATR inhibitor on day 9. In some such embodiments, a DNA-damaging agent or ATR inhibitor may not be administered after the second dose of the ATR inhibitor for the remaining portion of the treatment cycle.
[0060] In some embodiments in which the DNA damaging agent is given twice per treatment cycle (e.g., 3 week treatment cycle, 4 week treatment cycle), the ATR inhibitor may be administered between about 12 hours and about 48 hours (e.g., between about 12 hours and about 36 hours, between about 20 hours and about 28 hours) after one administration of the DNA damaging agent or after each administration. In certain embodiments, a first dose of a DNA-damaging agent (e.g., antimetabolite) may be administered on day 1 and an ATR inhibitor (e.g., a compound of Formula A-2) may be administered between about 12 hours and about 48 hours (e.g., between about 12 hours and about 36 hours, between about 20 hours and about 28 hours) later. In some such embodiments, a second dose of the DNA-damaging agent (e.g., antimetabolite) may be administered between about 5 days to about 9 days after a prior (e.g., immediately prior) administration of the DNA damaging agent. For example, the second dose of the DNA19
WO 2017/059357
PCT/US2016/054996 damaging agent (e.g., antimetabolite) may be administered about between about 5 days and about 9 days, between about 5 days and about 8 days, between about 5 days and about 7 days, between about 6 days and about 9 days, between about 6 days and about 8 days, or between about 6 days and about 7 days after the first dose of the DNA damaging agent. In some instances, the second dose of the DNA-damaging agent may be administered after between about 6 days and about 8 days or after about 7 days. In some embodiments, a second dose of an ATR inhibitor may be administered between about 12 hours and about 48 hours (e.g., between about 12 hours and about 36 hours, between about 20 hours and about 28 hours) after the second dose of the DNA damaging agent.
[0061] In one example, a method of treating a proliferative disorder may comprise administering a first dose of an antimetabolite (e.g., gemcitabine) on day 1, a first dose of an ATR inhibitor (e.g., a compound of Formula A-2) on day 2 between about 20 hours and about 28 hours (e.g., 24 hours or 24 hours + 2 hours) after administration of the antimetabolite, and a second dose of the antimetabolite between about 6 days and about 8 days (e.g., on day 8) after the first dose of the antimetabolite. The method, in some instances, further comprises administering a second dose of an ATR inhibitor (e.g., a compound of Formula A-2) between about 20 hours and about 28 hours (e.g., 24 hours or 24 hours + 2 hours) after administration of the second dose of the antimetabolite. The method may be part of a 3 week or 4 week treatment cycle. In some such embodiments, a DNA-damaging agent or ATR inhibitor may not be administered after the second dose of the antimetabolite or, when present, the second dose of the ATR inhibitor for the remaining portion of the treatment cycle. For instance, a method of treating a proliferative disorder using a 3 week treatment cycle may comprise administering a first dose of an antimetabolite (e.g., gemcitabine) on day 1, a first dose of an ATR inhibitor on day 2 (e.g., about 24 hours, or 24 hours + 2 hours, after administration of the antimetabolite on day 1), and a second dose of the antimetabolite on day 8. The method, in some instances, further comprises administering a second dose of an ATR inhibitor (e.g., a compound of Formula A-2) on day 9 (e.g., about 24 hours, or 24 hours + 2 hours, after administration of the second dose of the antimetabolite). In some such embodiments, a DNA-damaging agent or ATR inhibitor may not be administered after the second dose of the antimetabolite or, when present, the second dose of the ATR inhibitor for the remaining portion of the treatment cycle. In certain embodiments, a method of treating a proliferative disorder using a 4 week treatment cycle may comprise administering a first dose of an antimetabolite (e.g., gemcitabine) on day 1, a first dose of an ATR inhibitor on day 2 (e.g., about 24 hours, or 24 hours + 2 hours, after administration of the antimetabolite on day
WO 2017/059357
PCT/US2016/054996
1) , and a second dose of the antimetabolite on day 8. The method, in some instances, further comprises administering a second dose of an ATR inhibitor (e.g., a compound of Formula A2) on day 9 (e.g., about 24 hours, or 24 hours + 2 hours, after administration of the second dose of the antimetabolite). In some such embodiments, a DNA-damaging agent or ATR inhibitor may not be administered after the second dose of the antimetabolite or, when present, the second dose of the ATR inhibitor for the remaining portion of the treatment cycle.
[0062] In some embodiments in which the DNA damaging agent (e.g., Topo I inhibitor, Topo II inhibitor) is administered three or more times per treatment cycle (e.g., 3-5 administrations), the ATR inhibitor may be administered between about 12 hours and about 48 hours (e.g., between about 12 hours and about 36 hours, between about 20 hours and about 28 hours) after at least one administration of the DNA damaging agent (e.g., after one administration, after each of two administrations, after each of three administrations) or after each administration.
[0063] In some embodiments, two or more different DNA damaging agents may be administered within a treatment cycle (e.g., 3 week treatment cycle, 4 week treatment cycle). The DNA damaging agents may differ in mechanism of action and/or administration frequency. For instance, a first DNA-damaging agent (e.g., antimetabolite) administered twice per treatment cycle and a second DNA damaging agent (e.g., platinating agent) administered once per treatment cycle may be used. In some such embodiments, the first DNA-damaging agent and a second DNA damaging agent may be administered as described above with respect to the administration of a single DNA-damaging agent. The ATR inhibitor may be administered between about 12 hours and about 48 hours (e.g., between about 12 hours and about 36 hours, between about 20 hours and about 28 hours) after at least one DNA damaging agent (e.g., two DNA damaging agents, after each of two administrations of a DNA damaging agent.
[0064] In one example, a platinating agent and an antimetabolite (e.g., carboplatin and gemcitabine, cisplatin and gemcitabine) may be administered on day 1 and a first dose of an ATR inhibitor (e.g., a compound of Formula A-2) may be administered between about 12 hours and about 48 hours (e.g., between about 12 hours and about 36 hours, between about 20 hours and about 28 hours) after the platinating agent and the antimetabolite. In some such embodiments, a second dose of the antimetabolite may be administered between about 6 days and about 8 days (e.g., on day 8) after the first dose of the antimetabolite. The method, in some instances, further comprises administering a second dose of an ATR inhibitor (e.g., a
WO 2017/059357
PCT/US2016/054996 compound of Formula A-2) between about 20 hours and about 28 hours (e.g., 24 hours or 24 hours + 2 hours) after administration of the second dose of the antimetabolite. The method may be part of a 3 week or 4 week treatment cycle. In some such embodiments, a DNAdamaging agent or ATR inhibitor may not be administered after the second dose of the antimetabolite or, when present, the second dose of the ATR inhibitor for the remaining portion of the treatment cycle. In other embodiments, a third dose of the ATR inhibitor may be administered between about 6 and about 8 days after the second dose of the ATR inhibitor. [0065] In some embodiments, a DNA damaging agent, ATR inhibitor, and an additional therapeutic agent may be administered within a treatment cycle (e.g., 3 week treatment cycle, 4 week treatment cycle). In some embodiments, the additional therapeutic agent is a chemotherapeutic agent, such as a taxane (e.g., taxol, docetaxol, cabazitaxel). For instance, a platinating agent (e.g., carboplatin, cisplatin), ATR inhibitor (e.g., a compound of Formula A2), and taxol may be administered within a single treatment cycle (e.g., 3 week treatment cycle, 4 week treatment cycle) . In some such embodiments, the DNA-damaging agent and ATR inhibitor may be administered as described herein. For instance, the ATR inhibitor may be administered between about 12 hours and about 48 hours (e.g., between about 12 hours and about 36 hours, between about 20 hours and about 28 hours) after a DNA damaging agent.
[0066] As used herein, the term “treatment cycle” has its ordinary meaning in the art and may refer to a course of treatment that is repeated on a regular schedule, including periods of rest. For example, a treatment cycle of four weeks may include administration of agents during week one followed by three weeks of rest (e.g., no treatment). In general, an ATR inhibitor may be administered at least once per treatment cycle and between about 12 hours and about 48 hours (e.g., between about 12 hours and about 36 hours, between about 20 hours and about 28 hours) after a DNA damaging agent. In some embodiments, the methods, described herein, may be part of a 3 week or 4 week treatment cycle.
[0067] In some embodiments, treatment of a proliferative disorder using the methods described herein may result in a RECIST stable disease, a RECIST partial response, or a RECIST complete response. For instance, treatment may result in a RECIST partial or a RECIST complete response. As used herein, the term “RECIST partial response” has its ordinary meaning in the art and may refer to a 30% decrease in the sum of the longest diameter of target lesions as determined according to the RECIST (i.e., Response Evaluation Criteria in Solid Tumors) guidelines version 1.1 (see Eisenhauer et. al., Eur. J. Cancer. 45 (2009) 228 - 247). As used herein, the term “RECIST complete response” has its ordinary
WO 2017/059357
PCT/US2016/054996 meaning in the art and may refer to the disappearance of all target lesions as determined according to the RECIST guidelines version 1.1. As used herein, the term “RECIST progressive disease” has its ordinary meaning in the art and may refer to a 20% increase in the sum of the longest diameter of target lesions as determined according to the RECIST guidelines version 1.1. As used herein, the term “RECIST stable disease” has its ordinary meaning in the art and may refer to small changes that do not meet above criteria as determined according to the RECIST guidelines version 1.1.
[0068] In general, treatment of a proliferative disorder (e.g., cancer) with the methods described herein may reverse, alleviate, delaying the onset of, or inhibit the progress of the proliferative disorder. In some embodiments, the methods described herein may decrease the sum of the longest diameter of target lesions, decrease the sum of the longest diameter of non-target lesions, and/or decrease tumor burden by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, or at least about 60%. In certain embodiments, the methods described herein may decrease the sum of the longest diameter of target lesions, decrease the sum of the longest diameter of non-target lesions, and/or decrease tumor burden by between about 20% and about 60% or between about 40% and about 60%. [0069] In some embodiments, the methods described herein may be particularly advantageous for the treatment of proliferative disorders in subjects that are refractory, resistant, or sensitive to one or more DNA damaging. In certain embodiments, the methods described herein may be used to treat a proliferative disorder (e.g., ovarian cancer, lung cancer, colorectal cancer, breast cancer) in a subject that is refractory to a platinating agent (e.g., cisplatin, carboplatin). In certain embodiments, the methods described herein may be used to treat a proliferative disorder (e.g., ovarian cancer, lung cancer, breast cancer) in a subject that is refractory to an antimetabolite (e.g., gemcitabine). For example, as described in more detail in the Examples, it was surprisingly found that treatment of a human subject having metastatic high grade serous ovarian cancer having gBRCAl and TP53 mutations with peritoneal, liver and nodal disease that was refractory to carboplatin and gemcitabine had a RECIST partial response after treatment with carboplatin and a compound of Formula A-2 as described herein.
[0070] In certain embodiments, the methods described herein may be used to treat a proliferative disorder (e.g., ovarian cancer, lung cancer, colorectal cancer, breast cancer) in a subject that is resistant to a platinating agent (e.g., cisplatin, carboplatin). In certain embodiments, the methods described herein may be used to treat a proliferative disorder (e.g., ovarian cancer, lung cancer) in a subject that is resistant to an antimetabolite (e.g.,
WO 2017/059357
PCT/US2016/054996 gemcitabine). In certain embodiments, the methods described herein may be used to treat a proliferative disorder (e.g., ovarian cancer, lung cancer, breast cancer, colorectal cancer) in a subject that is sensitive to a platinating agent (e.g., cisplatin, carboplatin). In certain embodiments, the methods described herein may be used to treat a proliferative disorder (e.g., ovarian cancer, lung cancer breast cancer, colorectal cancer) in a subject that is sensitive to an antimetabolite (e.g., gemcitabine). For example, as described in more detail in the Examples, it was surprisingly found that treatment of a human subject, who was a BRCA2 W2626Q (8106 C>G) carrier, having CA 125 positive ovarian cancer that was resistant to carboplatin had a RECIST partial response after treatment with cisplatin and a compound of Formula A-2 as described herein.
[0071] As used herein, the terms “refractory” has its ordinary meaning in the art and may refer to a proliferative disorder that progresses during treatment with an agent (e.g., DNA damaging agent) (first line treatment). As used herein, the terms “resistant” has its ordinary meaning in the art and may refer to a proliferative disorder that recurs within a certain period of time after completing treatment with an agent (e.g., DNA damaging agent). As used herein, the terms “sensitive” has its ordinary meaning in the art and may refer to a proliferative disorder that recurs after a certain period of time from completing treatment with an agent (e.g., DNA damaging agent). In general, recurrence occurs after a longer period of time for a sensitive cancer than for a resistant cancer. The periods of time to classify a proliferative disorder as resistance or sensitive would be known to those of ordinary skill in the art and may depend on certain factors, such as the type of cancer, the treatment used, and the stage of cancer, amongst others. For instance, resistant ovarian cancer may refer to ovarian cancer that recurs within 6 months from completing treatment. Sensitive ovarian cancer may refer to ovarian cancer that recurs after greater than 6 months from completing treatment. For instance, resistant small cell lung cancer (SCLC) may refer to SCLC that recurs within 3 months from completing treatment. Sensitive SCLC may refer to SCLC that recurs after greater than 3 months from completing treatment.
[0072] In some embodiments, the methods described herein may be particularly advantageous for the treatment of proliferative disorders having a defect in the ATM signaling cascade. In some embodiments, the defect is altered expression or activity of one or more of the following: ATM and p53. In certain embodiments, the proliferative disorder may have a mutation (e.g., somatic) in p53. For example, treatment of a proliferative disorder (e.g., ovarian cancer) having a somatic mutation in the TP53 gene by administering a platinating agent (e.g., carboplatin, cisplatin) on day 1, a first dose of an ATR inhibitor (e.g.,
WO 2017/059357
PCT/US2016/054996 a compound of Formula A-2) between about 20 hours and about 28 hours (e.g., 24 hours or 24 hours + 2 hours) after administration of the platinating agent on day 1, and a second dose of the ATR inhibitor between about 6 days and about 8 days (e.g., on day 9) after the first dose, as part of a three or four week treatment cycle including a rest period after the second dose of the ATR inhibitor, may result in at least a RECIST partial response. In some such embodiments, the methods described herein may decrease the sum of the longest diameter of target lesions, decrease the sum of the longest diameter of non-target lesions, and/or decrease tumor burden by between about 20% and about 60% or between about 40% and about 60%. [0073] In some embodiments, the proliferative disorder may have a complete loss of ATM signaling. For example, treatment of a proliferative disorder (e.g., colorectal cancer) having a complete loss of ATM signaling with a monotherapy (e.g., at a dosage of about 60 mg/m ,
2 2 2 between about 60 mg/m and about 480 mg/m , about 120 mg/m , about 240 mg/m , about 480 mg/m ) or a combination therapy with a DNA damaging agent, as described herein may result in a decrease in the sum of the longest diameter of target lesions, decrease in the sum of the longest diameter of non-target lesions, and/or decrease in tumor burden by at least about 80% or RECIST complete response.
Compounds [0074] In some aspects of the present disclosure, the compound that inhibits ATR protein kinase is a compound represented by Formula A-I:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is a 5-6 membered monocyclic aryl or heteroaryl ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein said monocyclic aryl or heteroaryl ring is optionally fused to another ring to form an 8-10 membered bicyclic aryl or heteroaryl ring having 0-6 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; each R1 is optionally substituted with 1-5 J1 groups;
WO 2017/059357
PCT/US2016/054996
R is a 5-6 membered monocyclic aryl or heteroaryl ring having 0-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein said monocyclic aryl or heteroaryl ring is optionally fused to another ring to form an 8-10 membered bicyclic aryl or heteroaryl ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; each R is optionally substituted with 1-5 J groups;
L is -C(O)NH- or -C(O)N(Ci_6alkyl)-;
n is 0 or 1;
each J1 and J2 is independently halo, -CN, -NO2, -V^R, or -(V2)m-Q;
V1 is a Ci_ioaliphatic chain, wherein 0-3 methylene units are optionally and independently replaced with O, NR”, S, C(O), S(O), or S(O)2; V1 is optionally substituted with 1-6 occurrences of Jvl;
V is a Ci_ioaliphatic chain, wherein 0-3 methylene units are optionally and independently replaced with O, NR”, S, C(O), S(O), or S(O)2; V2 is optionally substituted with 1-6 occurrences of Jv2;
m is 0 or 1;
Q is a 3-8 membered saturated or unsaturated monocyclic ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, or a 910 membered saturated or unsaturated bicyclic ring having 0-6 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; each Q is optionally substituted with 0-5 JQ;
each JV1 or Jv2 is independently halogen, CN, NH2, NO2, C^aliphatic, NH(C^aliphatic), N(Ci_4aliphatic)2, OH, O(Ci_4aliphatic), CO2H, CO2(Ci_4aliphatic), C(O)NH2, C(O)NH(Ci_4aliphatic), C(O)N(CMaliphatic)2,NHCO(CMaliphatic), N(Ci_4aliphatic)CO(Ci_4aliphatic), SO2(Cigaliphatic), NHSO2(Ci_4aliphatic), or N(Ci_4aliphatic)SO2(Ci_4aliphatic), wherein said Ci-4aliphatic is optionally substituted with halo;
R is H or Ci_6aliphatic, wherein said C^aliphatic is optionally substituted with 1-4 occurrences of NH2, NH(Ci_4aliphatic), N(Cigaliphatic)2, halogen, C^aliphatic, OH, O(Ci_4aliphatic), NO2, CN, CO2H, CO2(Ci_4aliphatic), CO(Ci_4aliphatic), O(haloCi_4aliphatic), or haloCi^aliphatic;
each JQ is independently halo, oxo, CN, NO2, X-R, or -(X)p-Q4;
p is 0 or 1;
WO 2017/059357
PCT/US2016/054996
X is Ci_ioaliphatic, wherein 1-3 methylene units of said Ci_6aliphatic are optionally replaced with -NR, -0-, -S-, C(O), S(O)2, or S(O); wherein X is optionally and independently substituted with 1-4 occurrences of NH2, NH(Ci_4aliphatic), N(Ci_4aliphatic)2, halogen, Ci_4aliphatic, OH, O(Ci_4aliphatic), NO2, CN, CO(Ci_4aliphatic), CO2H,
CO2(Ci_4aliphatic), C(0)NH2, C(O)NH(CMaliphatic), C(O)N(CMaliphatic)2, SO(Ci_4aliphatic), SO2(Ci_4aliphatic), SO2NH(Ci_4aliphatic), SO2N(Ci_4aliphatic)2, NHC(O)(Ci_4aliphatic), N(Ci_4aliphatic)C(O)(Ci_4aliphatic), wherein said Ci-4aliphatic is optionally substituted with 1-3 occurrences of halo;
Q4 is a 3-8 membered saturated or unsaturated monocyclic ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, or a 810 membered saturated or unsaturated bicyclic ring having 0-6 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; each Q4 is optionally substituted with 1-5 JQ4;
J*·’4 is halo, CN, or Ci_4alkyl, wherein up to 2 methylene units are optionally replaced with O, NR*, S, C(O), S(O), or S(O)2;
R is H or Ci_4alkyl, wherein said Ci-4alkyl is optionally substituted with 1-4 halo;
R” and R* are each independently H, Ci_4alkyl, or is absent; wherein said Ci_4alkyl is optionally substituted with 1-4 halo.
2 [0075] In some embodiments, L is -C(O)NH-; and R and R are phenyl.
[0076] In another embodiment the compound that inhibits ATR kinase is a compound represented by Formula A-I-a:
or a pharmaceutically salt thereof, wherein:
n~n Ο-N
Ring A is U!OAV,)r AN,
J5o is H, F, Cl, Ci_4aliphatic, O(Ci_3aliphatic), or OH;
WO 2017/059357
PCT/US2016/054996
J5pi is H, Ci^aliphatic, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl; wherein J5pi is optionally substituted with 1-2 occurrences of OH or halo;
J5p2 is H, methyl, ethyl, CH2F, CF3, or CH2OH;
J2o is H, CN, or SO2CH3;
J2m is H, F, Cl, or methyl;
J2p is -SO2(Ci-6alkyl), -SO2(C3-6cycloalkyl), -SO2(4-6 membered heterocyclyl), -SO2(Ci_4alkyl)N(Ci_4alkyl)2, or -SO2(CMalkyl)-(4-6 membered heterocyclyl), wherein said heterocyclyl contains 1 heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur; and wherein said J p is optionally substituted with 1-3 occurences halo, OH, or O(Ci_4alkyl).
[0077]
In some embodiments, Ring A is ’ O O'N [0078] In other embodiments, Ring A is ’ .
[0079] In some embodiments, the compound that inhibits ATR kinase is a compound represented by Formula A-l :
O=S=O
A-l or a pharmaceutically acceptable salt thereof, or a compound represented by Formula A-2:
WO 2017/059357
PCT/US2016/054996
A-2 or a pharmaceutically acceptable salt thereof.
[0080] In certain embodiments, the compound that inhibits ATR kinase is a compound represented by Formula A-l:
A-l or a pharmaceutically acceptable salt thereof.
[0081] In another embodiment, the compound that inhibits ATR kinase is a compound
or a pharmaceutically acceptable salt thereof.
WO 2017/059357
PCT/US2016/054996 [0082] In another aspect of the present disclosure, the compound that inhibits ATR protein kinase is represented by Formula A-II:
or a pharmaceutically salt or derivative thereof, wherein:
R10 is selected from fluoro, chloro, or -C(J10)2CN;
J10 is independently H or Ci_2alkyl; or two occurrences of J10 Together with the carbon atom to which they are attached, form a 3-4 membered optionally substituted carbocyclic ring;
R is H, halo, -CN, NH2, a Ci_2alkyl optionally substituted with 0-3 occurrences of fluoro; or a Ci_3aliphatic chain, wherein up to two methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or -S(O)Z;
a
R is H, halo, Ci_4alkyl optionally substituted with 1-3 occurrences of halo, C3_4cycloalkyl, CN, or a Ci-3aliphatic chain, wherein up to two methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or -S(O)Z;
R4 is Q1 or a C ικγΐ iphatic chain, wherein up to four methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or -S(O)Z-; each R4 is optionally substituted with 0-5 occurrences of JQ1; or
R3 and R4, taken together with the atoms to which they are bound, form a 5-6 membered aromatic or non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; the ring formed by R3 and R4 is optionally substituted with 0-3 occurrences of J ;
Q1 is a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring, the 3-7 membered ring having 0-3 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or an 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;
J is independently C^aliphatic, =0, halo, or ->0;
WO 2017/059357
PCT/US2016/054996
ΟΙ 2
J is independently-CN, halo, =0, Q , or a Ci_saliphatic chain, wherein up to three methylene units of the aliphatic chain are optionally replaced with -0-, -NRa-, -C(O)-, or S(O)Z-; each occurrence of J is optionally substituted by 0-3 occurrences of J ; or two occurrences of JQI on the same atom, taken together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein the ring formed by two occurrences of J is optionally substituted with 0-3 occurrences of J ; or two occurrences of JQ1, together with Q1, form a 6-10 membered saturated or partially unsaturated bridged ring system;
Q is independently selected from a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring having 0-3 heteroatoms selected from oxygen, nitrogen, or sulfur; or an 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from oxygen, nitrogen, or sulfur;
J is independently -CN, halo, =0, ->O; Q , or a Ci_6aliphatic chain, wherein up to three methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or R T
S(O)Z-; each J is optionally substituted with 0-3 occurrences of J ; or
D two occurrences of J on the same atom, together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from oxygen, nitrogen, or
D sulfur; wherein the ring formed by two occurrences of J is optionally substituted with 03 occurrences of J ; or
R 2 two occurrences of J , together with Q , form a 6-10 membered saturated or partially unsaturated bridged ring system;
a
Q is a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring having 0-3 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or an 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;
J is independently -CN, =0, halo, or a Ci_4aliphatic chain, wherein up to two methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or -S(O)Z-;
J is independently halo, -CN, ->O; =0, -OH, a Ci_6aliphatic chain, wherein up to two methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or S(O)Z-; or a 3-6 membered non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; each occurrence of J is optionally substituted with 0-3 occurrences of JM; or
WO 2017/059357
PCT/US2016/054996 τ
two occurrences of J on the same atom, together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or two occurrences of J , together with Q , form a 6-10 membered saturated or partially unsaturated bridged ring system;
JM is independently halo or C^aliphatic;
z is 0, 1 or 2; and
Ra is independently H or Ci ^aliphatic.
3 [0083] In some embodiments, R and R are fluoro.
[0084] In other embodiments, R4 is Q1.
[0085] In still other embodiments, Q1 is independently piperidinyl and imidazolyl.
[0086] In yet another embodiment, the compound that inhibits ATR is a compound represented by Formula A-3:
or a pharmaceutically acceptable salt thereof.
[0087] In another embodiment, the compound that inhibits ATR is represented by Formula A-II-a:
or a pharmaceutically acceptable salt or prodrug thereof, wherein:
R10 is fluoro, chloro, or -C(J10)2CN;
J10 is independently H or Ci_2alkyl; or two occurrences of J1 ,together with the carbon atom to which they are attached, form an optionally substituted 3-4 membered carbocyclic ring;
WO 2017/059357
PCT/US2016/054996 α
R is H; chloro; fluoro; Ci_4alkyl optionally substituted with 1-3 occurrences of halo; C3_ 4cycloalkyl; -CN; or a Ci_3aliphatic chain, wherein up to two methylene units of the aliphatic chain are optionally replaced with -0-, -NRa-, -C(O)-, or -S(O)Z;
L1 is H; a 3-7 membered aromatic or non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or a Ci_6aliphatic chain, wherein up to two methylene units of the aliphatic chain are optionally replaced with -0-, -NRa-, C(O)-, or -S(O)Z; each L1 is optionally substituted with C i 4aliphatic; -CN; halo; -OH; or a 3-6 membered non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;
L is H; a 3-7 membered aromatic or non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or a Ci_6aliphatic chain, wherein up to two methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, C(O)-, or -S(O)Z; each L is optionally substituted with C i 4aliphatic; -CN; halo; -OH; or a 3-6 membered non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or
L and L , together with the nitrogen to which they are attached, form a Ring D; Ring D is optionally substituted with 0-5 occurrences of J ;
L3 is H, Ci_3aliphatic, or CN;
Ring D is a 3-7 membered heterocyclyl ring having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or an 7-12 membered fully saturated or partially unsaturated bicyclic ring having 1-5 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;
J is independently halo; -CN; -N(R°)2; ~>O; a 3-6 membered carbocycyl; a 3-6 membered heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or a Ci_4alkyl chain, wherein up to two methylene units of the alkyl chain are optionally replaced with -O-, -NRa-, -C(O)-, or -S(O)Z; each JG is optionally substituted with 0-2 occurrences of J .
two occurrences of J on the same atom, together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or two occurrences of J , together with Ring D, form a 6-10 membered saturated or partially unsaturated bridged ring system;
J is a 3-7 membered aromatic or non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;
WO 2017/059357
PCT/US2016/054996 z is 0, 1, or 2; and
Ra and R° are independently H or Ci_4alkyl.
3 [0088] In another embodiment, R and R are fluoro.
[0089] In still other embodiments, the compound that inhibits ATR is a compound represented by Formula A-4:
A-4 or a pharmaceutically acceptable salt thereof.
[0090] In yet another embodiment, the compound is an ATR inhibitor selected from a compound described in WO 2013/049726, WO 2013/152298, WO 2013/049859, US-20130089625, US-2013-0115312, US-2014-0107093, US-2013-0096139, WO 2011/143426, US2013-0095193, WO 2014/055756, WO 2011/143419, WO 2011/143422, WO 2011/143425, US-2013-0115311, US-2013-0115312, US-2013-0115313, US-2013-0115314, WO 2011/163527, WO 2012/178123, WO 2012/178124, WO 2012/178125, US-2014-0113005, WO2013/049726, WO 2013/071085, WO 2010/071837, WO 2014/089379, WO 2014/143242, WO 2014/143241, WO 2015/084384, and/or WO 2014/143240. In certain embodiments, the ATR inhibitor is a compound of Formula (A-I) or (A-II). In certain embodiments, the ATR inhibitor is a compound of Formula A-l, A-2, A-3, or A-4.
[0091] In yet another embodiment, the compound is an ATR inhibitor selected from a compound described in WO 2015/187451, WO 2015/085132, WO 2014/062604; WO 2014/143240; WO 2013/071094; WO 2013/071093; WO 2013/071090; WO 2013/071088; WO 2013/049859; WO 2013/049719; WO 2013/049720; WO 2013/049722; WO 2012/138,938; WO 2011/163527; WO 2011/143,423; WO 2011/143,426; WO 2011/143,399; and/or WO 2010/054398.
[0092] In certain embodiments, the compound that inhibits ATR is selected from a compound described in WO 2013/014448. In certain embodiments, the compound that inhibits ATR is AZD-6738.
WO 2017/059357
PCT/US2016/054996 [0093] For purposes of this application, it will be understood that the terms embodiment, example, and aspect are used interchangeably.
[0094] For example, for the purposes of this application, it will be understood that when two occurrences of JQ1, together with Q1, form a bridged ring system, the two occurrences of JQ1 are attached to separate atoms of Q1. Additionally, when two occurrences of JR, together with Q , form a bridged ring system, the two occurrences of J are attached to separate atoms
T 3 of Q . Moreover, when two occurrences of J , together with Q , form a bridged ring system,
T 3 the two occurrence of J are attached to separate atoms of Q . Finally, when two occurrences of J , together with Ring D, form a bridged ring system, the two occurrences of J are attached to separate atoms of Ring D.
[0095] For purposes of this application, it will be understood that the terms ATR, ATR kinase, and ATR protein kinase, as well as an ATR inhibitor and a compound that inhibits ATR, are used interchangeably.
[0096] It will be understood by those skilled in the art that the arrow in -+0 represents a dative bond.
[0097] This application refers to various issued patent, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. [0098] Compounds of this invention include those described generally herein, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, and “March’s Advanced Organic Chemistry”, 5th Ed., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.
[0099] As described herein, a specified number range of atoms includes any integer therein. For example, a group having from 1-4 atoms could have 1, 2, 3, or 4 atoms.
[00100] As described herein, compounds of the invention may optionally be substituted with one or more substituents, such as are illustrated generally herein, or as exemplified by particular classes, subclasses, and species of the invention. It will be appreciated that the phrase “optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted.” In general, the term “substituted”, whether preceded by the term “optionally” or not, refers to the replacement of hydrogen radicals in a given structure with the radical of a
WO 2017/059357
PCT/US2016/054996 specified substituent. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds.
[00101] Unless otherwise indicated, a substituent connected by a bond drawn from the center of a ring means that the substituent can be bonded to any position in the ring. In example i below, for instance, J1 can be bonded to any position on the pyridyl ring. For bicyclic rings, a bond drawn through both rings indicates that the substituent can be bonded from any position of the bicyclic ring. In example ii below, for instance, J1 can be bonded to the 5-membered ring (on the nitrogen atom, for instance), and to the 6-membered ring.
i ii [00102] The term “stable”, as used herein, refers to compounds that are not substantially altered when patiented to conditions to allow for their production, detection, recovery, purification, and use for one or more of the purposes disclosed herein. In some embodiments, a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40°C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
[00103] The term “dative bond”, as used herein, is defined as the coordination bond formed upon interaction between molecular species, one of which serves as a donor and the other as an acceptor of the electron pair to be shared in the complex formed.
[00104] The term “aliphatic” or “aliphatic group”, as used herein, means a straight-chain (i.e., unbranched), branched, or cyclic, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation that has a single point of attachment to the rest of the molecule.
[00105] Unless otherwise specified, aliphatic groups contain 1-20 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-10 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms, and in yet other embodiments aliphatic groups contain 1-4 aliphatic carbon atoms. Aliphatic groups may be
WO 2017/059357
PCT/US2016/054996 linear or branched, substituted or unsubstituted alkyl, alkenyl, or alkynyl groups. Specific examples include, but are not limited to, methyl, ethyl, isopropyl, n-propyl, sec-butyl, vinyl, n-butenyl, ethynyl, and tert-butyl. Aliphatic groups may also be cyclic, or have a combination of linear or branched and cyclic groups. Examples of such types of aliphatic groups include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, -Cfl·cyclopropyl, CH2CH2CH(CH3)-cyclohexyl.
[00106] The term “cycloaliphatic” (or “carbocycle” or “carbocyclyl”) refers to a monocyclic C3-C8 hydrocarbon or bicyclic Cs-Cn hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule wherein any individual ring in said bicyclic ring system has 3-7 members. Examples of cycloaliphatic groups include, but are not limited to, cycloalkyl and cycloalkenyl groups. Specific examples include, but are not limited to, cyclohexyl, cyclopropenyl, and cyclobutyl.
[00107] The term “heterocycle”, “heterocyclyl”, or “heterocyclic” as used herein means nonaromatic, monocyclic, bicyclic, or tricyclic ring systems in which one or more ring members are an independently selected heteroatom. In some embodiments, the “heterocycle”, “heterocyclyl”, or “heterocyclic” group has three to fourteen ring members in which one or more ring members is a heteroatom independently selected from oxygen, sulfur, nitrogen, or phosphorus, and each ring in the system contains 3 to 7 ring members.
[00108] Examples of heterocycles include, but are not limited to, 3-lH-benzimidazol-2-one, 3-(l-alkyl)-benzimidazol-2-one, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 2-morpholino, 3-morpholino, 4-morpholino, 2thiomorpholino, 3-thiomorpholino, 4-thiomorpholino, 1-pyrrolidinyl, 2-pyrrolidinyl, 3pyrrolidinyl, 1-tetrahydropiperazinyl, 2-tetrahydropiperazinyl, 3-tetrahydropiperazinyl, 1piperidinyl, 2-piperidinyl, 3-piperidinyl, 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, 5pyrazolinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2-thiazolidinyl, 3thiazolidinyl, 4-thiazolidinyl, 1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 5imidazolidinyl, indolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzothiolane, benzodithiane, and l,3-dihydro-imidazol-2-one.
[00109] Cyclic groups, (e.g. cycloaliphatic and heterocycles), can be linearly fused, bridged, or spirocyclic.
[00110] The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quatemized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for
WO 2017/059357
PCT/US2016/054996 example N (as in 3,4-dihydro-2//-pyrrolyl), NH (as in pyrrolidinyl) or NR+ (as in Nsubstituted pyrrolidinyl)).
[00111] The term unsaturated, as used herein, means that a moiety has one or more units of unsaturation. As would be known by one of skill in the art, unsaturated groups can be partially unsaturated or fully unsaturated. Examples of partially unsaturated groups include, but are not limited to, butene, cyclohexene, and tetrahydropyridine. Fully unsaturated groups can be aromatic, anti-aromatic, or non-aromatic. Examples of fully unsaturated groups include, but are not limited to, phenyl, cyclooctatetraene, pyridyl, thienyl, and 1methylpyridin-2( lH)-one.
[00112] The term “alkoxy”, or “thioalkyl”, as used herein, refers to an alkyl group, as previously defined, attached through an oxygen (“alkoxy”) or sulfur (“thioalkyl”) atom. [00113] The terms “haloalkyl”, “haloalkenyl”, “haloaliphatic”, and “haloalkoxy” mean alkyl, alkenyl or alkoxy, as the case may be, substituted with one or more halogen atoms. This term includes perfluorinated alkyl groups, such as -CF3 and -CF2CF3.
[00114] The terms “halogen”, “halo”, and “hal” mean F, Cl, Br, or I.
[00115] The term “aryl” used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term “aryl” may be used interchangeably with the term “aryl ring”.
[00116] The term “heteroaryl”, used alone or as part of a larger moiety as in “heteroaralkyl” or “heteroarylalkoxy”, refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic, at least one ring in the system contains one or more heteroatoms, and wherein each ring in the system contains 3 to 7 ring members. The term “heteroaryl” may be used interchangeably with the term “heteroaryl ring” or the term “heteroaromatic”. Examples of heteroaryl rings include, but are not limited to, 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5imidazolyl, benzimidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl,
4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g., 3-pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5thiazolyl, tetrazolyl (e.g., 5-tetrazolyl), triazolyl (e.g., 2-triazolyl and 5-triazolyl), 2-thienyl, 3-thienyl, benzofuryl, benzothiophenyl, indolyl (e.g., 2-indolyl), pyrazolyl (e.g., 2-pyrazolyl), isothiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,3thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, purinyl, pyrazinyl, 1,3,5-triazinyl,
WO 2017/059357
PCT/US2016/054996 quinolinyl (e.g., 2-quinolinyl, 3-quinolinyl, 4-quinolinyl), and isoquinolinyl (e.g., 1isoquinolinyl, 3-isoquinolinyl, or 4-isoquinolinyl).
[00117] It shall be understood that the term “heteroaryl” includes certain types of heteroaryl rings that exist in equilibrium between two different forms. More specifically, for example, species such hydropyridine and pyridinone (and likewise hydroxypyrimidine and pyrimidinone) are meant to be encompassed within the definition of “heteroaryl.”
NH
OH [00118] The term “protecting group” and “protective group” as used herein, are interchangeable and refer to an agent used to temporarily block one or more desired functional groups in a compound with multiple reactive sites. In certain embodiments, a protecting group has one or more, or preferably all, of the following characteristics: a) is added selectively to a functional group in good yield to give a protected substrate that is b) stable to reactions occurring at one or more of the other reactive sites; and c) is selectively removable in good yield by reagents that do not attack the regenerated, deprotected functional group. As would be understood by one skilled in the art, in some cases, the reagents do not attack other reactive groups in the compound. In other cases, the reagents may also react with other reactive groups in the compound. Examples of protecting groups are detailed in Greene, T.W., Wuts, P. G in “Protective Groups in Organic Synthesis”, Third Edition, John Wiley & Sons, New York: 1999 (and other editions of the book), the entire contents of which are hereby incorporated by reference. The term “nitrogen protecting group”, as used herein, refers to an agent used to temporarily block one or more desired nitrogen reactive sites in a multifunctional compound. Preferred nitrogen protecting groups also possess the characteristics exemplified for a protecting group above, and certain exemplary nitrogen protecting groups are also detailed in Chapter 7 in Greene, T.W., Wuts, P. G in “Protective Groups in Organic Synthesis”, Third Edition, John Wiley & Sons, New York: 1999, the entire contents of which are hereby incorporated by reference.
[00119] In some embodiments, a methylene unit of an alkyl or aliphatic chain is optionally replaced with another atom or group. Examples of such atoms or groups include, but are not limited to, nitrogen, oxygen, sulfur, -C(O)-, -C(=N-CN)-, -C(=NR)-, -C(=NOR)-, -SO-, and -SO2-. These atoms or groups can be combined to form larger groups. Examples of such larger groups include, but are not limited to, -OC(O)-, -C(O)CO-, -CO2-, -C(O)NR-, -C(=N39
WO 2017/059357
PCT/US2016/054996
CN), -NRCO-, -NRC(O)O-, -SO2NR-, -NRSO2-, -NRC(O)NR-, -OC(O)NR-, and -NRSO2NR-, wherein R is, for example, H or C ^aliphatic. It should be understood that these groups can be bonded to the methylene units of the aliphatic chain via single, double, or triple bonds. An example of an optional replacement (nitrogen atom in this case) that is bonded to the aliphatic chain via a double bond would be -CH2CH=N-CH3. In some cases, especially on the terminal end, an optional replacement can be bonded to the aliphatic group via a triple bond. One example of this would be CH2CH2CH2C=N. It should be understood that in this situation, the terminal nitrogen is not bonded to another atom.
[00120] It should also be understood that, the term “methylene unit” can also refer to branched or substituted methylene units. For example, in an isopropyl moiety [-CH(CH3)2], a nitrogen atom (e.g. NR) replacing the first recited “methylene unit” would result in dimethylamine [-N(CH3)2]. In instances such as these, one of skill in the art would understand that the nitrogen atom will not have any additional atoms bonded to it, and the “R” from “NR” would be absent in this case.
[00121] Unless otherwise indicated, the optional replacements form a chemically stable compound. Optional replacements can occur both within the chain and/or at either end of the chain; i.e. both at the point of attachment and/or also at the terminal end. Two optional replacements can also be adjacent to each other within a chain so long as it results in a chemically stable compound. For example, a C3 aliphatic can be optionally replaced by 2 nitrogen atoms to form -C-N=N. The optional replacements can also completely replace all of the carbon atoms in a chain. For example, a C3 aliphatic can be optionally replaced by -NR-, -C(O)-, and -NR- to form -NRC(O)NR- (a urea).
[00122] Unless otherwise indicated, if the replacement occurs at the terminal end, the replacement atom is bound to a hydrogen atom on the terminal end. For example, if a methylene unit of -CH2CH2CH3 were optionally replaced with -O-, the resulting compound could be -OCH2CH3, -CH2OCH3, or -CH2CH2OH. It should be understood that if the terminal atom does not contain any free valence electrons, then a hydrogen atom is not required at the terminal end (e.g., -CH2CH2CH=O or -CH2CH2C=N).
[00123] Unless otherwise indicated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, geometric, conformational, and rotational) forms of the structure. For example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers are included in this invention. As would be understood to one skilled in the art, a substituent can freely rotate
WO 2017/059357
PCT/US2016/054996 ιΛΛ/V around any rotatable bonds. For example, a substituent drawn as \AAZV also represents [00124] Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, geometric, conformational, and rotational mixtures of the present compounds are within the scope of the invention.
[00125] Unless otherwise indicated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
[00126] Additionally, unless otherwise indicated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools or probes in biological assays.
[00127] The compounds disclosed herein can be prepared by any suitable methods known in the art, for example, WO 2015/187451, WO 2015/085132, WO 2014/062604; WO 2014/143240; WO 2013/071094; WO 2013/071093; WO 2013/071090; WO 2013/071088; WO 2013/049859; WO 2013/049719; WO 2013/049720; WO 2013/049722; WO 2012/138,938; WO 2011/163527; WO 2011/143,423; WO 2011/143,426; WO 2011/143,399; WO 2010/054398; WO 2013/049726, WO 2013/152298, WO 2013/049859, US-20130089625, US-2013-0115312, US-2014-0107093, US-2013-0096139, WO 2011/143426, US2013-0095193, WO 2014/055756, WO 2011/143419, WO 2011/143422, WO 2011/143425, US-2013-0115311, US-2013-0115312, US-2013-0115313, US-2013-0115314, WO 2011/163527, WO 2012/178123, WO 2012/178124, WO 2012/178125, US-2014-0113005, WO2013/049726, WO 2013/071085, WO 2010/071837, WO 2014/089379, WO 2014/143242, WO 2014/143241, WO 2015/084384, and/or WO 2014/143240.
DNA Damaging Agents [00128] In some aspects of the present disclosure, the DNA damaging agent is radiation therapy. In certain embodiments, the DNA-damaging agent comprises chemotherapy. In certain embodiments, the ATR inhibitor is a compound of Formula A-l, a compound of
WO 2017/059357
PCT/US2016/054996
Formula A-2, a compound of Formula A-3, a compound of Formula A-4, or AZD-6738, and the DNA-damaging agent is radiation or chemotherapy.
[00129] In certain embodiments, the DNA damaging agent comprises radiation therapy. Examples of radiation therapy include, but are not limited to, ionizing radiation, gammaradiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, systemic radioactive isotopes and radiosensitizers. Radiosensitizers work in various different ways, including, but not limited to, making cancer cells more sensitive to radiation, working in synergy with radiation to provide an improved synergistic effect, acting additively with radiation, or protecting surrounding healthy cells from damage caused by radiation.
[00130] In certain embodiments, the DNA-damaging agent comprises chemotherapy. Examples of chemotherapy include, but are not limited to, platinating agents, such as Carboplatin, Oxaliplatin, Cisplatin, Nedaplatin, Satraplatin, Lobaplatin, Triplatin, Tetranitrate, Picoplatin, Prolindac, Aroplatin and other derivatives; topo I inhibitors, such as Camptothecin, Topotecan, irinotecan/SN38, rubitecan, Belotecan, and other derivatives; topo II inhibitors, such as Etoposide (VP-16), Daunorubicin, Doxorubicin, Mitoxantrone, Aclarubicin, Epirubicin, Idarubicin, Amrubicin, Amsacrine, Pirarubicin, Valrubicin, Zorubicin, Teniposide and other derivatives; antimetabolites, such as Folic family (Methotrexate, Pemetrexed, Raltitrexed, Aminopterin, and relatives); Purine antagonists (Thioguanine, Fludarabine, Cladribine, 6-Mercaptopurine, Pentostatin, clofarabine and relatives) and Pyrimidine antagonists (Cytarabine, Floxuridine, Azacitidine, Tegafur, Carmofur, Capacitabine, Gemcitabine, hydroxyurea, 5-Fluorouracil(5FU), and relatives); alkylating agents, such as Nitrogen mustards (e.g., Cyclophosphamide, Melphalan, Chlorambucil, mechlorethamine, Ifosfamide, mechlorethamine, Trofosfamide, Prednimustine, Bendamustine, Uramustine, Estramustine, and relatives); nitrosoureas (e.g., Carmustine, Lomustine, Semustine, Fotemustine, Nimustine, Ranimustine, Streptozocin, and relatives); Triazenes (e.g., Dacarbazine, Altretamine, Temozolomide, and relatives); Alkyl sulphonates (e.g., Busulfan, Mannosulfan, Treosulfan, and relatives); Procarbazine; Mitobronitol, and Aziridines (e.g., Carboquone, Triaziquone, ThioTEPA, triethylenemalamine, and relatives); antibiotics, such as Hydroxyurea, Anthracyclines (e.g., doxorubicin, daunorubicin, epirubicin and other derivatives); Anthracenediones (e.g, Mitoxantrone and relatives); antibiotics from the Streptomyces family (e.g., Bleomycin, Mitomycin C, Actinomycin, Plicamycin); and ultraviolet light.
WO 2017/059357
PCT/US2016/054996 [00131] In certain embodiments, the ATR inhibitor is a compound of Formula A-l, compound of Formula A-2, compound of Formula A-3, compound of Formula A-4, or AZD6738, and the DNA damaging agent comprises chemotherapy. In certain embodiments, the ATR inhibitor is a compound of Formula A-l, a compound of Formula A-2, a compound of Formula A-3, a compound of Formula A-4, or AZD-6738 and the DNA damaging agent comprises a platinating agent (e.g., cisplatin, carboplatin). In certain embodiments, the ATR inhibitor is a compound of Formula A-l, a compound of Formula A-2, a compound of Formula A-3, a compound of Formula A-4, or AZD-6738 and the DNA damaging agent comprises a antimetabolite (e.g., gemcitabine). In certain embodiments, the ATR inhibitor is a compound of Formula A-2 and the DNA damaging agent is cisplatin or gemcitabine. [00132] In certain embodiments, the ATR inhibitor is a compound of Formula A-l and the DNA damaging agent is cisplatin or gemcitabine. In certain embodiments, the ATR inhibitor is a compound of Formula A-2 and the DNA damaging agent is cisplatin or gemcitabine. In certain embodiments, the ATR inhibitor is a compound of Formula A-3 and the DNA damaging agent is cisplatin or gemcitabine. In certain embodiments, the ATR inhibitor is a compound of Formula A-4 and the DNA damaging agent is cisplatin or gemcitabine. In certain embodiments, the ATR inhibitor is AZD-6738 and the DNA damaging agent is cisplatin or gemcitabine.
[00133] In certain embodiments, the ATR inhibitor is a compound of Formula A-l and the DNA damaging agent is carboplatin or gemcitabine. In certain embodiments, the ATR inhibitor is a compound of Formula A-2 and the DNA damaging agent is carboplatin or gemcitabine. In certain embodiments, the ATR inhibitor is a compound of Formula A-3 and the DNA damaging agent is carboplatin or gemcitabine. In certain embodiments, the ATR inhibitor is a compound of Formula A-4 and the DNA damaging agent is carboplatin or gemcitabine. In certain embodiments, the ATR inhibitor is AZD-6738 and the DNA damaging agent is carboplatin or gemcitabine.
Dosages of DNA Damaging Agent and ATR Inhibitor [00134] In general, any effective dose of an ATR inhibitor and DNA damaging agent may be administered. In some embodiments, an ATR inhibitor (e.g., a compound of Formula A2) when used in a combination therapy with a DNA-damaging agent, as described herein, may be administered at a dosage of between about 50 mg/m and about 300 mg/m , between
2 2 2 about 50 mg/m and about 240 mg/m , between about 60 mg/m and about 240 mg/m ,
2 2 between about 60 mg/m and about 180 mg/m , between about 60 mg/m and about 120
WO 2017/059357
PCT/US2016/054996
2 2 2 mg/m , between about 80 mg/m and about 120 mg/m , between about 90 mg/m and about
2 2
120 mg/m , or between about 80 mg/m and about 100 mg/m . In certain embodiments, an
ATR inhibitor may be administered at a dosage between about 50 mg/m and about 300
2 mg/m (e.g., about 240 mg/m ). In some instances, an ATR inhibitor may be administered at
2 2 a dosage between about 60 mg/m and about 180 mg/m (e.g., 120 mg/m ). In certain cases, an ATR inhibitor may be administered at a dosage between about 80 mg/m and about 100
2 mg/m (e.g., about 90 mg/m ). In some embodiments, ATR inhibitor (e.g., a compound of Formula A-2) may be administered at a dosage of about 90 mg/m or about 120 mg/m . [00135] In some embodiments, a platinating agent (e.g., carboplatin) when used in a combination therapy with an ATR inhibitor (e.g., a compound of Formula A-2), as described herein, may be administered at a target AUC of between about 3 mg/mL*min and about 6 mg/mL*min, between about 3.5 mg/mL*min and about 6 mg/mL*min, between about 4 mg/mL*min and about 6 mg/mL*min, between about 4 mg/mL*min and about 5.5 mg/mL*min, or between about 4 mg/mL*min and about 5 mg/mL*min. In some embodiments, a platinating agent (e.g., carboplatin) may be administered at a target AUC of between about 3 mg/mL*min and about 6 mg/mL*min. In certain embodiments, a platinating agent (e.g., carboplatin) may be administered with at a target AUC of between about 4 mg/mL*min and about 5 mg/mL*min. As used herein, the term “target AUC” refers the target area under the plasma concentration versus time curve. The term “AUC” refers the area under the plasma concentration versus time curve. The dosage of certain DNA damaging agents, such as carboplatin, may be determined from the drug label information. For example, the dosage in mg of carboplatin may be determined from the target AUC based on mathematical formula, which is based on a patient’s pre-existing renal function or renal function and desired platelet nadir. The Calvert formula, shown below, is used to calculate dosage in milligrams, based upon a patient’s glomerular filtration rate (GFR in mL/min) and carboplatin target area under the concentration versus time curve (AUC in mg/mL*min). GFR may be measured using 51Cr-EDTA clearance or may be estimated using methods known to ordinary skill in the art.
Total Dose (mg) = (target AUC) x (GFR + 25) [00136] It should be understood that all combinations of the above-referenced ranges for dosage of ATR inhibitor and dosage of a DNA damaging agent for use in a combination therapy, as described herein, may be possible. For instance, in some embodiments, a platinating agent (e.g., carboplatin) may be administered with at a target AUC of between
WO 2017/059357
PCT/US2016/054996 about 3 mg/mL*min and about 6 mg/mL*min (e.g., between about 4 mg/mL*min and about 6 mg/mL*min, between about 4 mg/mL*min and about 5 mg/mL*min) and an ATR inhibitor (e.g., a compound of Formula A-2) may be administered with at a dosage between about 50 mg/m and about 300 mg/m (e.g., between about 60 mg/m and about 180 mg/m , between about 80 mg/m2 and about 100 mg/m2).
[00137] In certain embodiments, a platinating agent (e.g., carboplatin) may be administered with at a target AUC of between about 3 mg/mL*min and about 6 mg/mL*min (e.g., between about 4 mg/mL*min and about 6 mg/mL*min) and an ATR inhibitor (e.g., a compound of Formula A-2) may be administered with at a dosage between about 60 mg/m and about 180 mg/m (e.g., about 90 mg/m , about 120 mg/m ). In one example, a method of treating a proliferative disorder (e.g., ovarian, lung, colorectal) may comprise administering a platinating agent (e.g., carboplatin) at a target AUC of between about 4 mg/mL*min and about 5 mg/mL*min on day 1, a dose of between about 90 mg/m and about 120 mg/m of a first dose of ATR inhibitor (e.g., a compound of Formula A-2) on day 2 between about 20 hours and about 28 hours (e.g., about 24 hours or 24 hours + 2 hours) after administration of the platinating agent, and a second dose of the ATR inhibitor between about 6 days and about 8 days (e.g., on day 9) after the first dose. Such a treatment method may lead to at least a RECIST partial response and/or may decrease the sum of the longest diameter of target lesions, decrease the sum of the longest diameter of non-target lesions, and/or decrease tumor burden by between about 20% and about 60%, or between about 40% and about 60%. In some such embodiments, the proliferative disorder (e.g., ovarian cancer, lung cancer, colorectal cancer, breast cancer) may have a defect in ATM signaling (e.g., mutation in p53, partial loss of ATM signaling, complete loss of ATM signaling).
[00138] In other embodiments in which the ATR inhibitor (e.g., a compound of Formula A2) is administered as a monotherapy or a combination therapy with a DNA-damaging agent, as described herein, said ATR inhibitor (e.g., a compound of Formula A-2) may be administered at a dosage of between about 50 mg/m and about 500 mg/m , between about
2 2 2
100 mg/m and about 500 mg/m , between about 120 mg/m and about 500 mg/m , between
2 2 2 about 240 mg/m and about 480 mg/m , between about 50 mg/m and about 480 mg/m ,
2 2 between about 50 mg/m and about 300 mg/m , between about 50 mg/m and about 240 mg/m , or between about 50 mg/m and about 120 mg/m . In some embodiments, said ATR inhibitor (e.g., a compound of Formula A-2) may be administered at a dosage of about 60 mg/m , about 120 mg/m , about 240 mg/m , or 480 mg/m . In some embodiments, said ATR inhibitor (e.g., a compound of Formula A-2) may be administered at a dosage of about 240
WO 2017/059357
PCT/US2016/054996
2 mg/m or about 480 mg/m as a monotherapy. In some embodiments, said ATR inhibitor is Compound A-2. In some embodiments, Compound A-2 is administered at a dosage of about 240 mg/m as a monotherapy. In some embodiments, Compound A-2 is administered at a dosage of about 240 mg/m as a monotherapy once weekly or twice weekly.
[00139] In some embodiments, cisplatin is used in a combination therapy with a compound of Formula A-2, wherein the dosage of cisplatin is at between about 30 and about 90 mg/m , between about 40 and about 75 mg/m , or between about 60 and about 90 mg/m , and wherein the dosage of the compound of Formula A-2 is between about 60 mg/m and
2 2 2 about 240 mg/m , between about 120 mg/m and 160 mg/m , or between about 90 mg/m and
2 about 210 mg/m . In some specific embodiments, the dosage of cisplatin is at 40 mg/m , 60
2 mg/m , or 75 mg/m . In some specific embodiments, the dosage of a compound of Formula
2 2
A-2 is about 90 mg/m , 140 mg/m , or 210 mg/m . In some specific embodiments, the dosage of cisplatin is at between about 30 and about 90 mg/m , and the dosage of the
2 compound of Formula A-2 is between about 60 mg/m and about 240 mg/m . In some specific embodiments, the dosage of cisplatin is at between about 40 and about 75 mg/m , and the dosage of a compound of Formula A-2 is between about 90 mg/m and 210 mg/m . In some specific embodiments, the dosage of cisplatin is at between about 60 and about 90 mg/m , and the dosage of the compound of Formula A-2 is between about 120 mg/m and
2
160 mg/m . In some specific embodiments, the dosage of cisplatin is at about 75 mg/m , and the dosage of the compound of Formula A-2 is about 140 mg/m .
[00140] In some embodiments, gemcitabine is used in a combination therapy with a compound of Formula A-2, wherein the dosage of gemcitabine is between about 300 and about 1200 mg/m , between about 875 mg/m and 1125 mg/m , or between about 500 mg/m and about 1000 mg/m , and wherein the dosage of the compound of Formula A-2 is between
2 2 2 about 10 mg/m and about 240 mg/m , between about 18 mg/m and 210 mg/m , or between
2 about 180 mg/m and 240 mg/m . In some specific embodiments, gemcitabine may be
2 2 2 administered at 500 mg/m , 750 mg/m , 875 mg/m , or 1000 mg/m . In some specific
2 embodiments, the dosage of the compound of Formula A-2 is about 18 mg/m , 36 mg/m , 60
2 2 2 2 mg/m , 72 mg/m , 90 mg/m , 140 mg/m , or 210 mg/m . In some specific embodiments, the dosage of gemcitabine is between about 300 and about 1200 mg/m , and the dosage of a compound of Formula A-2 is between about 10 mg/m and about 240 mg/m . In some specific embodiments, the dosage of gemcitabine is between about 500 and about 1000 mg/m , and the dosage of the compound of Formula A-2 is between about 18 mg/m and about 210 mg/m . In some specific embodiments, the dosage of gemcitabine is between
WO 2017/059357
PCT/US2016/054996
2 about 875 mg/m and about 1125 mg/m , and the dosage of the compound of Formula A-2 is
2 between about 180 mg/m and about 240 mg/m . In some specific embodiments, the dosage of gemcitabine is about 1000 mg/m , and the dosage of the compound of Formula A-2 is about 210 mg/m2.
[00141] In some embodiments, gemcitabine and cisplatin are used in a combination therapy with a compound of Formula A-2, wherein the dosage of gemcitabine is between about 300 and about 1200 mg/m , between about 500 mg/m and 1,000 mg/m , or between
2 about 700 mg/m and about 1,000 mg/m , and wherein the dosage of the compound of
2 2
Formula A-2 is between about 10 mg/m and about 250 mg/m , between about 30 mg/m and
2 2 2
250 mg/m , or between about 50 mg/m and 200 mg/m , or between about 80 mg/m and 200
2 2 mg/m , and wherein the dosage of cisplatin is between about 30 mg/m and 90 mg/m , or
2 between about 50 mg/m and 90 mg/m . In some specific embodiments, gemcitabine may be
2 2 2 administered at 500 mg/m , 750 mg/m , 875 mg/m , or 1000 mg/m . In some specific
2 embodiments, the dosage of the compound of Formula A-2 is about 18 mg/m , 36 mg/m , 60
2 2 2 2 mg/m , 72 mg/m , 90 mg/m , 140 mg/m , or 210 mg/m . In some specific embodiments, the
2 2 2 2 dosage of cisplatin is about 40 mg/m , 60 mg/m , 75 mg/m , 90 mg/m , 140 mg/m , or 210 mg/m . In some specific embodiments, the dosage of gemcitabine is between about 500 and
2 about 1000 mg/m ; the dosage of the compound of Formula A-2 is between about 60 mg/m and about 210 mg/m ; and the dosage of cisplatin is between about 50 mg/m and about 90
2 mg/m . In some specific embodiments, the dosage of gemcitabine is about 875 mg/m ; the dosage of the compound of Formula A-2 is about 90 mg/m ; and the dosage of cisplatin is about 60 mg/m .
Biomarkers [00142] In some embodiments, one or more biomarkers may be used to monitor or determine the efficacy of the treatment. In certain embodiments, the percentage of phosphorylated Chkl (i.e., pChkl) in paired samples may be used as a biomarker; pChkl is believed to correlate with the level of ATR activity. For instance, in some embodiments, the amount of pChkl in the nuclei of cancer cells/mm of a tumor biopsy may be used to determine the efficacy of monotherapy with an ATR inhibitor or combination therapy including an ATR inhibitor in a subject. In some such embodiments, a first tumor biopsy may be taken between about one to about three hours (e.g., two hours) before administration of the ATR inhibitor and a second tumor biopsy may be taken between about one to about three hours (e.g., two hours) after administration of the ATR inhibitor. The amount of pChkl
WO 2017/059357
PCT/US2016/054996 in the nuclei of cancer cells/mm tumor in the first biopsy is set to be 100%, such that the amount of pChkl in the nuclei of cancer cells/mm tumor in the second biopsy is normalized by the amount in the first biopsy.
[00143] In some embodiments, a method of treating a proliferative disorder comprising administering a platinating agent (e.g., carboplatin) at a target AUC of between about 4 mg/mL*min and about 5 mg/mL*min on day 1, a dose of between about 90 mg/m and about 120 mg/m of a first dose of a ATR inhibitor (e.g., a compound of Formula A-2) between about 20 hours and about 28 hours (e.g., about 24 hours or 24 hours + 2 hours) after administration of the platinating agent on day 1, and a second dose of the ATR inhibitor between about 6 days and about 8 days (e.g., on day 9) after the first dose, may substantially reduce the percentage of pChkl in the nuclei of cancer cells/mm . In some such embodiments, the percentage of pChkl in the nuclei of cancer cells/mm may be less than about 40%, less than about 30%, less than about 20%, or less than about 10% between about one to about three hours (e.g., two hours) after administration of the ATR inhibitor.
[00144] In some embodiments, certain cancer specific biomarkers may be used to monitor or determine the efficacy of the treatment. For instance, CA125 ovarian cancer tumor burden marker may be used to assess treatment of ovarian cancer with monotherapy or with combination therapy including an ATR inhibitor and a DNA damaging agent.
[00145] In some embodiments, certain treatment related adverse events in a subject may be used as biomarkers to monitor or determine the efficacy of the treatment. In certain embodiments, an adverse event may be indicative of the mechanism of action of the ATR inhibitor in a combination therapy. For example, the presence of neutropenia and thrombocytopenia may be used as biomarkers.
Pharmaceutically Acceptable Salts, Solvates, Chlatrates, Prodrugs and Other Derivatives [00146] The compounds described herein can exist in free form, or, where appropriate, as salts. Those salts that are pharmaceutically acceptable are of particular interest since they are useful in administering the compounds described below for medical purposes. Salts that are not pharmaceutically acceptable are useful in manufacturing processes, for isolation and purification purposes, and in some instances, for use in separating stereoisomeric forms of the compounds of the invention or intermediates thereof.
[00147] As used herein, the term pharmaceutically acceptable salt refers to salts of a compound which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue side effects, such as, toxicity,
WO 2017/059357
PCT/US2016/054996 irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
[00148] Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds described herein include those derived from suitable inorganic and organic acids and bases. These salts can be prepared in situ during the final isolation and purification of the compounds.
[00149] Where the compound described herein contains a basic group, or a sufficiently basic bioisostere, acid addition salts can be prepared by 1) reacting the purified compound in its free-base form with a suitable organic or inorganic acid and 2) isolating the salt thus formed. In practice, acid addition salts might be a more convenient form for use and use of the salt amounts to use of the free basic form.
[00150] Examples of pharmaceutically acceptable, non-toxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, glycolate, gluconate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.
[00151] Where the compound described herein contains a carboxy group or a sufficiently acidic bioisostere, base addition salts can be prepared by 1) reacting the purified compound in its acid form with a suitable organic or inorganic base and 2) isolating the salt thus formed.
In practice, use of the base addition salt might be more convenient and use of the salt form inherently amounts to use of the free acid form. Salts derived from appropriate bases include alkali metal (e.g., sodium, lithium, and potassium), alkaline earth metal (e.g., magnesium and calcium), ammonium and N+(Ci_4alkyl)4 salts. This invention also envisions the
WO 2017/059357
PCT/US2016/054996 quatemization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quatemization.
[00152] Basic addition salts include pharmaceutically acceptable metal and amine salts. Suitable metal salts include the sodium, potassium, calcium, barium, zinc, magnesium, and aluminum. The sodium and potassium salts are usually preferred. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate. Suitable inorganic base addition salts are prepared from metal bases, which include sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminium hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide and the like. Suitable amine base addition salts are prepared from amines which are frequently used in medicinal chemistry because of their low toxicity and acceptability for medical use. Ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N, N’-dibenzylethylenediamine, chloroprocaine, dietanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, triethylamine, dibenzylamine, ephenamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, ethylamine, basic amino acids, dicyclohexylamine and the like are examples of suitable base addition salts.
[00153] Other acids and bases, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds described herein and their pharmaceutically acceptable acid or base addition salts.
[00154] It should be understood that this invention includes mixtures/combinations of different pharmaceutically acceptable salts and also mixtures/combinations of compounds in free form and pharmaceutically acceptable salts.
[00155] The compounds described herein can also exist as pharmaceutically acceptable solvates (e.g., hydrates) and clathrates. As used herein, the term “pharmaceutically acceptable solvate,” is a solvate formed from the association of one or more pharmaceutically acceptable solvent molecules to one of the compounds described herein. The term solvate includes hydrates (e.g., hemihydrate, monohydrate, dihydrate, trihydrate, tetrahydrate, and the like).
[00156] As used herein, the term “hydrate” means a compound described herein or a salt thereof that further includes a stoichiometric or non-stoichiometric amount of water bound by
WO 2017/059357
PCT/US2016/054996 non-covalent intermolecular forces.
[00157] As used herein, the term “clathrate” means a compound described herein or a salt thereof in the form of a crystal lattice that contains spaces (e.g., channels) that have a guest molecule (e.g., a solvent or water) trapped within.
[00158] In addition to the compounds described herein, pharmaceutically acceptable derivatives or prodrugs of these compounds may also be employed in compositions to treat or prevent the herein identified disorders.
[00159] A “pharmaceutically acceptable derivative or prodrug” includes any pharmaceutically acceptable ester, salt of an ester, or other derivative or salt thereof of a compound described herein which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound described herein or an inhibitorily active metabolite or residue thereof. Particularly favoured derivatives or prodrugs are those that increase the bioavailability of the compounds when such compounds are administered to a patient (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.
[00160] As used herein and unless otherwise indicated, the term “prodrug” means a derivative of a compound that can hydrolyze, oxidize, or otherwise react under biological conditions (in vitro or in vivo) to provide a compound described herein. Prodrugs may become active upon such reaction under biological conditions, or they may have activity in their unreacted forms. Examples of prodrugs contemplated in this invention include, but are not limited to, analogs or derivatives of compounds of the invention that comprise biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues. Other examples of prodrugs include derivatives of compounds described herein that comprise -NO, -NO2, -ONO, or -ONO2 moieties. Prodrugs can typically be prepared using well-known methods, such as those described by Burger’s Medicinal Chemistry and Drug Discovery (1995) 172-178, 949-982 (Manfred E. Wolff ed., 5th ed).
Therapeutic Uses [00161] The present disclosure provides a method of treating diseases, disorders, and conditions characterized by excessive or abnormal cell proliferation, including proliferative or hyperproliferative diseases, in a subject. A “proliferative disease” refers to a disease that
WO 2017/059357
PCT/US2016/054996 occurs due to abnormal growth or extension by the multiplication of cells (Walker,
Cambridge Dictionary of Biology, Cambridge University Press: Cambridge, UK, 1990). A proliferative disease may be associated with: 1) the pathological proliferation of normally quiescent cells; 2) the pathological migration of cells from their normal location (e.g., metastasis of neoplastic cells); 3) the pathological expression of proteolytic enzymes such as the matrix metalloproteinases (e.g., collagenases, gelatinases, and elastases); or 4) the pathological angiogenesis as in proliferative retinopathy and tumor metastasis. Exemplary proliferative diseases include cancers (z.e., “malignant neoplasms”), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases.
[00162] The term “angiogenesis” refers to the physiological process through which new blood vessels form from pre-existing vessels. Angiogenesis is distinct from vasculogenesis, which is the de novo formation of endothelial cells from mesoderm cell precursors. The first vessels in a developing embryo form through vasculogenesis, after which angiogenesis is responsible for most blood vessel growth during normal or abnormal development. Angiogenesis is a vital process in growth and development, as well as in wound healing and in the formation of granulation tissue. However, angiogenesis is also a fundamental step in the transition of tumors from a benign state to a malignant one, leading to the use of angiogenesis inhibitors in the treatment of cancer. Angiogenesis may be chemically stimulated by angiogenic proteins, such as growth factors (e.g., VEGF). “Pathological angiogenesis” refers to abnormal (e.g., excessive or insufficient) angiogenesis that amounts to and/or is associated with a disease.
[00163] The terms “neoplasm” and “tumor” are used herein interchangeably and refer to an abnormal mass of tissue wherein the growth of the mass surpasses and is not coordinated with the growth of a normal tissue. A neoplasm or tumor may be “benign” or “malignant,” depending on the following characteristics: degree of cellular differentiation (including morphology and functionality), rate of growth, local invasion, and metastasis. A “benign neoplasm” is generally well differentiated, has characteristically slower growth than a malignant neoplasm, and remains localized to the site of origin. In addition, a benign neoplasm does not have the capacity to infiltrate, invade, or metastasize to distant sites. Exemplary benign neoplasms include, but are not limited to, lipoma, chondroma, adenomas, acrochordon, senile angiomas, seborrheic keratoses, lentigos, and sebaceous hyperplasias. In some cases, certain “benign” tumors may later give rise to malignant neoplasms, which may result from additional genetic changes in a subpopulation of the tumor’s neoplastic cells, and these tumors are referred to as “pre-malignant neoplasms.” An exemplary pre-malignant
WO 2017/059357
PCT/US2016/054996 neoplasm is a teratoma. In contrast, a “malignant neoplasm” is generally poorly differentiated (anaplasia) and has characteristically rapid growth accompanied by progressive infiltration, invasion, and destruction of the surrounding tissue. Furthermore, a malignant neoplasm generally has the capacity to metastasize to distant sites. The term “metastasis,” “metastatic,” or “metastasize” refers to the spread or migration of cancerous cells from a primary or original tumor to another organ or tissue and is typically identifiable by the presence of a “secondary tumor” or “secondary cell mass” of the tissue type of the primary or original tumor and not of that of the organ or tissue in which the secondary (metastatic) tumor is located. For example, a prostate cancer that has migrated to bone is said to be metastasized prostate cancer and includes cancerous prostate cancer cells growing in bone tissue.
[00164] The term “cancer” refers to a class of diseases characterized by the development of abnormal cells that proliferate uncontrollably and have the ability to infiltrate and destroy normal body tissues. See, e.g., Stedman’s Medical Dictionary, 25th ed.; Hensyl ed.; Williams & Wilkins: Philadelphia, 1990. Exemplary cancers include, but are not limited to, hematological malignancies. The term “hematological malignancy” refers to tumors that affect blood, bone marrow, and/or lymph nodes. Exemplary hematological malignancies include, but are not limited to, leukemia, such as acute lymphocytic leukemia (ALL) (e.g., Bcell ALL, T-cell ALL), acute myelocytic leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myelocytic leukemia (CML) (e.g., B-cell CML, T-cell CML), and chronic lymphocytic leukemia (CLL) (e.g., B-cell CLL, T-cell CLL)); lymphoma, such as Hodgkin lymphoma (HL) (e.g., B-cell HL, T-cell HL) and non-Hodgkin lymphoma (NHL) (e.g., Bcell NHL, such as diffuse large cell lymphoma (DLCL) (e.g., diffuse large B-cell lymphoma (DLBCL, e.g., activated B-cell (ABC) DLBCL (ABC-DLBCL))), follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphoma (e.g., mucosa-associated lymphoid tissue (MALT) lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt lymphoma, Waldenstrom’s macroglobulinemia (WM, lymphoplasmacytic lymphoma), hairy cell leukemia (HCL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, central nervous system (CNS) lymphoma (e.g., primary CNS lymphoma and secondary CNS lymphoma); and T-cell NHL, such as precursor T-lymphoblastic lymphoma/leukemia, peripheral T-cell lymphoma (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (e.g., mycosis fungoides, Sezary syndrome), angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathy type T-cell lymphoma, subcutaneous panniculitis-like T-cell
WO 2017/059357
PCT/US2016/054996 lymphoma, and anaplastic large cell lymphoma); lymphoma of an immune privileged site (e.g., cerebral lymphoma, ocular lymphoma, lymphoma of the placenta, lymphoma of the fetus, testicular lymphoma); a mixture of one or more leukemia/lymphoma as described above; myelodysplasia; and multiple myeloma (MM). Additional exemplary cancers include, but are not limited to, lung cancer (e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung); kidney cancer (e.g., nephroblastoma, a.k.a. Wilms’ tumor, renal cell carcinoma); acoustic neuroma; adenocarcinoma; adrenal gland cancer; anal cancer; angiosarcoma (e.g., lymphangiosarcoma, lymphangioendotheliosarcoma, hemangiosarcoma); appendix cancer; benign monoclonal gammopathy; biliary cancer (e.g., cholangiocarcinoma); bladder cancer; breast cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast); brain cancer (e.g., meningioma, glioblastomas, glioma (e.g., astrocytoma, oligodendroglioma), medulloblastoma); bronchus cancer; carcinoid tumor; cervical cancer (e.g., cervical adenocarcinoma); choriocarcinoma; chordoma; craniopharyngioma; colorectal cancer (e.g., colon cancer, rectal cancer, colorectal adenocarcinoma); connective tissue cancer; epithelial carcinoma; ependymoma; endotheliosarcoma (e.g., Kaposi’s sarcoma, multiple idiopathic hemorrhagic sarcoma); endometrial cancer (e.g., uterine cancer, uterine sarcoma); esophageal cancer (e.g., adenocarcinoma of the esophagus, Barrett’s adenocarcinoma); Ewing’s sarcoma; ocular cancer (e.g., intraocular melanoma, retinoblastoma); familiar hypereosinophilia; gall bladder cancer; gastric cancer (e.g., stomach adenocarcinoma); gastrointestinal stromal tumor (GIST); germ cell cancer; head and neck cancer (e.g., head and neck squamous cell carcinoma, oral cancer (e.g., oral squamous cell carcinoma), throat cancer (e.g., laryngeal cancer, pharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer)); heavy chain disease (e.g., alpha chain disease, gamma chain disease, mu chain disease; hemangioblastoma; hypopharynx cancer; inflammatory myofibroblastic tumors; immunocytic amyloidosis; liver cancer (e.g., hepatocellular cancer (HCC), malignant hepatoma); leiomyosarcoma (LMS); mastocytosis (e.g., systemic mastocytosis); muscle cancer; myelodysplastic syndrome (MDS); mesothelioma; myeloproliferative disorder (MPD) (e.g., polycythemia vera (PV), essential thrombocytosis (ET), agnogenic myeloid metaplasia (AMM) a.k.a. myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myelocytic leukemia (CMF), chronic neutrophilic leukemia (CNF), hypereosinophilic syndrome (HES)); neuroblastoma; neurofibroma (e.g., neurofibromatosis (NF) type 1 or type 2, schwannomatosis); neuroendocrine cancer (e.g., gastroenteropancreatic neuroendoctrine tumor (GEP-NET), carcinoid tumor, neuroendocrine
WO 2017/059357
PCT/US2016/054996 prostate); osteosarcoma (e.g.,bone cancer); ovarian cancer (e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma); papillary adenocarcinoma; pancreatic cancer (e.g., pancreatic andenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), Islet cell tumors); penile cancer (e.g., Paget’s disease of the penis and scrotum); pinealoma; primitive neuroectodermal tumor (PNT); plasma cell neoplasia; paraneoplastic syndromes; intraepithelial neoplasms; prostate cancer (e.g., prostate adenocarcinoma); rectal cancer; rhabdomyosarcoma; salivary gland cancer; skin cancer (e.g., squamous cell carcinoma (SCC), keratoacanthoma (KA), melanoma, basal cell carcinoma (BCC)); small bowel cancer (e.g., appendix cancer); soft tissue sarcoma (e.g., malignant fibrous histiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor (MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma); sebaceous gland carcinoma; small intestine cancer; sweat gland carcinoma; synovioma; testicular cancer (e.g., seminoma, testicular embryonal carcinoma); thyroid cancer (e.g., papillary carcinoma of the thyroid, papillary thyroid carcinoma (PTC), medullary thyroid cancer); urethral cancer; vaginal cancer; adenoid cystic carcinoma; and vulvar cancer (e.g., Paget’s disease of the vulva).
[00165] The term “inflammatory disease” refers to a disease caused by, resulting from, or resulting in inflammation. The term “inflammatory disease” may also refer to a dysregulated inflammatory reaction that causes an exaggerated response by macrophages, granulocytes, and/or T-lymphocytes leading to abnormal tissue damage and/or cell death. An inflammatory disease can be either an acute or chronic inflammatory condition and can result from infections or non-infectious causes. Inflammatory diseases include, without limitation, atherosclerosis, arteriosclerosis, autoimmune disorders, multiple sclerosis, systemic lupus erythematosus, polymyalgia rheumatica (PMR), gouty arthritis, degenerative arthritis, tendonitis, bursitis, psoriasis, cystic fibrosis, arthrosteitis, rheumatoid arthritis, inflammatory arthritis, Sjogren’s syndrome, giant cell arteritis, progressive systemic sclerosis (scleroderma), ankylosing spondylitis, polymyositis, dermatomyositis, pemphigus, pemphigoid, diabetes (e.g., Type I), myasthenia gravis, Hashimoto’s thyroiditis, Graves’ disease, Goodpasture’s disease, mixed connective tissue disease, sclerosing cholangitis, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, pernicious anemia, inflammatory dermatoses, usual interstitial pneumonitis (UIP), asbestosis, silicosis, bronchiectasis, berylliosis, talcosis, pneumoconiosis, sarcoidosis, desquamative interstitial pneumonia, lymphoid interstitial pneumonia, giant cell interstitial pneumonia, cellular interstitial pneumonia, extrinsic allergic alveolitis, Wegener’s granulomatosis and related forms of angiitis (temporal arteritis and polyarteritis nodosa), inflammatory dermatoses,
WO 2017/059357
PCT/US2016/054996 hepatitis, delayed-type hypersensitivity reactions (e.g., poison ivy dermatitis), pneumonia, respiratory tract inflammation, Adult Respiratory Distress Syndrome (ARDS), encephalitis, immediate hypersensitivity reactions, asthma, hayfever, allergies, acute anaphylaxis, rheumatic fever, glomerulonephritis, pyelonephritis, cellulitis, cystitis, chronic cholecystitis, ischemia (ischemic injury), reperfusion injury, appendicitis, arteritis, blepharitis, bronchiolitis, bronchitis, cervicitis, cholangitis, chorioamnionitis, conjunctivitis, dacryoadenitis, dermatomyositis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, gingivitis, ileitis, iritis, laryngitis, myelitis, myocarditis, nephritis, omphalitis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, pharyngitis, pleuritis, phlebitis, pneumonitis, proctitis, prostatitis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, testitis, tonsillitis, urethritis, urocystitis, uveitis, vaginitis, vasculitis, vulvitis, vulvovaginitis, angitis, chronic bronchitis, osteomyelitis, optic neuritis, temporal arteritis, transverse myelitis, necrotizing fasciitis, and necrotizing enterocolitis. An ocular inflammatory disease includes, but is not limited to, post-surgical inflammation.
[00166] An “autoimmune disease” refers to a disease arising from an inappropriate immune response of the body of a subject against substances and tissues normally present in the body. In other words, the immune system mistakes some part of the body as a pathogen and attacks its own cells. This may be restricted to certain organs (e.g., in autoimmune thyroiditis) or involve a particular tissue in different places (e.g., Goodpasture’s disease which may affect the basement membrane in both the lung and kidney). The treatment of autoimmune diseases is typically with immunosuppression, e.g., medications which decrease the immune response. Exemplary autoimmune diseases include, but are not limited to, glomerulonephritis, Goodpasture’s syndrome, necrotizing vasculitis, lymphadenitis, peri-arteritis nodosa, systemic lupus erythematosis, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosis, psoriasis, ulcerative colitis, systemic sclerosis, dermatomyositis/polymyositis, anti-phospholipid antibody syndrome, scleroderma, pemphigus vulgaris, ANCA-associated vasculitis (e.g., Wegener’s granulomatosis, microscopic polyangiitis), uveitis, Sjogren’s syndrome, Crohn’s disease, Reiter’s syndrome, ankylosing spondylitis, Lyme disease, Guillain-Barre syndrome, Hashimoto’s thyroiditis, and cardiomyopathy.
[00167] In some embodiments, the term “cancer” includes, but is not limited to the following types of cancers: oral, lung, gastrointestinal, genitourinary tract, liver, bone, nervous system, gynecological, skin, thyroid gland, or adrenal gland. More specifically, “cancer” includes, but is not limited to the following cancers: oral cancers, such as buccal cavity cancer, lip
WO 2017/059357
PCT/US2016/054996 cancer tongue cancer, mouth cancer, and pharynx cancer; cardiac cancers: sarcoma (e.g., angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma, and teratoma; lung cancers, such as bronchogenic carcinoma (e.g., squamous cell or epidermoid, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (e.g., bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous, hamartoma, and mesothelioma; gastrointestinal cancers, such as esophageal cancer (e.g., squamous cell carcinoma, larynx, adenocarcinoma, leiomyosarcoma, lymphoma), stomach cancer (e.g., carcinoma, lymphoma, leiomyosarcoma), pancreatic cancer (e.g., ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel or small intestinal cancer (e.g., adenocarcinoma, lymphoma, carcinoid tumors, Karposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel or large intestinal cancer (e.g., adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), colon cancer, colon-rectum cancer, colorectal cancer, and rectum cancer, genitourinary tract cancers, such as kidney cancer (e.g., adenocarcinoma, Wilm's tumor [nephroblastoma], lymphoma, leukemia), bladder cancer, urethral cancer (e.g., squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate cancer (e.g., adenocarcinoma, sarcoma), and testicular cancer (e.g., seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); liver cancers, such as hepatoma (e.g., hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma, and biliary passages; bone cancers, such as osteogenic sarcoma (e.g., osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (e.g. ,osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, and osteoid osteoma and giant cell tumors; Nervous system cancers, such as: skull cancer (e.g., osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meningeal cancer (e.g., meningioma, meningiosarcoma, gliomatosis), brain cancer (e.g., astrocytoma, medulloblastoma, glioma, ependymoma, germinoma [pinealoma], glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), and spinal cord cancer (e.g., neurofibroma, meningioma, glioma, sarcoma); gynecological cancers: uterine cancer (e.g., endometrial carcinoma), cervical cancer (e.g., cervical carcinoma, pretumor cervical dysplasia), ovarian cancer (e.g., ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], granulosa57
WO 2017/059357
PCT/US2016/054996 thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulvar cancer (e.g., squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vaginal cancer (e.g., clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tube cancer (e.g., carcinoma), an breast cancer; hematologic cancers, such as blood cancer (e.g., myeloid leukemia [acute and chronic], acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma [malignant lymphoma] hairy cell, and lymphoid disorders; skin cancers, such as malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, keratoacanthoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; thyroid gland cancers, such as papillary thyroid carcinoma, follicular thyroid carcinoma, undifferentiated thyroid cancer, medullary thyroid carcinoma, multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type 2B, familial medullary thyroid cancer, pheochromocytoma, paraganglioma, and Adenoid cystic carcinoma; and adrenal gland cancers, such as neuroblastoma.
[00168] In other embodiments, the cancer is lung cancer (e.g., non-small cell lung cancer, small cell lung cancer, mesothelioma), head and neck cancer (e.g., nasopharyngeal cancer), pancreatic cancer, breast cancer (e.g., triple negative breast cancer), gastric cancer, brain cancer, endometrial carcinoma, pancreatic cancer, biliary tract cancer, bladder cancer, colorectal cancer, glioblastoma, esophageal cancer, hepatocellular carcinoma, neuroendocrine cancer, or ovarian cancer. In certain embodiments, the cancer is lung cancer (e.g., mesothelioma), breast cancer (e.g., triple negative breast cancer), neuroendocrine cancer (e.g., neuroendocrine prostate cancer), or ovarian cancer (e.g., CA 125 positive ovarian cancer). In certain embodiments, the cancer is nasopharyngeal cancer. In certain embodiments, the cancer is fallopian tube cancer, peritoneal cancer, urothelial carcinoma, esophageal cancer, or head and neck squamous cell carcinoma.
[00169] The method comprises administering to a subject in need thereof a DNA damaging agent, and between about 12-48 hours later administering to the subject a compound that inhibits ATR protein kinase. In some embodiments, the compound that inhibits ATR is administered about 18-42 hours after administration of the DNA damaging agent. In some embodiments, the compound that inhibits ATR is administered about 20-40 hours after administration of the DNA damaging agent. In some embodiments, the compound that inhibits ATR is administered about 12-36 hours after administration of the DNA damaging agent. In some embodiments, the compound that inhibits ATR is administered about 18-36
WO 2017/059357
PCT/US2016/054996 hours after administration of the DNA damaging agent. In some embodiments, the compound that inhibits ATR is administered about 20-28 hours after administration of the DNA damaging agent. In some embodiments, the compound that inhibits ATR is administered about 24 hours after administration of the DNA damaging agent. In some embodiments, the compound that inhibits ATR is administered 24 hours + 2 hours after administration of the DNA damaging agent. In some embodiments, said DNA-damaging agent is chemotherapy or radiation treatment.
[00170] A “subject” to which administration is contemplated includes, but is not limited to, humans; commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and/or dogs) and birds (e.g., commercially relevant birds such as chickens, ducks, geese, and/or turkeys). A subject in need of treatment is a subject identified as having a proliferative disorder i.e., the subject has been diagnosed by a physician (e.g., using methods well known in the art) as having a proliferative disorder (e.g., a cancer). In some embodiments, the subject in need of treatment is a subject suspected of having or developing a proliferative disorder, such as a subject presenting one or more symptoms indicative of a proliferative disorder. The term “subject in need of treatment” further includes people who once had a proliferative disorder but whose symptoms have ameliorated. For cancer, the one or more symptoms or clinical features depend on the type and location of the tumor. For example, lung tumors may cause coughing, shortness of breath, or chest pain. Tumors of the colon can cause weight loss, diarrhea, constipation, iron deficiency anemia, and blood in the stool. The following symptoms occur with most tumors: chills, fatigue, fever, loss of appetite, malaise, night sweats, and weight loss.
[00171] The terms “administer,” “administering,” or “administration,” as used herein refers to implanting, absorbing, ingesting, injecting, or inhaling the one or more therapeutic agents. [00172] As used herein, the terms “treatment,” “treat,” and “treating” refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of proliferative disorder. In some embodiments, treatment may be administered after one or more signs or symptoms have developed or have been observed. In other embodiments, treatment may be administered in the absence of signs or symptoms of the proliferative disorder. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example, to delay or prevent recurrence.
WO 2017/059357
PCT/US2016/054996 [00173] As used herein, the terms “tumor burden” has its ordinary meaning in the art and may refer to the number of cancer cells, the size of a tumor, or the amount of cancer in the body.
[00174] As used herein, the terms “about” has its ordinary meaning in the art. In some embodiments with respect to time, about may be within 50 minutes, within 40 minutes, within 30 minutes, within 20 minutes, within 10 minutes, within 5 minutes, or within 1 minute of the specified time. In some embodiments with respect to dosage, about may be within 20%, within 15%, within 10%, within 5%, or within 1% of the specified dosage. [00175] An “effective amount” refers to an amount sufficient to elicit the desired biological response, i.e., treating the proliferative disorder. As will be appreciated by those of ordinary skill in this art, the effective amount of the compounds described herein may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the condition being treated, the mode of administration, and the age and health of the subject. An effective amount includes, but is not limited to, that amount necessary to slow, reduce, inhibit, ameliorate or reverse one or more symptoms associated with neoplasia. For example, in the treatment of cancer, such terms may refer to a reduction in the size of the tumor. [00176] An effective amount of a compound may vary from about 0.001 mg/kg to about 1000 mg/kg in one or more dose administrations, for one or several days (depending on the mode of administration). In certain embodiments, the effective amount varies from about 0.001 mg/kg to about 1000 mg/kg, from about 0.01 mg/kg to about 750 mg/kg, from about 0.1 mg/kg to about 500 mg/kg, from about 1.0 mg/kg to about 250 mg/kg, and from about 10.0 mg/kg to about 150 mg/kg.
[00177] The compounds provided herein can be administered by any route, including enteral (e.g., oral), parenteral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders, ointments, creams, and/or drops), mucosal, nasal, buccal, sublingual; by intratracheal instillation, bronchial instillation, and/or inhalation; and/or as an oral spray, nasal spray, and/or aerosol. Specifically contemplated routes are oral administration, intravenous administration (e.g., systemic intravenous injection), regional administration via blood and/or lymph supply, and/or direct administration to an affected site. In general, the most appropriate route of administration will depend upon a variety of factors including the nature of the agent (e.g., its stability in the environment of the gastrointestinal tract), and/or the condition of the subject (e.g., whether the subject is able to tolerate oral administration).
WO 2017/059357
PCT/US2016/054996 [00178] The exact amount of a compound required to achieve an effective amount will vary from subject to subject, depending, for example, on species, age, and general condition of a subject, severity of the side effects or disorder, identity of the particular compound, mode of administration, and the like. The desired dosage can be delivered three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks. In certain embodiments, the desired dosage can be delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations).
[00179] In certain embodiments, an effective amount of a compound for administration one or more times a day to a 70 kg adult human may comprise about 0.0001 mg to about 3000 mg, about 0.0001 mg to about 2000 mg, about 0.0001 mg to about 1000 mg, about 0.001 mg to about 1000 mg, about 0.01 mg to about 1000 mg, about 0.1 mg to about 1000 mg, about 1 mg to about 1000 mg, about 1 mg to about 100 mg, about 10 mg to about 1000 mg, or about 100 mg to about 1000 mg, of a compound per unit dosage form.
[00180] In certain embodiments, the compounds provided herein may be administered at dosage levels sufficient to deliver from about 0.001 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, preferably from about 0.1 mg/kg to about 40 mg/kg, preferably from about 0.5 mg/kg to about 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, and more preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
[00181] It will be appreciated that dose ranges as described herein provide guidance for the administration of provided pharmaceutical compositions to an adult. The amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult.
Biological Samples [00182] As inhibitors of the ATR pathway, the compounds and compositions of this invention are also useful in biological samples. One aspect of the invention relates to inducing DNA damage and inhibiting ATR in a biological sample, which method comprises contacting said biological sample with a DNA damaging agent followed by contacting the sample about 12-48 hours later with a compound that inhibits ATR kinase activity. The term “biological sample”, as used herein, means an in vitro or an ex vivo sample, including,
WO 2017/059357
PCT/US2016/054996 without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
[00183] Inducing DNA damage followed by inhibition of ATR activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, blood transfusion, organ-transplantation, and biological specimen storage.
Examples [00184] Example 1. Optimization of Dose Schedule In Vitro [00185] The effect of altering a compound of Formula A-2 (Compound A-2) dosing schedule in combination with DNA damaging agents was assessed with gemcitabine in a pancreatic cancer cell line (PSN1) as shown in FIG. 1. Cells were treated with gemcitabine for 24 hours in combination with Compound A-2; Compound A-2 was added for 2 hour periods at various times both during and after gemcitabine treatment. Cell viability was measured by MTS assay (96 hours) and the data subjected to a statistical Bliss analysis. Compound A-2 synergized with gemcitabine when administered at the start of gemcitabine treatment. This synergistic effect markedly increased as Compound A-2 was administered progressively later through the 24 hour gemcitabine dosing period. Synergy was maximal when Compound A-2 was administered 24 hours after starting gemcitabine treatment as shown in FIG. 1; later administration of Compound A-2 was less effective. No synergy was seen when Compound A-2 was administered 48 hours or later, after gemcitabine treatment was started. The strong schedule dependence is attributed to an accumulation of cells in S phase, and concomitant increase in ATR activity (measured by P-Chkl) that occurs in response to gemcitabine treatment alone. Thus, maximal impact of Compound A-2 is expected at a time when most cells are in S phase as a result of gemcitabine treatment. Extended intervals (>48 hours) between gemcitabine therapy and Compound A-2 exposure allows DNA damage to be repaired, permitting cells to exit S phase and dramatically reducing the impact of ATR inhibition.
[00186] These data indicate that short exposures to Compound A-2 are sufficient to sensitize certain cancer cells to DNA damaging agents. Furthermore, the data suggest that administering Compound A-2 after treatment with a DNA damaging agent, to coincide with maximal S phase accumulation is optimal.
WO 2017/059357
PCT/US2016/054996 [00187] Example 2: Dose Schedule Optimization of a Compound of Formula A-2 in Combination With Gemcitabine or Cisplatin [00188] In vitro pharmacology studies have demonstrated that combinations of a compound of Formula A-2 (Compound A-2) and DNA damaging drugs are most effective when cells are treated with Compound A-2 after the DNA damaging drug, and when Compound A-2 addition is timed to coincide with peak accumulation of cells in S phase. The optimal in vivo dose schedule for Compound A-2 was assessed in combination with gemcitabine and cisplatin in 2 separate xenograft models.
[00189] In a human pancreatic cancer xenograft model (PSN1), Compound A-2 (20 mg/kg, dosed every 6 days) was most effective when dosed 12 to 24 hours after administration of gemcitabine (15 mg/kg, dosed every 3 days) Dosing with Compound A-2the within 12 hours of gemcitabine administration, or beyond 24 hours of gemcitabine administration, reduced efficacy. FIG. 2 shows the Compound A-2 dose schedule in combination with gemcitabine in vivo.
[00190] Dosing with Compound A-2 before gemcitabine, or 48 hours after gemcitabine, provided limited benefit over gemcitabine treatment. The addition of Compound A-2 to gemcitabine did not lead to increased body weight loss when compared with gemcitabine only treatment.
[00191] In a NSCLC xenograft model derived from primary human tumor tissue, in SCID mice, Compound A-2the (10 mg/kg, dosed twice weekly) was most effective when dosed 14 hours after administration of cisplatin (3 mg/kg, dosed weekly) as shown in FIG. 3. Under these conditions, marked tumor regression (43%) and substantial growth delay was observed. This contrasts with the effects of either agent given alone, where neither Compound A-2the nor cisplatin had any meaningful impact on tumor growth (<10% tumor growth inhibition). This combination was well tolerated with <2% body weight loss at nadir, though animals did not gain weight as rapidly as cisplatin only treated animals.
[00192] These studies demonstrate strong schedule dependence for intravenously administered Compound A-2. For combinations with either gemcitabine or cisplatin, efficacy was maximal when Compound A-2 was dosed 12 to 24 hours after the DNA-damaging agent.
[00193] Example 3 - Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor a compound of Formula A-2 as monotherapy (mono) or
WO 2017/059357
PCT/US2016/054996 in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity.
[00194] ATR mediates the homologous recombination DNA repair pathway and cellular response to replication stress. The compound of Formula A-2 (Compound A-2) is a potent and selective inhibitor of ATR (Ki<0.2 nM) that showed enhanced synergy of ATR inhibition with cytotoxic chemotherapy, and potential monotherapy ATR inhibitor activity in tumor cell lines with high levels of replication stress, such as defects in the DNA damage repair (DDR) pathway (e.g. ATM loss). A Phase I dose-escalation trial of Compound A-2 was undertaken to assess the safety and tolerability of an ATR inhibitor as a monotherapy and in combination with DNA-damaging chemotherapy, to show evidence of ATR inhibition in tumor tissue, and to explore antitumor activity.
[00195] Pts with advanced solid tumors enrolled in 2 sequential parts. In Part A, pts received IV Compound A-2 mono weekly in single-pt cohorts, with 3+3 cohorts initiated if grade (G) >2 Compound A-2 related adverse events (AEs) were observed. In Part B, pts received CP on day 1 and Compound A-2 on days 2 and 9 of a 21-day cycle in a 3+3 doseescalation design (Compound A-2 on days 2 and 9 every 3 weeks and CP on day 1 every 3 weeks). Paired Compound A-2 tumor biopsies were obtained in selected CP treated pts pre- and post- Compound A-2, and pS345 Chkl levels were assessed by immunohistochemistry (IHC).
[00196] Results: 25 pts were treated; M/F 10/15; median age 67 yr (range 49-76 yr); ECOG PS 0/1: 11/14. In Part A, 11 pts (colorectal [CRC; n=2]; mesothelioma [n=2]; other [n=7]; median prior lines of therapy=3) received Compound A-2 at 60 mg/rr+ (n=l), 120 mg/nY (n=2), 240 mg/nY (n=l) and 480 mg/nY (n=7). In Part B, 14 pts (CRC [n=6]; ovarian [n=2]; other [n=6]; median prior lines of therapy=3) received Compound A-2 240 mg/nY + CP AUC 5 mg/mL*min (n=3; dose level 1 [DL1]), Compound A-2 120 mg/nY + CP AUC 5 mg/mL*min (n=3; DL2), Compound A-2 120 mg/nY + CP AUC 4 mg/mL*min (n=3; DL3) and Compound A-2 90 mg/nY + CP AUC 5 mg/mL*min (n=5; DL4). In Part A, no dose-limiting toxicities (DLT) or drug-related G3-4 AEs were seen. In Part B, 2 pts had DLT: G4 neutropenia and fever (n=l; DL1) and G3 hypersensitivity (n=l; DL2). Non-DLT G3-4 AEs were neutropenia (n=4; DL12) and thrombocytopenia (n=l; DL2) requiring dose delays. No G3-4 AEs were seen at DL3-4. RP2D cohort expansion is ongoing at DL4. Compound A-2 displayed linear AUC and Cmax at all DLs; median half-life was 16h with no accumulation. Based on
WO 2017/059357
PCT/US2016/054996 preclinical models, efficacious exposures were achieved. When combined with CP,
DL1 and DL2 showed similar Compound A-2 exposure, suggesting no apparent drug interactions. Decreased Chkl phosphorylation was seen in 2/2 paired tumor biopsies (74% at DL4; 94% at DL2). An advanced CRC pt (serosal disease and abdominal lymphadenopathy; 3 prior lines of chemotherapy) with complete ATM loss by IHC achieved RECIST complete response to Compound A-2 mono at 60 mg/nA and remains on trial at 59+ wks. RECIST stable disease (SD) was seen with Compound A-2 mono in 4 pts (median duration of SD = 11 wks [11-17.4 wks]) and Compound A-2 + CP in 7 pts, who were still ongoing (duration of SD = 5+ to 20+ wks), including several pts who had progressed on prior platinum therapy.
[00197] Example 4. Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor a compound of Formula A-2 as monotherapy (mono) [00198] This example further describes the Phase I dose-escalation trial of a compound of Formula A-2 (Compound A-2) to assess the safety and tolerability of an ATR inhibitor as a monotherapy in Example 3.
[00199] The study included 17 patients. The subject demographic and baseline characteristics are shown in Table 1.
Table 1. Subject demographics and baseline characteristics.
Baseline Characteristics | |
Age, mean (SD), years | 63.4(10.3) |
Sex, n (%) | 7 (41.2) |
Male | 10(58.8) |
Female | |
Race, n (%) | 16(94.1) |
White | 0 |
Black or African American | 0 |
Asian | 1 (5.9) |
WO 2017/059357
PCT/US2016/054996
Other | |
ECOG PS at baseline, n (%) 0 1 | 4 (23.5) 13 (76.5) |
Primary malignancy, n (%) | 0 |
NSCLC | 1 (5.9) |
Breast cancer | 1 (5.9) |
Ovarian cancer | 3 (17.6) |
Colorectal cancer | 12 (70.6) |
Other |
[00200] The 17 subjects received once weekly intravenous doses of Compound A-2 ranging from 60 to 480 mg/m or twice weekly intravenous doses of 240 mg/m of Compound A-2. Eleven of the subjects were given a once weekly dosage of Compound A2 as a monotherapy. Six of the subjects were given a twice weekly dosage of Compound A-2 as a monotherapy. For the once weekly dosage, there were no dose limiting toxicities (DLTs) and adverse events began at a dose of 480 mg/m as shown in Table 2. DLTs were defined according to the National Cancer Institute (NCI) CTCAE (Version 4). FIG. 12 shows tumor response showing changes from baseline in cancer subjects who received treatment of Compound A-2 as a monotherapy, and FIG. 13 shows duration of progression-free survival (PFS).
Table 2. Compound A-2 monotherapy weekly treatment related adverse events.
WO 2017/059357
PCT/US2016/054996
-2- mg/m | 60 Once Weekly (n=1) | 120 Once Weekly (n=2) | 240 Once Weekly (n=1) | 480 Once Weekly (n=7) | 240 Twice Weekly (n=6) | Total (N=17) | ||||||
Event | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | ||||||
Grad e >3 | AH Grade s | Grad e >3 | AH Grade s | Grad e >3 | AH Grade s | Grad e >3 | AH Grade s | Grad e >3 | AH Grade s | Grad e >3 | AH Grade s | |
Any Event | 0 | 1 if 00) | 0 | •i (50.0) | 0 | 0 | 0 | 7(100) | 1 (16-7) | 6 if 00) | 1 (5-9) | 15 (38.2) |
Flushing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 (42,9) | 0 | (16.7) | 0 | 4 (23.5) |
Catheter site reiated reaction | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (38.3) | 0 | 2 (11.8) |
Nausea | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 (28.61 | 0 | 0 | 0 | 2 (11.8) |
Pruritus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (28.6) | 0 | 0 | 0 | (11.3) |
infusion reiated reaction | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (74.3} | 0 | •i (16.7) | 0 | 2 (:1.8) |
Headach e | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 (28.6-1 | 0 | 0 | 0 | 2 (11.8) |
[00201] As noted in Example 3, a subject with KRAS and BRAF wildtype metastatic colorectal cancer with serosal disease and abdominal lymphadenopathy had a RECIST complete response after treatment with 60 mg/m monotherapy (weekly) of Compound A-2. The colorectal cancer had a complete loss of ATM signaling based on IHC analysis. There was loss of MLH1 and PMS2, and weak heterogeneous staining of MSH2 and MSH6 on immunohistochemistry. Targeted and whole exome next-generation sequencing (NGS) revealed a somatic truncating mutation in MLH1 at position p.Lys33*/c.97A>T, which was likely to contribute to tumor microsatellite instability (MSI). PTEN and CTNNB1 somatic mutations were also detected on NGS. The subject remains on trial with ongoing RECIST complete response lasting more than 28 months. Radiographs of the left common iliac lymph node before treatment (i.e., baseline) and after 15 months of treatment is shown in FIG. 4. [00202] Prior to treatment with Compound A-2, the subject received 4 lines of treatment.
The first line of treatment was folinic acid, Fluorouracil, irinotecan, and cetuximab, which resulted in a RECIST partial response. The second line of treatment was folinic acid, fluorouracil, oxaliplatin, and Avastin, which resulted in a RECIST partial response. The third
WO 2017/059357
PCT/US2016/054996 line of treatment was fluorouracil and Avastin, which resulted in a RECIST progression. The fourth line of treatment was Capecitabine and mitomycin which resulted in a RECIST progression.
[00203] The tumor response and duration of progression free survival for several cancers are shown in FIGs.12 and 13, respectively.
[00204] Example 5. Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor a compound of Formula A-2 in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity.
[00205] This example further describes the Phase I dose-escalation trial of a compound of Formula A-2 (Compound A-2) in combination with carboplatin in Example 3.
[00206] The study included 19 patients. The subject demographic and baseline characteristics are shown in Table 3.
Table 3. Subject demographics and baseline characteristics.
Baseline Characteristics | Part B (N=19) |
Age, mean (SD), years | 63.3 (8.7) |
Sex, n (%) | 7 (36.8) |
Male | 12(63.2) |
Female | |
Race, n (%) | 18 (94.7) |
White | 0 |
Black or African American | 0 |
Asian | 1 (5.3) |
Other | |
ECOG PS at baseline, n (%) | 7 (36.8) |
WO 2017/059357
PCT/US2016/054996
0 1 | 12(63.2) |
Primary malignancy, n (%) | 1 (5.3) |
NSCLC | 1 (5.3) |
Breast cancer | 2(10.5) |
Ovarian cancer | 8(42.1) |
Colorectal cancer | 7 (36.8) |
Other |
[00207] The 15 subjects received a three week cycle of carboplatin on day 1, Compound A-2 on day 2, 24 hours after treatment with carboplatin, and Compound A-2 on day 9. The dose escalation and dose limiting toxicities are shown in Table 4.
Table 4. Dose escalation of Compound A-2 combination therapy.
Cohort | A-2 Dose (mg/m2) | Carboplatin Dose (AUC) | No. Subjects (Enrolled/ DLT evaluable) | DLTs |
1 | 240 | 5 mg/mL*min | 3/3 | 1 (febrile neutropenia) |
2 | 120 | 5 mg/mL*min | 3/3 | 1 (acute hypersensitivity) |
3 | 120 | 4 mg/mL*min | 3/3 | 0 |
4 | 90 | 5 mg/mL*min | 10/10 | 1 (febrile neutropenia) |
[00208] The adverse events are shown in Tables 5A-5B and include neutropenia and thrombocytopenia, which were believed to be a result of the mechanism of action of ATR when administered in combination with a DNA damaging agent.
Table 5A. Treatment related adverse events for combination therapy.
WO 2017/059357
PCT/US2016/054996
A-2 (mg/m2) + Carboplatin (AUC, mg/mL«min) | 240 + AUC5 (N=3) | 120 + AUC5 (N=3) | 120 + AUC4 (N=3) | 90 + AUC5 (N=6) | Total (N=15) | |||||
Adverse Event | >3 | All | >3 | All | >3 | All | >3 | All | >3 | All |
Anemia | 0 | 3 | 0 | 2 | 0 | 1 | 0 | 3 | 0 | 9 |
Neutropenia | 2 | 3 | 1 | 2 | 0 | 0 | 1 | 2 | 4 | 7 |
Thrombocytopenia | 1 | 3 | 0 | 1 | 0 | 1 | 0 | 2 | 1 | 7 |
Nausea | 0 | 3 | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 7 |
Fatigue | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 3 | 0 | 6 |
Flushing | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 3 |
Vomiting | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
Alopecia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 |
Headache | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
Neuropathy peripheral | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
Hypertension | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Respiratory tract infection | 1 | 1 | 0 | 0 | 0 | 0 | 0 | c | 1 | 1 |
Table 5B. Treatment related adverse events for combination therapy.
A-2 + : | ^xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx t2£ 4- i $0-3) | rxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx>, §2 K5 fO-SS) | |||||||||
............... | -------------- | ;N) | ______________ | ||||||||
S?aS$g | Αδ | STS3S <· | j; as | Stss | AS G!55£= | •.:.··κ5 | .......Ai!........ 2*3565 | GfSSS | .......Ai:........ ,,N55S=,,4 | ||
A'$$ S®35· : | £3=.7.- | 2 $702/ | 1$2=, < | j: £$702:: | £ | 7 $72.2: | S .:322./ | 3 $13 2) | $7-23=: | ||
<$20) | c | t 1 '23. 7: | o | 7 /3=:3/ | 0 | i $<0.G) | 2 | '2 =: = | |||
KiiaAsyssS ; | ΣήΚ,Τί | £ $702$: | 7 $235$: | J: £ $£».?) | '3 | 0 | 7 <722: | 3 <32 2: | •<$1N7) | : ^1' | |
s | 2· | 2 | j; £ | : i | ·' >)23.2) | I. | 5 :;35?.C> | 2 | |||
1 $53.-2$ | 3 :?h:c? | € | j : <33·3; | £ | 7 <22-3: | G | £ $10.2) | 7 <3 2) | .Ό . | ||
δ | 2<S3.?; | 2 | 7/233) | 3 | 0 | 2 | 4. :)42.0) | 2 | 7 <333) | ||
* | ·: <33.35 | o | j: | 5 | 7 <33.3:· | 5 | 7 $702) | δ | 3 $7 £37 | ||
: | δ | 7 $35.3; | 2 | G | 3 | 7 /35: 3/ | δ | < ::73.2:- | 2 | 3 <75.2) | |
: | 1 | :-.55.-, | δ | 1 * | : s- | 3 | 2 | 2 | δ | ||
2 | 7 <333? | 1 | j: 7 $33.3) | 2 | 0 | 2 | 2' $ 2 | ||||
AS&SvS : | 0 | £ | o | j: £ | o | 2 | 0 | 2 $20.0) | 2 | 2 $70.=) | |
:riS35&KS | V | £<S=.?; | S' | i c | 2 | 0 | 2 | 2< 2 | .£«2.3) | ||
:ASSiSKSK'j SSifsSX?® | δ | 1 $23,7· | c | j: - | 3 | 2 | G | 2 | 2 | 1 $70.3) | |
2 | 7 $33-.3) | 7 $32.3/ | 1: 7 $33.2) | 2 | 0 | 2 | 2 7 $=-37 | £ «23) | |||
0 | 2 | 0 | I 7 C-3 . < | 0 | 2 | G | 7 $70.2) 3 | 1 <70=7 |
WO 2017/059357
PCT/US2016/054996 [00209] The Compound A-2 plasma concentration-time profiles were similar with monotherapy and in combination with carboplatin as shown in FIG. 5A and FIG. 5B, respectively. This suggested that there was no interaction of Compound A-2 and carboplatin. In addition, exposure (AUCinf and Cmax) increased proportionally with increasing dose. Terminal elimination half-life (ti/2) was about 16 hours.
[00210] As noted in Example 3, phosphorylated Chkl was used as a biomarker in paired tumor biopsies of three subjects to determine the efficacy of the combination therapy. A first tumor biopsy was taken on day 2, two hours before Compound A-2 administration, and a second tumor biopsy was taken two hours after Compound A-2 administration. The amount of pChkl in the nuclei of cancer cells/mm tumor in the first biopsy was set to 100% and used to normalize the amount in the second biopsy. As shown in FIG. 6, subject 1 was given target AUC of 5 mg/mL*min of carboplatin and 120 mg/m of Compound A-2 and had a 94% decrease in pChkl. Subjects 2 and 3 were given target AUC of 5 mg/mL*min of carboplatin and 90 mg/m of Compound A-2 and had a 73% decrease in pChkl.
[00211] As noted in Example 3, a subject with platinum and antimetabolite refractory metastatic high grade serous ovarian cancer having gBRCAl QllllNfs*5 mutation and TP53 Y220C missense deleterious somatic mutation with peritoneal, liver and nodal disease had a RECIST partial response after combination treatment target AUC of 5 mg/m L· min of carboplatin on day 1 and 90 mg/m of Compound A-2 on day 2, 24 hours after treatment with carboplatin, and 90 mg/m of Compound A-2 on day 9. The subject remains on trial with ongoing RECIST partial response lasting more than 6 months. Radiographs of left peritoneal disease before treatment (i.e., baseline) and after 5 months of treatment is shown in FIG. 7.
[00212] Prior to treatment with Compound A-2, the subject had debulking surgery before receiving 7 lines of treatment. The seventh line of treatment was carboplatin and gemcitabine, which resulted in progressive disease after 3 cycles. Other lines of treatment included Talazoparib (BMN 673; Biomarin Pharmaceuticals) monotherapy, which resulted in progressive disease after 10 months; Olaparib (AstraZeneca) and AKT inhibitor AZD5363 (AstraZeneca), which resulted in progressive disease after 5 months; and aFR inhibitor, which resulted in progressive disease after 5 months.
[00213] The tumor response and duration of progression free survival for several cancers are shown in FIGs. 14 and 15, respectively.
[00214] Tumor response of subjects 1, 2, and 3 shown in FIG. 6 is summarized below:
WO 2017/059357
PCT/US2016/054996
Treatment | Compound A-2 120 mg/m2 + carboplatin AUC 5 mg/mL*min | Compound A-2 90 mg/m2 + carboplatin AUC 5 mg/mL*min | |
Tumor | Ovarian (Subject 1) | Ovarian (Subject 2) | Breast (Subject 3) |
PFS (progressionfree survival) (days) | 175 | 176 | 67 |
Response | SD (Stable Disease) | PR (Partial Response) | SD (Stable Disease) |
[00215] Example 6. Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor a compound of Formula A-2 as a monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts).
[00216] ATR mediates the homologous recombination DNA repair pathway and cellular response to replication stress. A compound of Formula A-2 (Compound A-2) is a potent, selective inhibitor of ATR that enhanced ATR inhibition with cytotoxic chemotherapy and inhibited ATR in tumor cell lines with DNA repair pathway defects. Pharmacokinetics (PK), pharmacodynamics (PD), tolerability, and efficacy of a compound of Formula A-2 + CP were assessed in a Phase I dose escalation trial.
[00217] Patients (pts) with advanced solid tumors measurable by RECIST 1.1 were enrolled in 2 parts. In part A, single pt cohorts received a compound of Formula A-2 once weekly in 21-day cycles with 3 + 3 dose escalation cohorts being implemented if > grade 2 drug-related adverse events (AEs) occurred. In part B, 3 + 3 pt cohorts received CP on day 1 + a compound of Formula A-2 on days 2 and 9 of each 21-day cycle. If no dose limiting toxicities (DLTs) occurred after 1 cycle, dose escalation was permitted in a new cohort. If a DLT was reported, the cohort was expanded to include 3 additional pts with subsequent dose escalation being permitted if no further DLTs occurred. Paired pre- and post-treatment biopsies from selected pts in part B were assessed for pCHKl levels by immunohistochemistry. Models based on preclinical and clinical data were used to simulate hematologic toxicities and pCHKl inhibition for pts treated with a compound of Formula A-2 and CP.
[00218] Twenty six (26) pts (10 males and 16 females) of median age, 68 years (range 49-76 years) in A and 65 yrs (range 49-74 yrs) in B, with Eastern Cooperative Oncology Group (ECOG) performance status 0/1: 9/17 were treated according to the above protocols using the dosage levels (DLs) shown in the table below.
WO 2017/059357
PCT/US2016/054996 [00219] Dose levels (DLs) were:
DL | A compound of Formula A-2 dose (mg/m2) | CP dose (AUC, mg/ml+min) | # pts treated |
A1 | 60 | - | 1 |
A2 | 120 | - | 2 |
A3 | 240 | - | 1 |
A4 | 480 | - | 7 |
BI | 240 | 5 | 3 |
B2 | 120 | 5 | 3 |
B3 | 120 | 4 | 3 |
B4 | 90 | 5 | 6 |
[00220] No DLTs occurred in part A. In part B, DLTs were: grade 3/4 neutropenia (2 pts at dosage levels BI and B2) and grade 3 hypersensitivity (1 pt at dosage level B2). Grade 3/4related AEs occurred in 5 pts in part B across the various DLs, while none occurred in part A The best responses were complete response (CR (n=l)) in part A and partial response (PR (n=l)) in part B. The pharmacokinetics (PK) for a compound of Formula A-2 was dose proportional both as a monotherapy and in combination with CP. Based on the above data, the recommended Phase II doses were established at DLs A4 and B4, with modeling predicting 73% pCHKl inhibition and 5% and <1% probabilities of grade 4 neutropenia and thrombocytopenia, respectively, at DL B4. A compound of Formula A-2 exposures at B4 also led to tumor regression in preclinical models.
[00221] Example 7. Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor a compound of Formula A-2 in combination with cisplatin (CIS) in patients (pts) with advanced solid tumors.
[00222] In this Example, patients (pts) received intravenous a compound of Formula A-2 (Compound A-2)in combination with CIS using a 3+3 dose escalation design. CIS was administered on day 1 and a compound of Formula A-2 was administered on days 2 and 9 in 21-day cycles. Twenty eight (28) pts (12 males and 16 females) of median age, 62.5 yrs (range 28-79 yrs), with Eastern Cooperative Oncology Group (ECOG) performance status
WO 2017/059357
PCT/US2016/054996
0-1 were treated. Primary tumors were breast (n=4), colorectal (n=3), ovarian (n=3), pancreatic (n=2), non-small cell lung cancer (NSCLC) (n=l), and other cancers (n=15). The following table describes the dosage levels (DLs) and various parameters for the various treatment cohorts.
Dose levels were:
Cohort | Compound A-2 dose (mg/m2) | Cisplatin dose (mg/m2) | No. pts treated/No. pts evaluable for dose limiting toxicities (DLTs) | No. DLTs |
1 | 90 | 40 | 3/3 | |
2 | 140 | 40 | 4/3 | |
3 | 210 | 40 | 4/4 | |
4 | 210 | 60 | 10/10 | 1 (grade 3 elevated ALT) |
5 | 140 | 75 | 7/6 | 1 (grade 3 drug hypersensitivity) |
[00223] Non-DLT grade 3-4 treatment-related adverse events occurred in 11 pts, including nausea, cytopenia, hypotension, hypoalbuminemia, hypokalemia, elevated liver function tests (LFTs), and drug hypersensitivity. The maximum tolerated combination dose was not reached. However, the Compound A-2 dose escalation was stopped because pharmacokinetic (PK) exposures of Compound A-2 at the 140mg/m DL exceeded exposures previously shown in preclinical models, which resulted in robust target engagement and tumor regression in combination with CIS. There was no effect of CIS on the pharmacokinetics of Compound A-2. Compound A-2 terminal elimination half-life was aboutl6 hours and the Compound A-2 PK was proportional across the dosage ranges. RECIST partial responses were observed in 3 platinum-resistant/refractory pts (mesothelioma, ovarian, and triplenegative breast cancers) receiving Compound A-2 at 140 mg/m . Based on the above data, the recommended Phase II doses of Compound A-2 is 140 mg/m and CIS is 75 mg/m with RECIST antitumor responses observed in platinum-refractory pts.
WO 2017/059357
PCT/US2016/054996 [00224] FIG. 8 shows tumor response where maximum percent changes in target tumor diameter from baseline are depicted. Durations of progression free survival (PFS) in various cancers are shown in FIG. 9.
[00225] As shown in FIG. 10, partial response in the target region was observed in an ovarian cancer subject having BRCA2 germline mutation (W2626Q), where the patient received CIS 75 mg/m on day 1 and Compound A-2 140 mg/m on days 2 and 9 in cycle 1, and CIS 60 mg/m in cycyle 2 due to AE. Prior to the treatment with Compound A-2, the subject received the following treatments:
(i) debulking and paclitaxel with carboplatin;
(ii) carboplatin and doxorubicin: platinum resistant;
(iii) paclitaxel and bevacizumab; and (iv) olaparib: no response.
[00226] As shown in FIG. 11, partial response in the target region was observed in a triplenegative breast cancer subject having mutations in TP53 (R213*) and RBI (deletion of exons 25-26), where the patient received CIS 75 mg/m on day 1 and Compound A-2 140 mg/m on days 2 and 9 in cycle 1. New brain metastases and leptomeningeal disease were discovered after completion of cycle 4, but no follow-up brain images are shown here as no brain imaging performed at the baseline. The subject Prior to the treatment with Compound A-2, the subject received the following treatments:
(i) mastectomy; doxorubicin, cyclophosphamide, paclitaxel; and radiation: progressive disease (PD) after 17 months;
(ii) re-excision; gemcitabine and ciaplatin: PD after 3 months; and (iii) certain investigation agent: PD after 6 weeks.
[00227] Example 8. Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor a compound of Formula A-2 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors.
[00228] In this Example, patients (pts), with advanced solid tumors measurable by RECIST 1.1 received IV a compound of Formula A-2 (Compound A-2) in combination with gem in a 3+3 dose-escalation design. Gem was administered on days 1 and 8 and Compound A-2 on days 2 and 9 of each 21-day cycle. Dose escalation was permitted if no dose-limiting toxicities (DLTs) were reported in a given treatment cycle. Fifty (50) pts (28 males and 22
WO 2017/059357
PCT/US2016/054996 females) of median age, 62 yrs (range 28-79 yrs), with Eastern Cooperative Oncology Group (ECOG) performance status 0/1: 15/35 were treated. Primary tumors included non-small cell lung (NSCLC; n=6), pancreatic (n=2), breast (n=4), colorectal (n =15), head and neck (n=l), and other/missing (n=22). The following table describes the dosage levels (DLs) and various parameters for the various treatment cohorts.
Dose levels (DLs) were:
DL | Compound A-2 dose (mg/m2) | Gem dose (mg/m ) | No. pts treated |
1 | 18 | 875 | 3 |
2 | 36 | 875 | 3 |
3 | 60 | 875 | 4 |
4 | 72 | 875 | 7 |
5 | 90 | 500 | 6 |
6 | 140 | 500 | 8 |
7 | 210 | 500 | 3 |
8 | 210 | 750 | 3 |
9 | 210 | 875 | 7 |
10 | 210 | 1000 | 6 |
[00229] Grade 3/4 treatment-related adverse events (AEs) occurred in 25 pts. DLTs occurred in 4 pts: 2 pts in DL4 (grade 3 thrombocytopenia; grade 3 elevated ALT and fatigue); 1 pt in DL5 (grade 3 elevated AST); 1 pt in DL6, (grade 3 elevated AST, ALT and grade 2 elevated ALP). The maximum tolerated dose was not reached but dose escalation was stopped at DL10 per investigator recommendation. The Compound A-2 exposure was relatively linear based on Cmax and AUCo-αο with the terminal elimination half-life of aboutl6 hours across DLs. No cumulative toxicity was observed. The best overall response was a partial response (PR) in 4 pts. The primary tumors in these four patients were breast cancer, head and neck cancer, NSCLC, and carcinoma of unknown primary origin. A pt with breast cancer in DL8 achieved PR at the 1st assessment and the pt remains on trial > 133 days. Two (2) pts had prolonged stable disease (SD) responses. The tumor response and duration of progression free survival (PFS) are shown in FIG. 16 and 17, respectively. For many patients, the duration of PFS extended beyond the 12-week primary endpoint. The median PFS was 8.3
WO 2017/059357
PCT/US2016/054996 weeks in patients treated at doses of Compound A-2 <90 mg/m in combination with gemcitabine 875 mg/m . Median PFS was 29.3 weeks in patients treated at doses of Compound A-2 >90 mg/m in combination with gemcitabine 500 mg/m . Progression-free survival (PFS) of 415 days in 1 patient with renal cancer( papillary carcinoma) and >191 days (pt with GIST) were observed. Based on the above data, the recommended Phase II doses of Compound A-2 is 210 mg/m and gem is 1000 mg/m .
[00230] Conclusion: Compound A-2 is well tolerated as monotherapy and in combination with CP, CIS, or gem with preliminary evidence of target modulation and antitumor activity. Compound A-2 will be further explored in early Phase II studies; in multiple tumor types, including triple-negative breast cancer and non-small cell lung cancer; and in patients with DDR aberrations.
[00231] Example 9: Phase I Dose Escalation Study of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor a compound of Formula A-2 in combination with gemcitabine (gem) and cisplatin (CP) in patients (pts) with advanced solid tumors.
[00232] In this Example, patients (pts) with advanced solid tumors received IV a compound of Formula A-2 (Compound A-2) in combination with gem and CP in a 3+3 dose-escalation design. Compound A-2 was administered days 2, 9, and 16 every 3 weeks; gem was administered days 1 and 8 every 3 weeks, and CP was administered on day 1 every 3 weeks. The following table describes the dosage levels (DLs) and various parameters for the various treatment cohorts. The tumor response is shown in FIG. 16.
Compound Gemcitabine Cisplatin Cohort A-2 Dose Dose Dose (mg/m2) (mg/m2) (mg/m2)
No. of Patients Treated/DLT Evaluable
No. of Patients with DLTs (DLT)
90 875 60
120 875 60
6/6 1 (thrombocytopenia/neutropenia) (febrile
2/2 neutropenia/thrombocytopenia, hypoxia/neutropenia)
WO 2017/059357
PCT/US2016/054996
OTHER EMBODIMENTS [00233] While we have described a number of embodiments of this invention, it is apparent that our basic examples may be altered to provide other embodiments that utilize the compounds, methods, and processes of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims rather than by the specific embodiments that have been represented by way of example here.
WO 2017/059357
PCT/US2016/054996
Claims (21)
- What is claimed is:1. A method of treating a proliferative disorder in a subject, the method comprising:administering to a subject in need thereof a DNA damaging agent and between about 12 and about 48 hours later administering to the subject a compound that inhibits ATR protein kinase.
- 2. The method of claim 2, wherein said DNA-damaging agent is selected from the group consisting of chemotherapy and radiation treatment.
- 3. The method of claim 1, wherein said DNA-damaging agent is selected from the group consisting of ionizing radiation, radiomimetic neocarzinostatin, platinating agents, Topo I inhibitors, Topo II inhibitors, antimetabolites, alkylating agents, and antibiotics.
- 4. The method of claim 3, wherein said DNA-damaging agent is a platinating agent selected from the group consisting of cisplatin, oxaliplatin, carboplatin, nedaplatin, Lobaplatin, triplatin tetranitrate, picoplatin, satraplatin, ProLindac, and aroplatin.
- 5. The method of claim 3, wherein said DNA-damaging agent is a Topo I inhibitor selected from the group consisting of camptothecin, topotecan, irinotecan/SN38, rubitecan, and belotecan.
- 6. The method of claim 3, wherein said DNA-damaging agent is a Topo II inhibitor selected from the group consisting of etoposide, daunorubicin, doxorubicin, Aclarubicin, epirubicin, idarubicin, amrubicin, pirarubicin, valrubicin, zorubicin, and teniposide.
- 7. The method of claim 3, wherein said DNA-damaging agent is a antimetabolite selected from the group consisting of aminopterin, methotrexate, pemetrexed, raltitrexed, pentostatin, cladribine, clofarabine, fludarabine, thioguanine, mercaptopurine, fluorouracil, capecitabine, tegafur, carmofur, floxuridine, cytarabine, gemcitabine, 6-mercaptopurine, 5-fluorouracil, azacitidine, and hydroxyurea.
- 8. The method of claim 3, wherein said DNA-damaging agent is an alkylating agent selected from the group consisting of Mechlorethamine, Cyclophosphamide, Ifosfamide,WO 2017/059357PCT/US2016/054996Trofosfamide, Chlorambucil, Melphalan, Prednimustine, Bendamustine, Uramustine, Estramustine, Carmustine, Lomustine, Semustine, Fotemustine, Nimustine, Ranimustine, Streptozocin, Busulfan, Mannosulfan, Treosulfan, Carboquone, ThioTEPA, Triaziquone, Triethylenemelamine, Procarbazine, Dacarbazine, Temozolomide, Altretamine,Mitobronitol, Actinomycin, Bleomycin, Mitomycin, nitrogen mustards, nitrosoureas, triazenes, alkyl sulfonates, Procarbazine, aziridines, and Plicamycin.
- 9. The method of claim 3, wherein said DNA-damaging agent is an antibiotic selected from the group consisting of hydroxyurea, Anthracyclines, Anthracenediones, and antibiotics from the Streptomyces family.
- 10. The method of any one of claims 1-9, wherein said proliferative disorder is cancer.
- 11. The method claim 10, wherein said cancer is a solid tumor cancer selected from the group consisting of oral cancers, lung cancers, gastrointestinal cancers, genitourinary tract cancers, liver, bone, nervous system, gynecological, skin, thyroid gland, and adrenal gland.
- 12. The method of claim 10, wherein said cancer is a solid tumor cancer selected from the group consisting of: Oral cancer selected from the group consisting of buccal cavity, lip, tongue, mouth, and pharynx cancer; Cardiac cancer selected from the group consisting of sarcoma, myxoma, rhabdomyoma, fibroma, lipoma, and teratoma; Lung cancer selected from the group consisting of bronchogenic carcinoma, alveolar carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, and mesothelioma; Gastrointestinal cancer selected from the group consisting of esophagus, stomach, pancreas, small bowel or small intestines, large bowel or large intestines, colon, colon-rectum, colorectal, and rectum; Genitourinary tract cancer selected from the group consisting of kidney, bladder and urethra, prostate, and testis cancer; Liver cancer selected from the group consisting of hepatoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma, and biliary passages cancer; Bone cancer selected from the group consisting of osteogenic sarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma, multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma, benign chondroma, chondroblastoma, chondromyxofibroma, and osteoid osteoma and giant cell tumors; Nervous system cancer selected from the group consisting of skull, meninges, and brain; Gynecological cancer selected from the group consisting ofWO 2017/059357PCT/US2016/054996 uterus, cervix, ovaries, vulva, vagina, and breast; Skin cancer selected from the group consisting of malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, keratoacanthoma, moles dysplastic nevi, lipoma, angioma, and dermatofibroma; Thyroid gland cancer selected from the group consisting of papillary thyroid carcinoma, follicular thyroid carcinoma; medullary thyroid carcinoma, multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type 2B, familial medullary thyroid cancer, pheochromocytoma, and paraganglioma; Adenoid cystic carcinoma; and Adrenal gland cancer.
- 13. The method of any one of claims 1-9, wherein said proliferative disorder is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, pancreatic cancer, biliary tract cancer, head and neck cancer, bladder cancer, colorectal cancer, glioblastoma, esophageal cancer, breast cancer, hepatocellular carcinoma, and ovarian cancer.
- 14. The method of claim 13, wherein said proliferative disorder is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, and triple negative breast cancer.
- 15. The method of any one of claims 1-14, wherein the compound that inhibits ATR is represented by Formula A-I:NHA-I or a pharmaceutically acceptable salt thereof, wherein:R1 is a 5-6 membered monocyclic aryl or heteroaryl ring having 0-4 heteroatoms independently nitrogen, oxygen, or sulfur, wherein said monocyclic aryl or heteroaryl ring is optionally fused to another ring to form an 8-10 membered bicyclic aryl or heteroaryl ring having 0-6 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; each R1 is optionally substituted with 1-5 J1 groups;WO 2017/059357PCT/US2016/054996R is a 5-6 membered monocyclic aryl or heteroaryl ring having 0-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein said monocyclic aryl or heteroaryl ring is optionally fused to another ring to form an 8-10 membered bicyclic aryl or heteroaryl ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; each R is optionally substituted with 1-5 J groups;L is -C(O)NH- or -C(O)N(Ci_6alkyl)-;n is 0 or 1;each J1 and J2 is independently halo, -CN, -NO2, -V^R, or -(V2)m-Q;V1 is a Ci_ioaliphatic chain wherein 0-3 methylene units are optionally and independently replaced with O, NR”, S, C(O), S(O), or S(O)2; V1 is optionally substituted with 1-6 occurrences of Jvl;V is a Ci_ioaliphatic chain wherein 0-3 methylene units are optionally and independently replaced with O, NR”, S, C(O), S(O), or S(O)2; V2 is optionally substituted with 1-6 occurrences of Jv2;m is 0 or 1;Q is a 3-8 membered saturated or unsaturated monocyclic ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, or a 910 membered saturated or unsaturated bicyclic ring having 0-6 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; each Q is optionally substituted with 0-5 IQ;each JV1 or Jv2 is independently halogen, CN, NH2, NO2, C^aliphatic, NH(C^aliphatic), N(Ci_4aliphatic)2, OH, O(Ci_4aliphatic), CO2H, CO2(Ci_4aliphatic), C(O)NH2, C(O)NH(Ci_4aliphatic), C(O)N(CMaliphatic)2,NHCO(CMaliphatic), N(Ci_4aliphatic)CO(Ci_4aliphatic), SO2(C|_4aliphatic), NHSO2(Ci_4aliphatic), or N(Ci_4aliphatic)SO2(Ci_4aliphatic), wherein said Ci_4aliphatic is optionally substituted with halo;R is H or Ci_6aliphatic wherein said Ci_6aliphatic is optionally substituted with 1-4 occurrences of NH2, NH(Ci_4aliphatic), N(C|_4aliphatic)2, halogen, C^aliphatic, OH, O(Ci_4aliphatic), NO2, CN, CO2H, CO2(Ci_4aliphatic), CO(Ci_4aliphatic), O(haloCi_4aliphatic), or haloCi^aliphatic;each IQ is independently halo, oxo, CN, NO2, X-R, or -(X)p-Q4;p is 0 or 1;WO 2017/059357PCT/US2016/054996X is Ci_ioaliphatic; wherein 1-3 methylene units of said Ci_6aliphatic are optionally replaced with -NR, -0-, -S-, C(O), S(O)2, or S(O); wherein X is optionally and independently substituted with 1-4 occurrences of NH2, NH(Ci_4aliphatic), N(Ci_4aliphatic)2, halogen, Ci_4aliphatic, OH, O(Ci_4aliphatic), NO2, CN, CO(Ci_4aliphatic), CO2H,CO2(Ci_4aliphatic), C(0)NH2, C(O)NH(CMaliphatic), C(O)N(CMaliphatic)2, SO(Ci_4aliphatic), SO2(Ci_4aliphatic), SO2NH(Ci_4aliphatic), SO2N(Ci_4aliphatic)2, NHC(O)(Ci_4aliphatic), N(Ci_4aliphatic)C(O)(Ci_4aliphatic), wherein said Ci_4aliphatic is optionally substituted with 1-3 occurrences of halo;Q4 is a 3-8 membered saturated or unsaturated monocyclic ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, or a 810 membered saturated or unsaturated bicyclic ring having 0-6 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; each Q4 is optionally substituted with 1-5 JQ4;J*·’4 is halo, CN, or Ci_4alkyl wherein up to 2 methylene units are optionally replaced with O, NR*, S, C(O), S(O), or S(O)2;R is H or Ci_4alkyl wherein said Ci^alkyl is optionally substituted with 1-4 halo;R” and R* are each independently H, Ci_4alkyl, or is absent; wherein said Ci_4alkyl is optionally substituted with 1-4 halo;wherein the proliferative disorder has one or more defects in the ATM signaling pathway.
- 16. The method of any one of claims 1-15, wherein the compound that inhibits ATR is a represented by Formula A-l:O=S=OA-l or a pharmaceutically acceptable salt thereof.
- 17. The method of any one of claims 1-15, wherein the compound that inhibits ATR is represented by Formula A-I-a:WO 2017/059357PCT/US2016/054996 or a pharmaceutically acceptable salt thereof;wherein:n~n Ο-NRing A is W!OAV,)r AN,J5o is H, F, Cl, Ci_4aliphatic, O(Ci_3aliphatic), or OH;., HN-J5psK5J5p is J P2 ;J5p 1 is H, Ci_4aliphatic, oxetanyl, tetrahydrofuranyl, or tetrahydropyranyl; wherein J5p 1 is optionally substituted with 1-2 occurrences of OH or halo;J5p2 is H, methyl, ethyl, CH2F, CF3, or CH2OH;J2o is H, CN, or SO2CH3;J2m is H, F, Cl, or methyl;J2p is -SO2(Ci_6alkyl), -SO2(C3_6cycloalkyl), -SO2(4-6 membered heterocyclyl), -SO2(Ci_4alkyl)N(Ci_4alkyl)2, or -SO2(CMalkyl)-(4-6 membered heterocyclyl), wherein said heterocyclyl contains 1 heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur; and wherein said J p is optionally substituted with 1-3 occurences halo, OH, or O(Ci_4alkyl).The method of claim 15, wherein Ring A isThe method of claim 15, wherein Ring A is20. The method of claim 15, wherein the compound that inhibits ATR is represented by Formula A-2:WO 2017/059357PCT/US2016/054996A-2 or a pharmaceutically acceptable salt thereof.21. The method of any one of claims 1-15, wherein the compound that inhibits ATR is represented by Formula A-II:or a pharmaceutically salt thereof, wherein:R10 is independently fluoro, chloro, or -C(J10)2CN;J10 is independently H or Ci_2alkyl; or two occurrences of J10 Together with the carbon atom to which they are attached, form a 3-4 membered optionally substituted carbocyclic ring;R is independently H; halo; -CN; NH2; a Ci_2alkyl optionally substituted with 0-3 occurrences of fluoro; or a Ci_3aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with -0-, -NRa-, -C(O)-, or -S(O)Z;aR is independently H; halo; Ci-4alkyl optionally substituted with 1-3 occurrences of halo; C3 4cycloalkyl; -CN; or a Ci_3aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or -S(O)Z;R4 is independently Q1 or a Ci-ioaliphatic chain wherein up to four methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or -S(O)Z-; each R4 is optionally substituted with 0-5 occurrences of JQ1; orR3 and R4, taken together with the atoms to which they are bound, form a 5-6 membered aromatic or non-aromatic ring having 0-2 heteroatoms selected from the group consistingWO 2017/059357PCT/US2016/054996 of oxygen, nitrogen, and sulfur; the ring formed by R3 and R4 is optionally substituted with 0-3 occurrences of J ;Q1 is independently a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring, the 3-7 membered ring having 0-3 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or an 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from the group consisting of oxygen, nitrogen, or sulfur;Jz is independently Ci ^aliphatic, =0, or halo;J is independently -CN; halo; =0; Q ; or a Ci-galiphatic chain wherein up to three methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or S(O)Z-; each occurrence of J is optionally substituted by 0-3 occurrences of J ; or two occurrences of JQI on the same atom, taken together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein the ring formed by two occurrences of J is optionally substituted with 0-3 occurrences of J ; or two occurrences of JQ1, together with Q1, form a 6-10 membered saturated or partially unsaturated bridged ring system;Q is independently a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring having 0-3 heteroatoms selected from oxygen, nitrogen, or sulfur; or an 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from oxygen, nitrogen, or sulfur;J is independently -CN; halo; =0; Q ; or a Ci_6aliphatic chain wherein up to three methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or -S(O)Z-;R T each J is optionally substituted with 0-3 occurrences of J ; orD two occurrences of J on the same atom, together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from oxygen, nitrogen, orD sulfur; wherein the ring formed by two occurrences of J is optionally substituted with 03 occurrences of J ; orR 2 two occurrences of J , together with Q , form a 6-10 membered saturated or partially unsaturated bridged ring system;aQ is a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring having 0-3 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or an 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclicWO 2017/059357PCT/US2016/054996 ring having 0-5 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;J is independently -CN; =0; halo; or a Ci_4aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with -0-, -NRa-, -C(O)-, or -S(O)Z-;J is independently halo, -CN; =0; -OH; a Ci_6aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with -0-, -NRa-, -C(O)-, or -S(O)Z-; or a 3-6 membered non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; each occurrence of J is optionally substituted with 0-3 occurrences of JM; or two occurrences of J on the same atom, together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or two occurrences of J , together with Q , form a 6-10 membered saturated or partially unsaturated bridged ring system;JM is independently halo or Ci ^aliphatic;z is 0, 1 or 2; andRa is independently H or C ^aliphatic.22. The method of claim 21, wherein R and R are fluoro.23. The method of claim 21, wherein R4 is Q1.24. The method of claim 21, wherein Q1 is independently piperidinyl and imidazolyl.25. The method of claim 21, wherein the compound that inhibits ATR is represented byFormula A-3:or a pharmaceutically acceptable salt thereof.WO 2017/059357PCT/US2016/05499626. The method of claim 21, wherein the compound that inhibits ATR is represented by Formula A-II-a:or a pharmaceutically acceptable salt thereof, wherein:R10 is independently fluoro, chloro, or -C(J10)2CN;J10 is independently H or Ci^alkyl; or two occurrences of J1 ,together with the carbon atom to which they are attached, form an optionally substituted 3-4 membered carbocyclic ring;aR is independently H; chloro; fluoro; Ci^alkyl optionally substituted with 1-3 occurrences of halo; C3_4cycloalkyl; -CN; or a Ci-3aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with -0-, -NRa-, -C(O)-, or -S(O)Z;L1 is H; a 3-7 membered aromatic or non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen nitrogen, and sulfur; or a C ^aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with -0-, -NRa-, -C(O), or -S(O)Z; each L1 is optionally substituted with Ci ^aliphatic; -CN; halo; -OH; or a 3-6 membered non-aromatic ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur;L is H; a 3-7 membered aromatic or non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen nitrogen, and sulfur; or a C ^aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O), or -S(O)Z; each L is optionally substituted with C^aliphatic; -CN; halo; -OH; or a 3-6 membered non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; orL and L , together with the nitrogen to which they are attached, form a Ring D; Ring D is optionally substituted with 0-5 occurrences of J ;L3 is H; Ci_3aliphatic; or CN;Ring D is independently a 3-7 membered heterocyclyl ring having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or an 7-12 membered fullyWO 2017/059357PCT/US2016/054996 saturated or partially unsaturated bicyclic ring having 1-5 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;J is independently halo; -CN; -N(R°)2; ->O; a 3-6 membered carbocycyl; a 3-6 membered heterocyclyl having 1-2 heteroatoms selected from oxygen nitrogen, or sulfur; or a Ci_ 4alkyl chain wherein up to two methylene units of the alkyl chain are optionally replaced with -0-, -NRa-, -C(O)-, or -S(O)Z; each JG is optionally substituted with 0-2 occurrences of JK two occurrences of J on the same atom, together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from oxygen, nitrogen, or sulfur; or two occurrences of J , together with Ring D, form a 6-10 membered saturated or partially unsaturated bridged ring system;LZJ is a 3-7 membered aromatic or non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;z is 0, 1, or 2; andRa and R° are H or Ci_4alkyl.27. The method of claim 26, wherein R and R are fluoro.28. The method of claim 21, wherein the compound that inhibits ATR is represented by Formula A-4:WO A-4 or a pharmaceutically acceptable salt thereof.29. The method of any one of claims 1-14, wherein the compound that inhibits ATR is:WO 2017/059357PCT/US2016/054996A-l,AO A-4, or a pharmaceutically acceptable salt thereof.30. The method of any one of claims 1-29, wherein the compound that inhibits ATR is administered between about 18 and about 42 hours after administration of the DNA damaging agent.WO 2017/059357PCT/US2016/05499631. The method of any one of claims 1-29, wherein the compound that inhibits ATR is administered between about 20 and about 40 hours after administration of the DNA damaging agent.32. The method of any one of claims 1-29, wherein the compound that inhibits ATR is administered between about 12 and about 36 hours after administration of the DNA damaging agent.33. The method of any one of claims 1-29, wherein the compound that inhibits ATR is administered between about 18 and about 36 hours after administration of the DNA damaging agent.34. The method of any one of claims 1-29, wherein the compound that inhibits ATR is administered between about 20 and about 28 hours after administration of the DNA damaging agent.35. The method of any one of claims 1-29, wherein the compound that inhibits ATR is administered about 24 hours after administration of the DNA damaging agent.36. A method of treating a proliferative disorder in a subject, the method comprising: administering to the subject in need thereof carboplatin and between about 12 and about 24 hours later administering to the subject a compound that inhibits ATR protein kinase.37. A method for achieving complete response in a subject having colorectal cancer, the method comprising:administering to the subject in need thereof a compound that inhibits ATR protein kinase as a monotherapy, wherein the colorectal cancer comprises cells having a defect in ATM.38. A method of treating a proliferative disorder in a subject, the method comprising: administering to the subject in need thereof carboplatin and between about 12 and about 48 hours later administering to the subject a compound represented by formula A-2:WO 2017/059357PCT/US2016/054996A-2, or a pharmaceutically acceptable salt thereof, wherein the target AUC of carboplatin is about 4 mg/mL*min or about 5 mg/mL*min and wherein the dosage of a compound of Formula A-2 is about 120 mg/m .39. A method of treating a proliferative disorder in a subject, the method comprising:administering to the subject in need thereof carboplatin and between about 12 and about 48 hours later administering to the subject a compound represented by formula A-2:or a pharmaceutically acceptable salt thereof, wherein the target AUC of carboplatin is about5 mg/mL*min and wherein the dosage of a compound of Formula A-2 is about 90 mg/m .40. A method of treating a proliferative disorder in a subject, the method comprising:administering to the subject in need thereof a platinating agent on day 1 and between about 12 and about 48 hours later administering to the subject a first dose of a compound that inhibits ATR protein kinase; and administering to the subject in need thereof a second dose of the compound that inhibits ATR protein kinase on day 9.41. The method of claim 40, wherein the platinating agent is selected from the group consisting of Cisplatin, Oxaliplatin, Carboplatin, Nedaplatin, Lobaplatin, Triplatin Tetranitrate, Picoplatin, Satraplatin, ProLindac, and Aroplatin.WO 2017/059357PCT/US2016/05499642. The method of any one of claims 36-41, wherein said proliferative disorder is cancer.43. The method of claim 42, wherein said cancer is a solid tumor cancer selected from the group consisting of lung cancers, gastrointestinal cancers, or gynecological cancers.44. The method of any one of claims 42-43, wherein said cancer is selected from the group consisting of non-small cell lung cancer, breast cancer, colorectal cancer, and ovarian cancer.45. The method of any one of claim 42-44, wherein the cancer has a defect in the ATM signaling cascade.46. The method of any one of claim 42-44, wherein the cancer has a defect in TP53.47. The method of any one of claims 36 and 42-46, wherein the carboplatin is administered on day 1 and the compound that inhibits ATR protein kinase is administered on day 2.48. The method of any one of claims 38, 39, and 42-46, wherein the carboplatin is administered on day 1 and the compound of formula A-2 is administered on day 2.49. The method of any one of claims 41-46, wherein the compound that inhibits ATR protein kinase is administered on day 2.50. The method of any one of claims 36, 37, and 40-49, wherein the compound that inhibits ATR is represented by Formula A-I:NHA-I or a pharmaceutically acceptable salt thereof,WO 2017/059357PCT/US2016/054996 wherein:R1 is a 5-6 membered monocyclic aryl or heteroaryl ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein said monocyclic aryl or heteroaryl ring is optionally fused to another ring to form an 8-10 membered bicyclic aryl or heteroaryl ring having 0-6 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; each R1 is optionally substituted with 1-5 J1 groups;R is a 5-6 membered monocyclic aryl or heteroaryl ring having 0-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein said monocyclic aryl or heteroaryl ring is optionally fused to another ring to form an 8-10 membered bicyclic aryl or heteroaryl ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; each R is optionally substituted with 1-5 J groups;L is -C(O)NH- or -C(O)N(Ci_6alkyl)-;n is 0 or 1;each J1 and J2 is independently halo, -CN, -NO2, -V^R, or -(V2)m-Q;V1 is a Ci_ioaliphatic chain wherein 0-3 methylene units are optionally and independently replaced with O, NR”, S, C(O), S(O), or S(O)2; V1 is optionally substituted with 1-6 occurrences of Jvl;V is a Ci-ioaliphatic chain wherein 0-3 methylene units are optionally and independently replaced with O, NR”, S, C(O), S(O), or S(O)2; V2 is optionally substituted with 1-6 occurrences of Jv2;m is 0 or 1;Q is a 3-8 membered saturated or unsaturated monocyclic ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, or a 910 membered saturated or unsaturated bicyclic ring having 0-6 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; each Q is optionally substituted with 0-5 JQ;each JV1 or Jv2 is independently halogen, CN, NH2, NO2, C^aliphatic, NH(C^aliphatic), N(Ci-4aliphatic)2, OH, O(Ci_4aliphatic), CO2H, CO2(Ci_4aliphatic), C(O)NH2, C(O)NH(Ci_4aliphatic), C(O)N(Ci.4aliphatic)2,NHCO(Ci.4aliphatic), N(Ci_4aliphatic)CO(Ci_4aliphatic), SO2(CMaliphatic), NHSO2(Ci_4aliphatic), orWO 2017/059357PCT/US2016/054996N(Ci_4aliphatic)SO2(Ci_4aliphatic), wherein said Ci_4aliphatic is optionally substituted with halo;R is H or Ci_6aliphatic wherein said Ci_6aliphatic is optionally substituted with 1-4 occurrences of NH2, NH(Ci_4aliphatic), N(C|-4aliphatic)2, halogen, Ci ^aliphatic, OH, O(Ci_4aliphatic), NO2, CN, CO2H, CO2(Ci_4aliphatic), CO(Ci_4aliphatic), O(haloCi_4aliphatic), or haloC^aliphatic;each JQ is independently halo, oxo, CN, NO2, X-R, or -(X)p-Q4;p is 0 or 1;X is Ci_ioaliphatic; wherein 1-3 methylene units of said Ci_6aliphatic are optionally replaced with -NR, -0-, -S-, C(O), S(O)2, or S(O); wherein X is optionally and independently substituted with 1-4 occurrences of NH2, NH(Ci_4aliphatic), N(Ci_4aliphatic)2, halogen, Ci_4aliphatic, OH, O(Ci_4aliphatic), NO2, CN, CO(Ci_4aliphatic), CO2H,CO2(CMaliphatic), C(0)NH2, C(O)NH(CMaliphatic), C(O)N(CMaliphatic)2, SO(Ci_4aliphatic), SO2(Ci_4aliphatic), SO2NH(Ci_4aliphatic), SO2N(Ci_4aliphatic)2, NHC(O)(Ci_4aliphatic), N(Ci-4aliphatic)C(O)(Ci_4aliphatic), wherein said Ci-4aliphatic is optionally substituted with 1-3 occurrences of halo;Q4 is a 3-8 membered saturated or unsaturated monocyclic ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, or a 810 membered saturated or unsaturated bicyclic ring having 0-6 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; each Q4 is optionally substituted with 1-5 JQ4;J*·’4 is halo, CN, or Ci_4alkyl wherein up to 2 methylene units are optionally replaced with O, NR*, S, C(O), S(O), or S(O)2;R is H or Ci_4alkyl wherein said Ci^alkyl is optionally substituted with 1-4 halo;R” and R* are each independently H, Ci_4alkyl, or is absent; wherein said Ci_4alkyl is optionally substituted with 1-4 halo.51. The method of any one of claims 36, 37, and 40-50, wherein the compound that inhibits ATR is represented by Formula A-I-a:WO 2017/059357PCT/US2016/054996 or a pharmaceutically acceptable salt thereof;wherein:n~n Ο-NRing A is YoYor AN,J5o is H, F, Cl, Ci_4aliphatic, O(Ci_3aliphatic), or OH;., HN-J5psK5J5p is J P2 ;J5p 1 is H, Ci_4aliphatic, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl; wherein J5p 1 is optionally substituted with 1-2 occurrences of OH or halo;J5p2 is H, methyl, ethyl, CH2F, CF3, or CH2OH;J2o is H, CN, or SO2CH3;J2m is H, F, Cl, or methyl;J2p is -SO2(Ci_6alkyl), -SO2(C3_6cycloalkyl), -SO2(4-6 membered heterocyclyl), -SO2(Ci_4alkyl)N(Ci_4alkyl)2, or -SO2(Cigalkyl)-(4-6 membered heterocyclyl), wherein said heterocyclyl contains 1 heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur; and wherein said J p is optionally substituted with 1-3 occurences halo, OH, or O(Ci_4alkyl).52,The method of claim 51 wherein Ring A isThe method of claim 51 wherein Ring A is54. The method of claim 51, wherein the compound that inhibits ATR is represented by Formula A-2:WO 2017/059357PCT/US2016/054996A-2 or a pharmaceutically acceptable salt thereof.55. The method of any one of claims 36, 37, and 40-49, wherein the compound that inhibits ATR is represented by Formula A-II:or a pharmaceutically salt thereof, wherein:R10 is independently fluoro, chloro, or -C(J 10)2CN;J10 is independently H or Ci_2alkyl; or two occurrences of J10 Together with the carbon atom to which they are attached, form a 3-4 membered optionally substituted carbocyclic ring;R is independently H; halo; -CN; NH2; a Ci_2alkyl optionally substituted with 0-3 occurrences of fluoro; or a Ci_3aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or -S(O)Z;aR is independently H; halo; Ci-4alkyl optionally substituted with 1-3 occurrences of halo; C3 4cycloalkyl; -CN; or a Ci_3aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or -S(O)Z;R4 is independently Q1 or a Ci-ioaliphatic chain wherein up to four methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or -S(O)Z-; each R4 is optionally substituted with 0-5 occurrences of JQ1; orR3 and R4, taken together with the atoms to which they are bound, form a 5-6 membered aromatic or non-aromatic ring having 0-2 heteroatoms selected from the group consistingWO 2017/059357PCT/US2016/054996 of oxygen, nitrogen, and sulfur; the ring formed by R3 and R4 is optionally substituted with 0-3 occurrences of J ;Q1 is independently a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring, the 3-7 membered ring having 0-3 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or an 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;Jz is independently Ci ^aliphatic, =0, or halo;J is independently-CN; halo; =0; Q ; or a Ci_saliphatic chain wherein up to three methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or S(O)Z-; each occurrence of J is optionally substituted by 0-3 occurrences of J ; or two occurrences of JQI on the same atom, taken together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein the ring formed by two occurrences of J is optionally substituted with 0-3 occurrences of J ; or two occurrences of JQ1, together with Q1, form a 6-10 membered saturated or partially unsaturated bridged ring system;Q is independently a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring having 0-3 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or an 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from the group consisting of oxygen, nitrogen, or sulfur;R 3J is independently-CN; halo; =0; ->0; Q ; or a Ci_6aliphatic chain wherein up to three methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or R TS(O)Z-; each J is optionally substituted with 0-3 occurrences of J ; orD two occurrences of J on the same atom, together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from the group consisting ofD oxygen, nitrogen, and sulfur; wherein the ring formed by two occurrences of J is optionally substituted with 0-3 occurrences of J ; or R 2 two occurrences of J , together with Q , form a 6-10 membered saturated or partially unsaturated bridged ring system;aQ is a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring having 0-3 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or an 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclicWO 2017/059357PCT/US2016/054996 ring having 0-5 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;J is independently -CN; =0; halo; or a Ci_4aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with -0-, -NRa-, -C(O)-, or -S(O)Z-;J is independently halo, -CN; =0; -OH; a Ci_6aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with -0-, -NRa-, -C(O)-, or -S(O)Z-; or a 3-6 membered non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; each occurrence of J is optionally substituted with 0-3 occurrences of JM; or two occurrences of J on the same atom, together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or two occurrences of J , together with Q , form a 6-10 membered saturated or partially unsaturated bridged ring system;JM is independently halo or Ci ^aliphatic;z is 0, 1 or 2; andRa is independently H or C ^aliphatic.56. The method of claim 55, wherein R and R are fluoro.57. The method of claim 55, wherein R4 is Q1.58. The method of claim 55, wherein Q1 is independently selected from the group consisting of piperidinyl and imidazolyl.59. The method of claim 55, wherein the compound that inhibits ATR is represented by Formula A-3:or a pharmaceutically acceptable salt thereof.WO 2017/059357PCT/US2016/05499660. The method of claim 55, wherein the compound that inhibits ATR is represented by Formula A-II-a:or a pharmaceutically acceptable salt thereof, wherein:R10 is independently fluoro, chloro, or -C(J10)2CN;J10 is independently H or Ci_2alkyl; or two occurrences of J1 Together with the carbon atom to which they are attached, form an optionally substituted 3-4 membered carbocyclic ring;aR is independently H; chloro; fluoro; Ci^alkyl optionally substituted with 1-3 occurrences of halo; C3_4cycloalkyl; -CN; or a Ci_3aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with -0-, -NRa-, -C(O)-, or -S(O)Z;L1 is H; a 3-7 membered aromatic or non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, or sulfur; or a C ^aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O), or -S(O)Z; each L1 is optionally substituted with C^aliphatic; -CN; halo; -OH; or a 3-6 membered non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, or sulfur;L is H; a 3-7 membered aromatic or non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or a Ci_6aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, C(O)-, or -S(O)Z; each L is optionally substituted with Ci^aliphatic; -CN; halo; -OH; or a 3-6 membered non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; orL and L , together with the nitrogen to which they are attached, form a Ring D; Ring D is optionally substituted with 0-5 occurrences of J ;L3 is H; Ci_3aliphatic; or CN;Ring D is independently a 3-7 membered heterocyclyl ring having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or an 7-12 membered fully100WO 2017/059357PCT/US2016/054996 saturated or partially unsaturated bicyclic ring having 1-5 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;J is independently halo; -CN; -N(R°)2; =0; a 3-6 membered carbocycyl; a 3-6 membered heterocyclyl having 1-2 heteroatoms selected from the group consisting of oxygen nitrogen, and sulfur; or a Ci_4alkyl chain wherein up to two methylene units of the alkyl chain are optionally replaced with -0-, -NRa-, -C(O)-, or -S(O)Z; each JG is optionally substituted with 0-2 occurrences of J .two occurrences of J on the same atom, together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or two occurrences of J , together with Ring D, form a 6-10 membered saturated or partially unsaturated bridged ring system;J is a 3-7 membered aromatic or non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;z is 0, 1, or 2; andRa and R° are H or Ci_4alkyl.61. The method of claim 60, wherein R and R are fluoro.62. The method of claim 55, wherein the compound that inhibits ATR is represented by Formula A-4:Ο A-4 or a pharmaceutically acceptable salt thereof.63. The method of any one of claims 36, 37, and 40-49, wherein the compound that inhibits ATR is:101WO 2017/059357PCT/US2016/054996A-l, vo a-4, or a pharmaceutically acceptable salt thereof.64. The method of any one of claims 38-63, wherein the compound that inhibits ATR is administered between about 18 and about 42 hours after administration of the DNA damaging agent.102WO 2017/059357PCT/US2016/05499665. The method of any one of claims 38-63, wherein the compound that inhibits ATR is administered between about 20 and about 40 hours after administration of the DNA damaging agent.66. The method of any one of claims 38-63, wherein the compound that inhibits ATR is administered between about 12 and about 36 hours after administration of the DNA damaging agent.67. The method of any one of claims 38-63, wherein the compound that inhibits ATR is administered between about 18 and about 36 hours after administration of the DNA damaging agent.68. The method of any one of claims 38-63, wherein the compound that inhibits ATR is administered between about 20 and about 28 hours after administration of the DNA damaging agent.69. The method of any one of claims 38-63, wherein the compound that inhibits ATR is administered about 24 hours after administration of the DNA damaging agent.70. A method of treating a proliferative disorder in a subject, the method comprising: administering to the subject in need thereof a DNA damaging agent and between about 12 and about 48 hours later administering to the subject a first dose of a compound that inhibits ATR protein kinase; and administering to the subject in need thereof a second dose of the compound that inhibits ATR protein kinase between about 6 to about 9 days after administering the first dose of the compound.71. The method of claim 70, wherein the DNA damaging agent is administered on day 1.72. The method of any one of claims 70 and 71, wherein the first dose is administered on day 2.103WO 2017/059357PCT/US2016/05499673. The method of any one of claims 70-72, wherein the second dose is administered on day 9.74. The method of any one of claims 70-73, wherein said DNA-damaging agent is chemotherapy or radiation treatment.75. The method of any one of claims 70-73, wherein said DNA-damaging agent is independently ionizing radiation, radiomimetic neocarzinostatin, a platinating agent, a Topo I inhibitor, a Topo II inhibitor, an antimetabolite, an alkylating agent, or an antibiotic.76. The method of claim 75, wherein said DNA-damaging agent is a platinating agent selected from the group consisting of cisplatin, oxaliplatin, carboplatin, nedaplatin, lobaplatin, triplatin tetranitrate, picoplatin, satraplatin, ProLindac, and aroplatin.77. The method of claim 75, wherein said DNA-damaging agent is a topo I inhibitor selected from the group consisting of camptothecin, topotecan, irinotecan/SN38, rubitecan, and belotecan.78. The method of claim 75, wherein said DNA-damaging agent is a Topo II inhibitor selected from the group consisting of etoposide, daunorubicin, doxorubicin, aclarubicin, epirubicin, idarubicin, amrubicin, pirarubicin, valrubicin, zorubicin, and teniposide.79. The method of claim 75, wherein said DNA-damaging agent is a antimetabolite selected from the group consisting of aminopterin, methotrexate, pemetrexed, raltitrexed, pentostatin, cladribine, clofarabine, fludarabine, thioguanine, mercaptopurine, fluorouracil, capecitabine, tegafur, carmofur, floxuridine, cytarabine, gemcitabine, 6-mercaptopurine, 5fluorouracil, azacitidine, and hydroxyurea.80. The method of claim 75, wherein said DNA-damaging agent is an alkylating agent selected from the group consisting of Mechlorethamine, Cyclophosphamide, Ifosfamide, Trofosfamide, Chlorambucil, Melphalan, Prednimustine, Bendamustine, Uramustine, Estramustine, Carmustine, Lomustine, Semustine, Fotemustine, Nimustine, Ranimustine, Streptozocin, Busulfan, Mannosulfan, Treosulfan, Carboquone, ThioTEPA, Triaziquone, Triethylenemelamine, Procarbazine, Dacarbazine, Temozolomide, Altretamine,104WO 2017/059357PCT/US2016/054996Mitobronitol, Actinomycin, Bleomycin, Mitomycin, nitrogen mustards, nitrosoureas, triazenes, alkyl sulfonates, Procarbazine, aziridines, and Plicamycin.81. The method of claim 75, wherein said DNA-damaging agent is an antibiotic selected from the group consisting of Hydroxyurea, Anthracyclines, Anthracenediones, and antibiotics from the Streptomyces family.82. A method of treating a proliferative disorder in a subject, the method comprising: administering to the subject in need thereof a platinating agent and between about 12 and about 48 hours later administering to the subject a compound that inhibits ATR protein kinase, wherein the subject is refractory to a treatment with the platinating agent.83. A method of treating a proliferative disorder in a subject, the method comprising: administering to the subject in need thereof a platinating agent and between about 12 and about 48 hours later administering to the subject a compound that inhibits ATR protein kinase, wherein the subject is resistant to a treatment with the platinating agent.84. The method of any one of claims 82 and 83, wherein the platinating agent is selected from the group consisting of Cisplatin, Oxaliplatin, Carboplatin, Nedaplatin, Lobaplatin, Triplatin Tetranitrate, Picoplatin, Satraplatin, ProLindac, and Aroplatin.85. The method of any one of claims 82 and 83, wherein the platinating agent is selected from the group consisting of Cisplatin and Carboplatin.86. The method of any one of claims 70-85, wherein said proliferative disorder is cancer.87. The method of claim 86, wherein said cancer is a solid tumor cancer selected from the group consisting of lung cancer, gastrointestinal cancer, and gynecological cancer.88. The method of any one of claims 86-87, wherein said cancer is non-small cell lung cancer, colorectal cancer, breast cancer, or ovarian cancer.89. The method of any one of claims 86-88, wherein the cancer has a defect in the ATM signaling cascade.105WO 2017/059357PCT/US2016/05499690. The method of any one of claims 86-89, wherein the cancer has a defect in TP53.91. The method of any one of claims 86-90, wherein the cancer is ovarian cancer.92. The method of any one of claims 70-91, wherein the compound that inhibits ATR is represented by Formula A-I:(L)n—R1R2 A-I or a pharmaceutically acceptable salt thereof, wherein:R1 is a 5-6 membered monocyclic aryl or heteroaryl ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein said monocyclic aryl or heteroaryl ring is optionally fused to another ring to form an 8-10 membered bicyclic aryl or heteroaryl ring having 0-6 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; each R1 is optionally substituted with 1-5 J1 groups;R is a 5-6 membered monocyclic aryl or heteroaryl ring having 0-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein said monocyclic aryl or heteroaryl ring is optionally fused to another ring to form an 8-10 membered bicyclic aryl or heteroaryl ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; each R is optionally substituted with 1-5 J groups;F is -C(O)NH- or -C(O)N(Ci_6alkyl)-;n is 0 or 1;each J1 and J2 is independently halo, -CN, -NO2, -V^R, or -(V2)m-Q;V1 is a Ci_ioaliphatic chain wherein 0-3 methylene units are optionally and independently replaced with O, NR”, S, C(O), S(O), or S(O)2; V1 is optionally substituted with 1-6 occurrences of Jvl;106WO 2017/059357PCT/US2016/054996V is a Ci_ioaliphatic chain wherein 0-3 methylene units are optionally and independently replaced with O, NR”, S, C(O), S(O), or S(O)2; V2 is optionally substituted with 1-6 occurrences of Jv2;m is 0 or 1;Q is a 3-8 membered saturated or unsaturated monocyclic ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, or a 910 membered saturated or unsaturated bicyclic ring having 0-6 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; each Q is optionally substituted with 0-5 JQ;each JV1 or Jv2 is independently halogen, CN, NH2, NO2, C^aliphatic, NH(C^aliphatic), N(Ci_4aliphatic)2, OH, O(Ci_4aliphatic), CO2H, CO2(Ci_4aliphatic), C(O)NH2, C(O)NH(Ci_4aliphatic), C(O)N(CMaliphatic)2,NHCO(CMaliphatic), N(Ci_4aliphatic)CO(Ci_4aliphatic), SO2(CMaliphatic), NHSO2(Ci_4aliphatic), or N(Ci_4aliphatic)SO2(Ci_4aliphatic), wherein said Ci_4aliphatic is optionally substituted with halo;R is H or Ci_6aliphatic wherein said Ci_6aliphatic is optionally substituted with 1-4 occurrences of NH2, NH(Ci_4aliphatic), N(CMaliphatic)2, halogen, C^aliphatic, OH, O(Ci_4aliphatic), NO2, CN, CO2H, CO2(Ci_4aliphatic), CO(Ci_4aliphatic), O(haloCi_4aliphatic), or haloCi^aliphatic;each JQ is independently halo, oxo, CN, NO2, X-R, or -(X)p-Q4;p is 0 or 1;X is Ci-ioaliphatic; wherein 1-3 methylene units of said Ci_6aliphatic are optionally replaced with -NR, -O-, -S-, C(O), S(O)2, or S(O); wherein X is optionally and independently substituted with 1-4 occurrences of NH2, NH(Ci_4aliphatic), N(Ci_4aliphatic)2, halogen, Ci_4aliphatic, OH, O(Ci_4aliphatic), NO2, CN, CO(Ci_4aliphatic), CO2H, CO2(Ci_4aliphatic), C(O)NH2, C(O)NH(Ci_4aliphatic), C(O)N(Ci_4aliphatic)2, SO(Ci_4aliphatic), SO2(Ci_4aliphatic), SO2NH(Ci_4aliphatic), SO2N(Ci_4aliphatic)2, NHC(O)(Ci_4aliphatic), N(Ci_4aliphatic)C(O)(Ci_4aliphatic), wherein said Ci_4aliphatic is optionally substituted with 1-3 occurrences of halo;Q4 is a 3-8 membered saturated or unsaturated monocyclic ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, or a 810 membered saturated or unsaturated bicyclic ring having 0-6 heteroatoms107WO 2017/059357PCT/US2016/054996 independently selected from the group consisting of nitrogen, oxygen, and sulfur; each Q4 is optionally substituted with 1-5 JQ4;J*·’4 is halo, CN, or Ci_4alkyl wherein up to 2 methylene units are optionally replaced with O, NR*, S, C(O), S(O), or S(O)2;R is H or Ci_4alkyl wherein said Ci^alkyl is optionally substituted with 1-4 halo;R” and R* are each independently H, Ci_4alkyl, or is absent; wherein said Ci_4alkyl is optionally substituted with 1-4 halo.93. The method of any one of claims 70-92, wherein the compound that inhibits ATR is represented by Formula A-I-a:or a pharmaceutically acceptable salt thereof;wherein:N'N O'NRingAis V^O^VorJ5o is H, F, Cl, Ci_4aliphatic, O(Ci_3aliphatic), or OH;<, HN-J^!K5J5p is J P2 ;J5p 1 is H, Ci_4aliphatic, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl; wherein J5p 1 is optionally substituted with 1-2 occurrences of OH or halo;J5p2 is H, methyl, ethyl, CH2F, CF3, or CH2OH;J2o is H, CN, or SO2CH3;J2m is H, F, Cl, or methyl;J2p is -SO2(Ci-6alkyl), -SO2(C3-6cycloalkyl), -SO2(4-6 membered heterocyclyl), -SO2(Ci_4alkyl)N(Ci_4alkyl)2, or -SO2(CMalkyl)-(4-6 membered heterocyclyl), wherein said heterocyclyl contains 1 heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur; and wherein said J p is optionally substituted with 1-3 occurrences halo, OH, or O(Ci_4alkyl).108WO 2017/059357PCT/US2016/054996N-N νΛΑν94. The method of claim 93, wherein Ring A is 5 O95. The method of claim 93, wherein Ring A is ,0'N96. The method of claim 93, wherein the compound that inhibits ATR is represented byFormula A-2:A-2 or a pharmaceutically acceptable salt thereof.97. The method of any one of claims 70-91, wherein the compound that inhibits ATR is represented by Formula A-II:NH2 O //R10 A-II or a pharmaceutically salt thereof, wherein:R10 is independently fluoro, chloro, or -C(J10)2CN;J10 is independently H or Ci_2alkyl; or two occurrences of J10 Together with the carbon atom to which they are attached, form a 3-4 membered optionally substituted carbocyclic ring;R is independently H; halo; -CN; NH2; a Ci_2alkyl optionally substituted with 0-3 occurrences of fluoro; or a Ci_3aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or -S(O)Z;109WO 2017/059357PCT/US2016/054996 αR is independently selected from H; halo; Ci_4alkyl optionally substituted with 1-3 occurrences of halo; C3_4cycloalkyl; -CN; or a Ci_3aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with -0-, -NRa-, -C(O)-, or -S(O)Z;R4 is independently Q1 or a C ii onl iphatic chain wherein up to four methylene units of the aliphatic chain are optionally replaced with -0-, -NRa-, -C(O)-, or -S(O)Z-; each R4 is optionally substituted with 0-5 occurrences of JQ1; orR3 and R4, taken together with the atoms to which they are bound, form a 5-6 membered aromatic or non-aromatic ring having 0-2 heteroatoms selected from oxygen, nitrogen or sulfur; the ring formed by R and R is optionally substituted with 0-3 occurrences of J ;Q1 is independently a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring, the 3-7 membered ring having 0-3 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or an 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;Jz is independently selected from Ci ^aliphatic, =0, or halo;J is independently-CN; halo; =0; Q ; or a Ci-saliphatic chain wherein up to three methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or S(O)Z-; each occurrence of J is optionally substituted by 0-3 occurrences of J ; or two occurrences of JQ1 on the same atom, taken together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; wherein the ring formed by two occurrences of J is optionally substituted with 0-3 occurrences of J ; or two occurrences of JQ1, together with Q1, form a 6-10 membered saturated or partially unsaturated bridged ring system;Q is independently a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring having 0-3 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or an 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;R 3J is independently -CN; halo; =0; ->O; Q ; or a Ci_6aliphatic chain wherein up to three methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or R TS(O)Z-; each J is optionally substituted with 0-3 occurrences of J ; or110WO 2017/059357PCT/US2016/054996D two occurrences of J on the same atom, together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from the group consisting ofD oxygen, nitrogen, and sulfur; wherein the ring formed by two occurrences of J is optionally substituted with 0-3 occurrences of J ; or R 2 two occurrences of J , together with Q , form a 6-10 membered saturated or partially unsaturated bridged ring system;aQ is a 3-7 membered fully saturated, partially unsaturated, or aromatic monocyclic ring having 0-3 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or an 7-12 membered fully saturated, partially unsaturated, or aromatic bicyclic ring having 0-5 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;J is independently -CN; =0; halo; or a Ci_4aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or -S(O)Z-;J is independently halo, -CN; ->0; =0; -OH; a Ci_6aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)-, or S(O)Z-; or a 3-6 membered non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; each occurrence of J is optionally substituted with 0-3 occurrences of JM; or two occurrences of J on the same atom, together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or two occurrences of J , together with Q , form a 6-10 membered saturated or partially unsaturated bridged ring system;JM is independently halo or Ci ^aliphatic;z is 0, 1 or 2; andRa is independently H or C ^aliphatic.98. The method of claim 97, wherein R and R are fluoro.99. The method of claim 97, wherein R4 is Q1.100. The method of claim 97, wherein Q1 is independently selected from the group consisting of piperidinyl and imidazolyl.IllWO 2017/059357PCT/US2016/054996101. The method of claim 97, wherein the compound that inhibits ATR is represented by Formula A-3:FA-3 or a pharmaceutically acceptable salt thereof.102. The method of claim 97, wherein the compound that inhibits ATR is represented by Formula A-II-a:or a pharmaceutically acceptable salt thereof, wherein:R10 is independently fluoro, chloro, or -C(J10)2CN;J10 is independently H or Ci_2alkyl; or two occurrences of J1 Together with the carbon atom to which they are attached, form an optionally substituted 3-4 membered carbocyclic ring;aR is independently H; chloro; fluoro; Ci-4alkyl optionally substituted with 1-3 occurrences of halo; C3_4cycloalkyl; -CN; or a Ci_3aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with -0-, -NRa-, -C(O)-, or -S(O)Z;L1 is H; a 3-7 membered aromatic or non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or a Ci_6aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, C(O)-, or -S(O)Z; each L1 is optionally substituted with Cigaliphatic; -CN; halo; -OH; or a 3-6 membered non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;L is H; a 3-7 membered aromatic or non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen nitrogen, and sulfur; or a C ^aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with -O-, -NRa-, -C(O)112WO 2017/059357PCT/US2016/054996 , or -S(O)Z; each L is optionally substituted with C^aliphatic; -CN; halo; -OH; or a 3-6 membered non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; orL and L , together with the nitrogen to which they are attached, form a Ring D; Ring D is optionally substituted with 0-5 occurrences of J ;L3 is H; Ci_3aliphatic; or CN;Ring D is independently a 3-7 membered heterocyclyl ring having 1-2 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur; or an 7-12 membered fully saturated or partially unsaturated bicyclic ring having 1-5 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;J is independently selected from the group consisting of halo; -CN; -N(R°)2; =0; a 3-6 membered carbocycyl; a 3-6 membered heterocyclyl having 1-2 heteroatoms selected from oxygen nitrogen, or sulfur; or a Ci_4alkyl chain wherein up to two methylene units of the alkyl chain are optionally replaced with -O-, -NRa-, -C(O)-, or -S(O)Z; each JG is optionally substituted with 0-2 occurrences of J .two occurrences of J on the same atom, together with the atom to which they are joined, form a 3-6 membered ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur; or two occurrences of J , together with Ring D, form a 6-10 membered saturated or partially unsaturated bridged ring system;J is a 3-7 membered aromatic or non-aromatic ring having 0-2 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur;z is 0, 1, or 2; andRa and R° are H or Ci_4alkyl.103. The method of claim 102, wherein R and R are fluoro.104. The method of claim 97, wherein the compound that inhibits ATR is represented by Formula A-4:113WO 2017/059357PCT/US2016/054996 or a pharmaceutically acceptable salt thereof.105. The method of any one of claims 70-91, wherein the compound that inhibits ATR is:114WO 2017/059357PCT/US2016/054996 uo a-4, or a pharmaceutically acceptable salt thereof.106. A method of treating a proliferative disorder in a subject, the method comprising: administering to the subject in need thereof carboplatin and a compound represented by Formula A-2, wherein the target AUC of carboplatin is between about 3 mg/mL*min and about 6 mg/mL*min and wherein the dosage of a compound of Formula A-2 is between about 60 mg/m2 and about 240 mg/m2.107. The method of claim 106, wherein the target AUC of carboplatin is about 4 mg/mL*min.108. The method of claim 106, wherein the target AUC of carboplatin is about 5 mg/mL*min.109. The method of claim 106, wherein the dosage of a compound represented byFormula A-2 is about 90 mg/m .110. The method of claim 106, wherein the dosage of a compound represented byFormula A-2 is about 120 mg/m .111. The method of claim 106, wherein the dosage of a compound represented byFormula A-2 is about 240 mg/m .112. The method of claim 106, wherein the target AUC of carboplatin is about 4 mg/mL*min and wherein the dosage of a compound of Formula A-2 is about 90 mg/m .115WO 2017/059357PCT/US2016/054996113. The method of claim 106, wherein the target AUC of carboplatin is about 5 mg/mL*min and wherein the dosage of a compound represented by Formula A-2 is about 90 mg/m2.114. A method of treating a proliferative disorder in a subject, the method comprising: administering to the subject in need thereof cisplatin and a compound represented byFormula A-2, wherein the dosage of cisplatin is between about 30 mg/m and about 90 mg/m and wherein the dosage of a compound of Formula A-2 is between about 60 mg/m and about 240 mg/m2.115. The method of claim 114, wherein the dosage of cisplatin is between about 402 2 mg/m and about 75 mg/m and wherein the dosage of a compound represented by Formula2 2A-2 is between about 90 mg/m and about 210 mg/m .116. The method of claim 114, wherein the dosage of cisplatin is about 40 mg/m .117. The method of claim 114, wherein the dosage of cisplatin is about 60 mg/m .118. The method of claim 114, wherein the dosage of cisplatin is about 75 mg/m .119. The method of claim 114, wherein the dosage of a compound represented byFormula A-2 is about 90 mg/m .120. The method of claim 114, wherein the dosage of a compound represented byFormula A-2 is about 140 mg/m .121. The method of claim 114, wherein the dosage of a compound represented byFormula A-2 is about 210 mg/m .122. The method of claim 114, wherein the dosage of cisplatin is between about 60 mg/m and about 90 mg/m and wherein the dosage of a compound represented by Formula A-2 is2 2 between about 120 mg/m and about 160 mg/m .116WO 2017/059357PCT/US2016/054996123. The method of claim 114, wherein the dosage of cisplatin is about 75 mg/m and wherein the dosage of a compound represented by Formula A-2 is about 140 mg/m .124. A method of treating a proliferative disorder in a subject, the method comprising:administering to the subject in need thereof gemcitabine and a compound represented by Formula A-2:O=S=O or a pharmaceutically acceptable salt thereof, wherein the dosage of gemcitabine is between about 300 and about 1200 mg/m and wherein the dosage of a compound of Formula A-2 is2 2 between about 10 mg/m and about 240 mg/m .125. The method of claim 124, wherein the dosage of gemcitabine is between about 500 and about 1000 mg/m and wherein the dosage of a compound of Formula A-2 is between2 2 about 18 mg/m and about 210 mg/m .126. The method of claim 124, wherein the dosage of gemcitabine is about 500 mg/m .127. The method of claim 124, wherein the dosage of gemcitabine is about 750 mg/m .128. The method of claim 124, wherein the dosage of gemcitabine is about 875 mg/m .129. The method of claim 124, wherein the dosage of gemcitabine is about 1000 mg/m .130. The method of claim 124, wherein the dosage of the compound represented byFormula A-2 is about 18 mg/m .131. The method of claim 124, wherein the dosage of the compound represented byFormula A-2 is about 36 mg/m .117WO 2017/059357PCT/US2016/054996132. The method of claim 124, wherein the dosage of the compound represented byFormula A-2 is about 60 mg/m .133. The method of claim 124, wherein the dosage of the compound represented byFormula A-2 is about 72 mg/m .134. The method of claim 124, wherein the dosage of the compound represented byFormula A-2 is about 90 mg/m .135. The method of claim 124, wherein the dosage of the compound represented byFormula A-2 is about 140 mg/m .136. The method of claim 124, wherein the dosage of the compound represented byFormula A-2 is about 210 mg/m .137. The method of claim 124, wherein the dosage of gemcitabine is about 875 mg/m to 1125 mg/m and the dosage of the compound represented by Formula A-2 is between about 180 mg/m2 and about 240 mg/m2.138. The method of claim 124, wherein the dosage of gemcitabine is about 1000 mg/m and the dosage of the compound represented by Formula A-2 is about 210 mg/m .139. The method of any one of claims 106-138, wherein the compound represented by Formula A-2 is administered between about 12 and about 48 hours after administration of the DNA damaging agent.140. The method of any one of claims 106-138, wherein the compound represented by Formula A-2 is administered between about 18 and about 42 hours after administration of the DNA damaging agent.141. The method of any one of claims 106-138, wherein the compound represented by Formula A-2 is administered between about 20 and about 40 hours after administration of the DNA damaging agent.118WO 2017/059357PCT/US2016/054996142. The method of any one of claims 106-138, wherein the compound represented by Formula A-2 is administered between about 12 and about 36 hours after administration of the DNA damaging agent.143. The method of any one of claims 106-138, wherein the compound represented by Formula A-2 is administered between about 18 and about 36 hours after administration of the DNA damaging agent.144. The method of any one of claims 106-138, wherein the compound represented by Formula A-2 is administered between about 20 and about 28 hours after administration of the DNA damaging agent.145. The method of any one of claims 106-138, wherein the compound represented by Formula A-2 is administered about 24 hours after administration of the DNA damaging agent.146. The method of any one of claims 1-4, 15-35, 70-85, 92-105, 114-123, and 139-145, wherein the proliferative disorder is lung cancer, breast cancer, neuroendocrine cancer, or ovarian cancer.147. The method of claim 146, wherein the cancer is mesothelioma, triple negative breast cancer, CA 125 positive ovarian cancer, or neuroendocrine prostate cancer.148. A method of treating a proliferative disorder in a subject, the method comprising: administering to the subject in need thereof a compound represented by Formula A2:HN—119WO 2017/059357PCT/US2016/054996 or a pharmaceutically acceptable salt thereof, wherein the dosage of the compound represented by Formula A-2 is between about 1202 2 mg/m and about 480 mg/m .149. The method of claim 148, wherein the dosage of the compound represented byFormula A-2 is about 120 mg/m .150. The method of claim 148, wherein the dosage of the compound represented byFormula A-2 is about 240 mg/m .151. The method of claim 148, wherein the dosage of the compound represented byFormula A-2 is about 480 mg/m .152. The method of any one of claims 148-151, wherein the compound represented by Formula A-2 is delivered as a monotherapy.153. A method of treating a proliferative disorder in a subject, the method comprising: administering to the subject in need thereof a DNA damaging agent and at least about 12 hours later administering to the subject a first dose of a compound that inhibits ATR protein kinase; and administering to the subject in need thereof a second dose of the compound that inhibits ATR protein kinase at least about 6 days after administering the first dose of the compound.154. The method of claim 153, wherein the compound that inhibits ATR protein kinase is administered at least about 24 hours later.120WO 2017/059357 PCT/US2016/0549961/21FIG. 1Time (hours)Optimization of Compound A-2 Dose Schedule In VitroSUBSTITUTE SHEET (RULE 26)WO 2017/059357PCT/US2016/0549962/21Tumor vobme (mm3)FIG. 2Time (days) ~0~ Vehicle (saline IP q3d + 5% Captisol/3% mannitol IV q6d)Compound A-2 (20 mg/kg IV q6d)-O Gemcitabine (15 mg/kg IP q3d)-tO Compound A-2 (20 mg/kg IV (-2 H) q6d) + Gemcitabine (15 mg/kg IP q3d) Gemcitabine (15 mg/kg IP q3d) + Compound A-2 (20 mg/kg IV (+12 h) q6d) Gemcitabine (15 mg/kg IP q3d) + Compound A-2 (20 mg/kg IV (+24 h) q6d) Gemcitabine (15 mg/kg IP q3d) + Compound A-2 (20 mg/kg IV (+48 h) q6d)Optimization of Intravenous Compound A-2 Dose Schedule in Combination With Gemcitabine In VivoSUBSTITUTE SHEET (RULE 26)WO 2017/059357PCT/US2016/0549963/21FIG. 3Tame (days)-Ο Vehicle (5% Capiisol/3% mannitol IV 2x weekly) ~Φ~ Compound A-2 (20 mg/kg IV 2x weekly) ~Q” Cisplatin (3 mg/kg IV 2x weekly) ~A~ Cisplatin (3 mg/kg IV q7d) + Compound A-2 (10 mg/kg IV (+14 h) 2x weekly)-V- Cisplatin (3 mg/kg IV q7d) + Compound A-2 (10 mg/kg IV (+24 h) 2x weekly)-Ο- Cisplatin (3 mg/kg IV q7d) + Compound A-2 (10 mg/kg IV (+48 h) 2x weekly)SUBSTITUTE SHEET (RULE 26)WO 2017/059357PCT/US2016/0549964/21SUBSTITUTE SHEET (RULE 26)WO 2017/059357PCT/US2016/0549965/21SO -ο- 120 240SUBSTITUTE SHEET (RULE 26)WO 2017/059357PCT/US2016/0549966/21 \ umor
A-2120mg/m2 A-2 90mg./m2 +Carbo AUC 5 +Carbo AUC 5 SUBSTITUTE SHEET (RULE 26)WO 2017/059357PCT/US2016/0549967/21FIG. 7SUBSTITUTE SHEET (RULE 26)WO 2017/059357PCT/US2016/0549968/21 % ‘suipseg iuoj j sSueyoSUBSTITUTE SHEET (RULE 26)WO 2017/059357PCT/US2016/0549969/21 σ>ΟΟ £xsHW.·Έ £«ζ ”5« ε:«Λ ,Ε ο*«* (ΛHS (Λ raΟ χζV raQUI srt >·ΟΌ <Ν4«ΟC <ϋ ra οΜ «£SUBSTITUTE SHEET (RULE 26)WO 2017/059357PCT/US2016/05499610/21Ο £xsHW.·Έ £«ζ ”5« ε:«Λ ,Ε ο*«* (ΛHS (Λ roΟ χζV «ϊUI srt >·ΟΌ <Ν4«ΟC <ϋ roλ.οΜ «£ σ>ΟSUBSTITUTE SHEET (RULE 26)WO 2017/059357PCT/US2016/05499611/21FIG. 10SUBSTITUTE SHEET (RULE 26)WO 2017/059357PCT/US2016/05499612/21FIG. 11SUBSTITUTE SHEET (RULE 26)WO 2017/059357PCT/US2016/05499613/21 (%) suijsseg luoj j eBueqo <3.3SUBSTITUTE SHEET (RULE 26)WO 2017/059357PCT/US2016/05499614/21CZ3C+J ?X j£3Ο ΐΰΟΟΟ οο e>...ο <u>&0Μ,1ϊ>«3ΟCM ^*2 οX*-, Χ-- S»»·· χ~> 5Ζ· Χχ 3£ ΣχΞ os 03 os 03 os Os os 03 os φ X* '“»κ 5> *£ϊ» . -S- α> ο> ο> 03 'J· 4ι <D ο ο ο «ο ί- c:: C '+22 £” ο Ο :: ¢.--4 Ο <·4 Ο C J U C£?·· osOS £~OS θco co Ο J os ££ θ’Ό*C--J θ<30 θC-J :< Ml·—ΟΈ ο>«3Q7 ++ Ο 'ο <ί>* ' β/.-.-,CO? Ο ο· ga LU oi Οί' Ο ίΧ ο ·»!-·'':€:::Ο» .· ’.ί~# «3W ™Γ· «Ρ ο -*-C α* ; .rti . S»W«· ; XSjl ο ίCVS + CCS os <*> α>>φνν<«β 1 α>« ι™,Γ-— ·Χ><£>«?>Ο·>xtso &ν>£Φ ϊϊϊ ί»*Μ> few 3Μ4« JWM ό ο ο “Ο Ό -ΊΟ 1 ο w ·Χ3SSK α>Β os <υ jJfcu «3 iwS JPg. ' isa “Ο Ο SC5 C». OS : ^3* ......Ο -ΩWi -^MW*Ο >*<«3Ο .JSSJX--SSS ο'ΰ>¢3JEJΟ ίφΜ*Ο»ΟJ3 osΜ*Μ fM** »m«s ε» ο ο /4% iwwW: <«*ϊ* ο α> Ε ο ***** «Κ****1·.*«*# Χ5»« οίΰ οο σ>ο ><mw λ— . ί 1CO «3Ο «3ΟΟ ο>ο οΟ«ϊ 03 Ϊίϊ ,£5 Ε 4&Ρ Ο >)μύΚ iPES ο λΟ Aw c&> «α ?W«i If' *4 φ ο tg Cm3 Jgg «ί X ο ' Ο os 03 13 03 03 fOu «ΚΕ Smw Ο ?α ό ο Ο JEZΟ0ΐ mosYu...225Ο <«>04 -SX SO Ο ¢72-3 οοX?:ο σιί.ί>ο>S.V.UU ο>ο ο·,OS .X??<osΧ3 οΧΧίS.X ί/3C.3 coSUBSTITUTE SHEET (RULE 26)WO 2017/059357PCT/US2016/05499615/21 <Z3 tin7X j£3 tS «3OOOSO1ft raOCM oT*-u X-- 'J>-U Xx x~> X-. 3Z’ jSS XT ΣχΞ as as as as as Os as as as as Ti* '“Sk s> *£y» . 7-^ a> as as as .j· 4i as 0 0 0 <u-3 es 0 0 0 C” O O :: ¢.--4 O <•4 O C J U CM os os?£~ os θtoOS cj os o’O' c-j θera toC-J :< -Ml·—.OΈ as «3QT o„ O 'o > <JL>* e*--.-.CO? O O ' ga LU as or o4X o':c:::,as «3 w ™r. ro ο -*-a* <Ξ o i JFs iO S™ «Ϊ as a> asS’, r \ A™, co c™.r— <£>U?>soXtso &v>*O a>«CEP <¥S3M4« JWM BW WWi0 0 O “Ο Ό -ΊΟ 1 o w ·Χ3 asSS' asB as as as iJib ra iwS JPg. ' isa “Ο O scs s». as .......“ j£ Ο Λ wi ^Amw* «3O .JSSJX.„„s§§O ’as ra as ίφΜ* asCL.jg asM*M fM** mmS ww0 0Λΐ »wwW: «**»«0 a>E 0 0 $·.*«*# ?S»« ts ra «ftO ><mw λ— . il·«i* «ft «3 :0:as ra asra ra _o E M3 o «IwmK (PCS 0 λΟ £.?. Aw ¢33 ra « w«< & A φ 0 0 Cu3 Jgg - ra Jw 0 0 «ft as *ra 0 as ra fOu os Smw 0 ra 0 0 0 JEZ6ft λ»·* as asYu...uu?5 <«><— θX?O OC2s as x?O ¢/3 i/3 asS.V.UU o>iSL.as .XT -»—<asO 'ΌS?T ¢/3 a?COSUBSTITUTE SHEET (RULE 26)WO 2017/059357PCT/US2016/05499616/21ΟCMCM »ujoj j eOuoqoSUBSTITUTE SHEET (RULE 26)WO 2017/059357PCT/US2016/05499617/21ΟCMCM »ujoj j eOuoqoSUBSTITUTE SHEET (RULE 26)WO 2017/059357PCT/US2016/054996 - 18/21TOColorectal cancer fcw ra «X ora «3 o
«-Γ4 «-Γ4 »<T <-O O o o O ,o ,o : Z> z> <c <c : «3 : << to θTO θCJ to θ<y>4XCLI(/) oajLi or2$^O •*4h>4*C3OS ex,X¥Srwx' o«ft «33 oC c>s?OS ex„TO :-: m rt'i Φ js?04 5*. w £™ O £3 Xs <ft φ £3 03S) <*> 04 o>*«rL...L.O coΌ» riS j£a<XT ra oΉ ra £4 oCIOSCT3E oΌ raTOΊΒ '*a*F <3CL,CL “0 *~oCXI • £-..:3 ·CXJ uoO “O H ~O ~O ~O ~O e—>I II I to....tu,...ih..,..jh......Ife......lh......lu. .„&,..Wr/. IMW», 'W' ' . JC, it' «*«*« F lf*g Jam c; O C3 fcto Ϊ5Ϊ ra £5 JsC ra 04 ora9emm oo oo JS3 S o>ΤτϊU . .« TO* o© λίΜ .o ooIIB w 1 B III 33;......333, «Jez X *(*W &4 -:'SUw, < 04 tn CCS ra > O £ Φ o O JBW ra o 0 ra « co ¢8 OXS © © ra ra •ra: o 04 040 o o o o o4»« i-flu o o «ft «ft 04 «14 ^*^ln>— . . Smm>«es?® # * ' **-*-aw< ra ££ ta ra _ o iMra mem «$ «3 εζ: ο» te««O o ra o E ° .ra «ft . : iX*«·”18,-,.,, /,7,3O oo ,<,.,,.o73,7O 'Ό toOK...oS33 o0¾ wTO5) o*<,·,,, o„ .^,,,, raX77 .^,,,,.TO' oΌ sr?:s’,ft o<Cm.' inOSUBSTITUTE SHEET (RULE 26)WO 2017/059357PCT/US2016/054996 - 19/21TOWWW ra «X ora «3 o
«-Γ4 «-Γ4 -»<T <-O O o o o .ra ra : ra ra <c <c : < : << o>to θTO θto θ<y>4XCLI(/) oajLi orSj±:o •*4h>4*CZSS3 ra ex,X¥Srwx' o«ftSX oc;;«£>s?OS ex..TO :-: mT~ Ό -*± rt'i Φ ίϊΐ04 5*. wF- o 03 Xs (ft φ C its S) Φ 04 -i=O o>*«rL...L.O coC-Z3 riS j£3<ra “Ό *~o • £-..:3'CXJ «ft uo inOO “O H ~O ~O ~Ο ~O e—>I II I toO oo oO ”OIIBB ,γ. .B..T..B...t..M..t..l ra...lh. .....Ife......lh......lh..,...lh.w 1 B III M.....SsLColorectal cancer oΉ raC4 oS3raCT3E oΌ ra-wr *«*** 'W' -τ'?' . -jc. a.' »*«*** r ra J™ c; o ¢3 X ϊίϊ ra TA ra 04 oTO3ww<raΊΒ 'xa*F <3 ra 'o9emm oo o° JS3 S o>axii ..-TTU . .« TO* o© λίΜ .o oo «Jez X *(*W &4 ^ea. 04 tn CCS ra > O £ Φ o O JBW ra o ra o co ¢8 OXS © © ra ra •ra: ra 04 040 o o o o o4»« i-flx o o «ft «ft 04 «14 ^*^ln>— . . Smm>^gS* ,:qS «es?® # * ra ££ ta ra _ <_4 iMra mem «$ «3S3 04 te««O o ra oE ° .raCL, toO5..,.oTO o</4TO5) o*<,,,, o„ ra .TOTO' oΌS-? l\.,CL s’.ft o<C <rraSUBSTITUTE SHEET (RULE 26)WO 2017/059357PCT/US2016/054996 - 20/21SUBSTITUTE SHEET (RULE 26)WO 2017/059357 PCT/US2016/054996
- 21/21FIG. 17Duration of Progression-Free Survival From Start of TreatmentColorectalColorectalColon Head and neck NSCLCMesotheliomaNSCLCEndometrialPancreaticRectalNSCLCNSCLCCervicalRectosigmoidAnalESCCNSCLCRenalGISTColorectalColorectalPancreatic0.1Colorectal Unknown primary NSCLCMesothelioma Ocular melanoma ColorectalColorectalColorectalMesothelioma Unknown primary AppendixBreastColorectalColorectalBreastMesotheliomaColorectalColorectalCervixColorectalMesotheliomaColorectalMesothelioma Unknown primary Breast Breast29.3I 63.3 * 62.4 —<j 13.3r...................................·»...................................r..................................f..................................τ
0 1* Endpoint /»12 24 36 Weeks 48 60 A-2 Gemcitabine A-2 Gemcitabine A-2 Gemcitabine CC 18 mg/m2 875 mq/m2 o 90 mg/m2 500 mq/m2 MB 210 mq/m2 750 mq/m2 36 mg/m2 875 mq/m2 L.J 140 mq/m2 500 mq/m2 m 210 mg/m2 875 mq/m2 S3 go mg/m2 72 mg/m2 875 mq/m2 875 mq/m2 SS3 210 mq/m2 500 mg/m2 SB 210 mg/m2 1000 mq/m2 GIST, gastrointestinal stromal tumor; ESCC, esophageal squamous cell carcinoma; NSCLC, non-small cell lung cancer: SCLC, small cell lung cancerSUBSTITUTE SHEET (RULE 26)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022256154A AU2022256154A1 (en) | 2015-09-30 | 2022-10-20 | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562235393P | 2015-09-30 | 2015-09-30 | |
US62/235,393 | 2015-09-30 | ||
US201562251640P | 2015-11-05 | 2015-11-05 | |
US62/251,640 | 2015-11-05 | ||
US201662287136P | 2016-01-26 | 2016-01-26 | |
US62/287,136 | 2016-01-26 | ||
US201662303153P | 2016-03-03 | 2016-03-03 | |
US62/303,153 | 2016-03-03 | ||
US201662323055P | 2016-04-15 | 2016-04-15 | |
US62/323,055 | 2016-04-15 | ||
US201662345191P | 2016-06-03 | 2016-06-03 | |
US62/345,191 | 2016-06-03 | ||
PCT/US2016/054996 WO2017059357A1 (en) | 2015-09-30 | 2016-09-30 | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2022256154A Division AU2022256154A1 (en) | 2015-09-30 | 2022-10-20 | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2016331955A1 true AU2016331955A1 (en) | 2018-04-12 |
AU2016331955B2 AU2016331955B2 (en) | 2022-07-21 |
Family
ID=58427990
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2016331955A Ceased AU2016331955B2 (en) | 2015-09-30 | 2016-09-30 | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
AU2022256154A Pending AU2022256154A1 (en) | 2015-09-30 | 2022-10-20 | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2022256154A Pending AU2022256154A1 (en) | 2015-09-30 | 2022-10-20 | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
Country Status (11)
Country | Link |
---|---|
US (2) | US11464774B2 (en) |
EP (1) | EP3355926A4 (en) |
JP (1) | JP7187308B2 (en) |
KR (1) | KR20180054657A (en) |
AU (2) | AU2016331955B2 (en) |
CA (1) | CA3000684A1 (en) |
HK (1) | HK1258570A1 (en) |
IL (1) | IL258410A (en) |
MX (1) | MX2018003657A (en) |
RU (1) | RU2768621C1 (en) |
WO (1) | WO2017059357A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2869309C (en) | 2012-04-05 | 2021-02-09 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
EP3402532B1 (en) | 2016-01-11 | 2022-04-13 | Celator Pharmaceuticals, Inc. | Inhibiting ataxia telangiectasia and rad3-related protein (atr) |
CA3038657A1 (en) * | 2016-09-27 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors |
WO2018115984A1 (en) | 2016-12-19 | 2018-06-28 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation |
EP3732301A4 (en) * | 2017-12-29 | 2022-02-09 | Vertex Pharmaceuticals Incorporated | Methods of cancer treatment using an atr inhibitor |
EP4056560A1 (en) | 2018-03-08 | 2022-09-14 | Incyte Corporation | Aminopyrazine diol compounds as pi3k-y inhibitors |
WO2019236673A1 (en) | 2018-06-06 | 2019-12-12 | Massachusetts Institute Of Technology | Circular rna for translation in eukaryotic cells |
WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
IL288284B1 (en) | 2019-05-22 | 2024-02-01 | Massachusetts Inst Technology | Circular rna compositions and methods |
ES2961245T3 (en) | 2019-12-04 | 2024-03-11 | Orna Therapeutics Inc | Circular RNA compositions and methods |
TWI794742B (en) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | Antiviral compounds |
AU2022256476A1 (en) | 2021-04-16 | 2023-10-12 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
TW202309299A (en) * | 2021-07-12 | 2023-03-01 | 大陸商北京輯因醫療科技有限公司 | Methods of identifying drug sensitive genes and drug resistant genes in cancer cells |
Family Cites Families (362)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4309430A (en) | 1980-06-27 | 1982-01-05 | Merck & Co., Inc. | Pyrazinyl-1,2,4-oxadiazole-5-ones, for treatment of edema, and processes for preparing same |
JPS62270623A (en) | 1985-12-07 | 1987-11-25 | Daicel Chem Ind Ltd | Bis(4-aminophenyl)pyrazine, its production, polyimide and its production |
JPS63208520A (en) | 1987-02-26 | 1988-08-30 | Terumo Corp | Blood platelet agglutination inhibitor containing pyrazine derivative |
US5329012A (en) | 1987-10-29 | 1994-07-12 | The Research Foundation Of State University Of New York | Bis(acyloxmethyl)imidazole compounds |
JPH0272372A (en) | 1988-09-07 | 1990-03-12 | Konica Corp | Electrophotographic sensitive body |
JPH0272370A (en) | 1988-09-07 | 1990-03-12 | Konica Corp | Electrophogoraphic sensitive body |
JPH0374370A (en) | 1989-08-16 | 1991-03-28 | Terumo Corp | Pyrazine derivative and platelet agglutination inhibiting agent or antiinflammatory agent containing the same |
JP2597917B2 (en) | 1990-04-26 | 1997-04-09 | 富士写真フイルム株式会社 | Novel dye-forming coupler and silver halide color photographic material using the same |
US5572248A (en) | 1994-09-19 | 1996-11-05 | Teleport Corporation | Teleconferencing method and system for providing face-to-face, non-animated teleconference environment |
ATE208778T1 (en) | 1995-05-09 | 2001-11-15 | Basf Ag | PYRAZOLO-1,5A)-PYRIMIDINES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE |
WO1997043267A1 (en) | 1996-05-11 | 1997-11-20 | Kings College London | Pyrazines |
EP0915880B1 (en) | 1996-07-24 | 2007-10-10 | Bristol-Myers Squibb Pharma Company | Azolo triazines and pyrimidines |
US6191131B1 (en) | 1997-07-23 | 2001-02-20 | Dupont Pharmaceuticals Company | Azolo triazines and pyrimidines |
US6060478A (en) | 1996-07-24 | 2000-05-09 | Dupont Pharmaceuticals | Azolo triazines and pyrimidines |
JP4026876B2 (en) | 1996-09-05 | 2007-12-26 | 日本食品化工株式会社 | Luminescent cyclodextrin derivative and method for producing the same |
JPH10218881A (en) | 1997-02-03 | 1998-08-18 | Pola Chem Ind Inc | New pyrrolopyrazolopyrimidine derivative |
JP2002241379A (en) | 1997-03-21 | 2002-08-28 | Dainippon Pharmaceut Co Ltd | 3-oxadiazolylquinoxaline derivative |
US6235741B1 (en) | 1997-05-30 | 2001-05-22 | Merck & Co., Inc. | Angiogenesis inhibitors |
JP2002501532A (en) | 1997-05-30 | 2002-01-15 | メルク エンド カンパニー インコーポレーテッド | Novel angiogenesis inhibitors |
WO1999044609A1 (en) | 1998-03-03 | 1999-09-10 | Merck & Co., Inc. | FUSED PIPERIDINE SUBSTITUTED ARYLSULFONAMIDES AS β3-AGONISTS |
DE19826671A1 (en) | 1998-06-16 | 1999-12-23 | Hoechst Schering Agrevo Gmbh | 1,3-oxazoline and 1,3-thiazoline derivatives, processes for their preparation and their use as pesticides |
KR20010071936A (en) | 1998-07-16 | 2001-07-31 | 시오노 요시히코 | Pyrimidine derivatives exhibiting antitumor activity |
US7023913B1 (en) | 2000-06-14 | 2006-04-04 | Monroe David A | Digital security multimedia sensor |
KR100632079B1 (en) | 1999-01-11 | 2006-10-04 | 아구론 파마슈티컬스, 인크. | Tricyclic inhibitors of polyADP-ribosepolymerases |
ATE330968T1 (en) | 1999-02-05 | 2006-07-15 | Debiopharm Sa | CYCLOSPORINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF |
US6245759B1 (en) | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6738073B2 (en) | 1999-05-12 | 2004-05-18 | Imove, Inc. | Camera system with both a wide angle view and a high resolution view |
EP1377554A1 (en) | 1999-06-16 | 2004-01-07 | University Of Iowa Research Foundation | Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases |
US7015954B1 (en) | 1999-08-09 | 2006-03-21 | Fuji Xerox Co., Ltd. | Automatic video system using multiple cameras |
US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
JP2001302666A (en) | 1999-09-21 | 2001-10-31 | Nissan Chem Ind Ltd | Azole-condensed heterocyclic anilide compound and herbicide |
MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
AU782858B2 (en) | 1999-12-17 | 2005-09-01 | Novartis Vaccines And Diagnostics, Inc. | Pyrazine based inhibitors of glycogen synthase kinase 3 |
AR029489A1 (en) | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | PIRIDINES, PYRIMIDINES, PIRAZINAS, TRIAZINES REPLACED BY ARILO, PHARMACEUTICAL COMPOSITIONS AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
US6723332B2 (en) | 2000-05-26 | 2004-04-20 | Neurogen Corporation | Oxomidazopyridine-carboxamides |
US20020041880A1 (en) | 2000-07-05 | 2002-04-11 | Defeo-Jones Deborah | Method of treating cancer |
US6849660B1 (en) | 2000-08-01 | 2005-02-01 | Isis Pharmaceuticals, Inc. | Antimicrobial biaryl compounds |
JP2002072370A (en) | 2000-08-29 | 2002-03-12 | Fuji Photo Optical Co Ltd | Paper magazine and photograph printing device |
JP2002072372A (en) | 2000-09-04 | 2002-03-12 | Fuji Photo Film Co Ltd | Cutter for image forming sheet body |
US6829391B2 (en) | 2000-09-08 | 2004-12-07 | Siemens Corporate Research, Inc. | Adaptive resolution system and method for providing efficient low bit rate transmission of image data for distributed applications |
AP1666A (en) | 2000-09-11 | 2006-09-29 | Chiron Corp | Quinolinone derivatives as tyrosine kinase inhibitors. |
US20030028018A1 (en) | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
US7067520B2 (en) | 2000-11-17 | 2006-06-27 | Ishihara Sangyo Kaisha, Ltd. | Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts |
EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
US6420637B1 (en) | 2001-01-29 | 2002-07-16 | Asgrow Seed Company L.L.C. | Plants and seeds of corn variety I389972 |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
US8085293B2 (en) | 2001-03-14 | 2011-12-27 | Koninklijke Philips Electronics N.V. | Self adjusting stereo camera system |
US6759657B2 (en) | 2001-03-27 | 2004-07-06 | Kabushiki Kaisha Toshiba | Infrared sensor |
WO2002080899A1 (en) | 2001-03-30 | 2002-10-17 | Eisai Co., Ltd. | Remedial agent for digestive disease |
US6469002B1 (en) | 2001-04-19 | 2002-10-22 | Millennium Pharmaceuticals, Inc. | Imidazolidine compounds |
EP1408986B1 (en) | 2001-05-08 | 2008-09-24 | Yale University | Proteomimetic compounds and methods |
EP1463742A4 (en) | 2001-06-21 | 2006-05-10 | Ariad Pharma Inc | Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof |
SE0102438D0 (en) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
SE0102439D0 (en) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
JP2003074370A (en) | 2001-09-05 | 2003-03-12 | Suzuki Motor Corp | Belt protector for engine |
JP2005508321A (en) | 2001-09-26 | 2005-03-31 | メルク エンド カムパニー インコーポレーテッド | Eltapenem sodium in crystalline form |
GB0124939D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
CA2465326C (en) | 2001-11-01 | 2011-03-29 | Icagen, Inc. | Pyrazolopyrimidines for decreasing ion flow through a voltage-dependent sodium channel |
BR0214309A (en) | 2001-11-21 | 2004-10-13 | Upjohn Co | Substituted aryl-1,4-pyrazine derivatives |
US6992087B2 (en) | 2001-11-21 | 2006-01-31 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
SG159380A1 (en) | 2002-02-06 | 2010-03-30 | Vertex Pharma | Heteroaryl compounds useful as inhibitors of gsk-3 |
CN101450934B (en) | 2002-03-13 | 2012-10-10 | 詹森药业有限公司 | Sulfonyl-derivatives as novel inhibitors of histone deacetylase |
GB0206860D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
BR0309475A (en) | 2002-04-23 | 2005-03-01 | Shionogi & Co | Pyrazolo [1,5-a] pyrimidine derivatives and nad (p) h oxidase inhibitors containing them |
US7043079B2 (en) | 2002-04-25 | 2006-05-09 | Microsoft Corporation | “Don't care” pixel interpolation |
GB0209715D0 (en) | 2002-04-27 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
EP1501514B1 (en) | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
TW200406385A (en) | 2002-05-31 | 2004-05-01 | Eisai Co Ltd | Pyrazole compound and pharmaceutical composition containing the same |
CA2487211C (en) | 2002-06-04 | 2010-09-14 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo(1,5a) pyrimidine compounds as antiviral agents |
US7449488B2 (en) | 2002-06-04 | 2008-11-11 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
WO2004000318A2 (en) | 2002-06-21 | 2003-12-31 | Cellular Genomics, Inc. | Certain amino-substituted monocycles as kinase modulators |
WO2004000820A2 (en) | 2002-06-21 | 2003-12-31 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
US7205308B2 (en) | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7196092B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corporation | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors |
KR101088922B1 (en) | 2002-09-04 | 2011-12-01 | 파마코페이아, 엘엘씨. | Pyrazolopyrimidines as cyclin-dependent kinase inhibitors |
US7563798B2 (en) | 2002-09-04 | 2009-07-21 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
US7601724B2 (en) | 2002-09-04 | 2009-10-13 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
NZ539161A (en) | 2002-09-04 | 2006-05-26 | Schering Corp | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
CA2497450C (en) | 2002-09-04 | 2011-05-31 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US8673924B2 (en) | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
KR20050058507A (en) | 2002-09-04 | 2005-06-16 | 쉐링 코포레이션 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
AU2003282679A1 (en) | 2002-10-04 | 2004-05-04 | Arena Pharmaceuticals, Inc. | Hydroxypyrazoles for use against metabolic-related disorders |
US20040075741A1 (en) | 2002-10-17 | 2004-04-22 | Berkey Thomas F. | Multiple camera image multiplexer |
US7385626B2 (en) | 2002-10-21 | 2008-06-10 | Sarnoff Corporation | Method and system for performing surveillance |
US20040100560A1 (en) | 2002-11-22 | 2004-05-27 | Stavely Donald J. | Tracking digital zoom in a digital video camera |
US7550470B2 (en) | 2002-12-11 | 2009-06-23 | Merck & Co. Inc. | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors |
SE0203752D0 (en) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
SE0203754D0 (en) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
SI1585749T1 (en) | 2003-01-09 | 2008-10-31 | Pfizer | Diazepinoindole derivatives as kinase inhibitors |
OA13151A (en) | 2003-02-26 | 2006-12-13 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors. |
KR20050115252A (en) | 2003-02-28 | 2005-12-07 | 데이진 화-마 가부시키가이샤 | Pyrazolo[1,5-a]pyrimidine derivatives |
US7684624B2 (en) | 2003-03-03 | 2010-03-23 | Smart Technologies Ulc | System and method for capturing images of a target area on which information is recorded |
WO2004080982A1 (en) | 2003-03-11 | 2004-09-23 | Pfizer Products Inc. | Pyrazine compounds as transforming growth factor (tgf) inhibitors |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
JP2006520794A (en) | 2003-03-21 | 2006-09-14 | スミスクライン ビーチャム コーポレーション | Compound |
JP2006521357A (en) | 2003-03-24 | 2006-09-21 | メルク エンド カムパニー インコーポレーテッド | Biaryl-substituted 6-membered heterocyclic compounds as sodium channel blockers |
GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
GB2400514B (en) | 2003-04-11 | 2006-07-26 | Hewlett Packard Development Co | Image capture method |
EP1625123A4 (en) | 2003-05-15 | 2007-08-29 | Merck & Co Inc | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
WO2004103991A1 (en) | 2003-05-20 | 2004-12-02 | 'chemical Diversity Research Institute', Ltd. | 2-substituted piperidines, focused library and a pharmaceutical compound |
US20050123902A1 (en) | 2003-05-21 | 2005-06-09 | President And Fellows Of Harvard College | Human papillomavirus inhibitors |
PE20050206A1 (en) | 2003-05-26 | 2005-03-26 | Schering Ag | PHARMACEUTICAL COMPOSITION CONTAINING AN INHIBITOR OF HISTONE DEACETILASE |
US7986339B2 (en) | 2003-06-12 | 2011-07-26 | Redflex Traffic Systems Pty Ltd | Automated traffic violation monitoring and reporting system with combined video and still-image data |
JP2005020227A (en) | 2003-06-25 | 2005-01-20 | Pfu Ltd | Picture compression device |
TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
WO2005028434A2 (en) | 2003-09-18 | 2005-03-31 | Conforma Therapeutics Corporation | Novel heterocyclic compounds as hsp90-inhibitors |
WO2005034952A2 (en) | 2003-10-07 | 2005-04-21 | The Feinstein Institute For Medical Research | Isoxazole and isothiazole compounds useful in the treatment of inflammation |
JP4768628B2 (en) | 2003-11-19 | 2011-09-07 | アレイ バイオファーマ、インコーポレイテッド | MEK bicyclic inhibitors and methods of use thereof |
MXPA06006120A (en) | 2003-12-01 | 2007-04-16 | Kudos Pharm Ltd | Dna damage repair inhibitors for treatment of cancer. |
US20050116968A1 (en) | 2003-12-02 | 2005-06-02 | John Barrus | Multi-capability display |
DE10356579A1 (en) | 2003-12-04 | 2005-07-07 | Merck Patent Gmbh | amine derivatives |
US20080194574A1 (en) | 2003-12-16 | 2008-08-14 | Axxima Pharmaceuticals Ag | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases |
CA2552050C (en) | 2004-01-05 | 2011-08-09 | Astrazeneca Ab | Substituted heterocycles and the uses thereof |
CA2555402A1 (en) | 2004-02-12 | 2005-09-01 | Celine Bonnefous | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 |
JP2007523939A (en) | 2004-02-25 | 2007-08-23 | ビーエーエスエフ アクチェンゲゼルシャフト | Azolopyrimidine compounds and their use to combat parasitic fungi |
CA2563699C (en) | 2004-04-23 | 2014-03-25 | Exelixis, Inc. | Kinase modulators and method of use |
US20050276765A1 (en) | 2004-06-10 | 2005-12-15 | Paul Nghiem | Preventing skin damage |
US20080153869A1 (en) | 2004-06-14 | 2008-06-26 | Bressi Jerome C | Kinase Inhibitors |
AU2005269387A1 (en) | 2004-07-27 | 2006-02-09 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
US7626021B2 (en) | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
UA87153C2 (en) | 2004-08-26 | 2009-06-25 | Пфайзер Инк. | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
CA2578075A1 (en) | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Aminoheteroaryl compounds as protein tyrosine kinase inhibitors |
US7730406B2 (en) | 2004-10-20 | 2010-06-01 | Hewlett-Packard Development Company, L.P. | Image processing system and method |
WO2006047504A1 (en) | 2004-10-22 | 2006-05-04 | Janssen Pharmaceutica, N.V. | Aromatic amides as inhibitors of c-fms kinase |
KR20070090172A (en) | 2004-11-04 | 2007-09-05 | 버텍스 파마슈티칼스 인코포레이티드 | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
WO2006053342A2 (en) | 2004-11-12 | 2006-05-18 | Osi Pharmaceuticals, Inc. | Integrin antagonists useful as anticancer agents |
CN101098872B (en) | 2004-11-22 | 2012-09-05 | 沃泰克斯药物股份有限公司 | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
JP4810669B2 (en) | 2004-11-25 | 2011-11-09 | コニカミノルタホールディングス株式会社 | Organic electroluminescence element, display device and lighting device |
GB0428235D0 (en) | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Novel compounds |
MX2007007797A (en) | 2004-12-27 | 2007-08-23 | Alcon Inc | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases. |
US7635699B2 (en) | 2004-12-29 | 2009-12-22 | Bristol-Myers Squibb Company | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
GB0500492D0 (en) | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
US20060156482A1 (en) | 2005-01-14 | 2006-07-20 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
KR20070107046A (en) | 2005-02-16 | 2007-11-06 | 쉐링 코포레이션 | Heterocyclic substituted piperazines with cxcr3 antagonist activity |
DE102005007534A1 (en) | 2005-02-17 | 2006-08-31 | Bayer Cropscience Ag | pyrazolopyrimidine |
US8093244B2 (en) | 2005-03-29 | 2012-01-10 | Icos Corporation | Heteroaryl urea derivatives useful for inhibiting CHK1 |
TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
WO2006114180A1 (en) | 2005-04-25 | 2006-11-02 | Merck Patent Gmbh | Novel aza- heterocycles serving as kinase inhibitors |
WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
US20060293345A1 (en) | 2005-05-20 | 2006-12-28 | Christoph Steeneck | Heterobicyclic metalloprotease inhibitors |
US20070155737A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
AU2006258101A1 (en) | 2005-06-09 | 2006-12-21 | Merck Sharp & Dohme Corp. | Inhibitors of checkpoint kinases |
AU2006275403A1 (en) | 2005-08-02 | 2007-02-08 | Lexicon Pharmaceuticals, Inc. | 2-aminoaryl pyridines as protein kinases inhibitors |
WO2007015632A1 (en) | 2005-08-04 | 2007-02-08 | Cgk Co., Ltd. | Atm and atr inhibitor |
US7394926B2 (en) | 2005-09-30 | 2008-07-01 | Mitutoyo Corporation | Magnified machine vision user interface |
AR056206A1 (en) | 2005-10-06 | 2007-09-26 | Schering Corp | PIRAZOLPIRIMIDINAS AS INHIBITORS OF PROTEIN KINASES |
US20070082900A1 (en) | 2005-10-06 | 2007-04-12 | Schering Corporation | Methods for inhibiting protein kinases |
CN101321759A (en) | 2005-10-06 | 2008-12-10 | 先灵公司 | Pyrazolopyrimidines as protein kinase inhibitors |
CA2624500A1 (en) | 2005-10-06 | 2007-04-19 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
US7806604B2 (en) | 2005-10-20 | 2010-10-05 | Honeywell International Inc. | Face detection and tracking in a wide field of view |
EP1948617B1 (en) | 2005-10-21 | 2011-07-27 | Exelixis, Inc. | Pyrimidinones as casein kinase ii (ck2) modulators |
WO2007046548A1 (en) | 2005-10-21 | 2007-04-26 | Mitsubishi Tanabe Pharma Corporation | Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists |
AR056786A1 (en) | 2005-11-10 | 2007-10-24 | Smithkline Beecham Corp | COMPOSITE OF 1H- IMIDAZO (4,5-C) PIRIDIN-2-ILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, PROCEDURE TO PREPARE SUCH COMPOSITION, ITS USE TO PREPARE A MEDICATION, USE OF A COMBINATION THAT UNDERTAKES THE COMPOSITE AND AT LEAST AN AGENT TO PREPARE A MEDICINAL PRODUCT AND SUCH COM |
CN101321525B (en) | 2005-12-01 | 2013-01-30 | 霍夫曼-拉罗奇有限公司 | Heteroaryl substituted piperidine derivatives as L-CPT1 inhibitors |
US7871982B2 (en) | 2005-12-09 | 2011-01-18 | Meiji Seika Kaisha, Ltd. | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient |
WO2007070606A2 (en) | 2005-12-14 | 2007-06-21 | E. I. Du Pont De Nemours And Company | Isoxazolines for controlling invertebrate pests |
MX2008008328A (en) | 2005-12-22 | 2008-09-15 | Alcon Res Ltd | (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions. |
PE20070978A1 (en) | 2006-02-14 | 2007-11-15 | Novartis Ag | HETEROCICLIC COMPOUNDS AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASES (PI3Ks) |
ITMI20060311A1 (en) | 2006-02-21 | 2007-08-22 | Btsr Int Spa | PERFECT DEVICE FOR WIRE OR FILATIO SUPPLY TO A TEXTILE MACHINE AND METHOD TO IMPLEMENT THIS POWER SUPPLY |
GB0603684D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
WO2007096764A2 (en) | 2006-02-27 | 2007-08-30 | Glenmark Pharmaceuticals S.A. | Bicyclic heteroaryl derivatives as cannabinoid receptor modulators |
TW200800203A (en) | 2006-03-08 | 2008-01-01 | Astrazeneca Ab | New use |
CA2646701A1 (en) | 2006-03-22 | 2007-10-04 | Vertex Pharmaceuticals Incorporated | C-met protein kinase inhibitors for the treatment of proliferative disorders |
BRPI0709699A2 (en) | 2006-03-29 | 2011-07-26 | Foldrx Pharmaceuticals Inc | inhibition of alpha synuclein toxicity |
US7574131B2 (en) | 2006-03-29 | 2009-08-11 | Sunvision Scientific Inc. | Object detection system and method |
EP2001870A2 (en) | 2006-03-31 | 2008-12-17 | Schering Corporation | Kinase inhibitors |
PE20080071A1 (en) | 2006-05-22 | 2008-02-11 | Schering Corp | PYRAZOLO [1,5-a] PYRIMIDINES |
US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
US9216963B2 (en) | 2006-06-22 | 2015-12-22 | Medibeacon Inc. | Pyrazine derivatives with extended conjugation and methods of using the same in optical applications |
CN101472912A (en) | 2006-06-22 | 2009-07-01 | 比奥维特罗姆上市公司 | Pyridine and pyrazine derivatives as MNK kinase inhibitors |
AR061793A1 (en) | 2006-07-05 | 2008-09-24 | Mitsubishi Tanabe Pharma Corp | PIRAZOLO COMPOUND [1,5-A] PYRIMIDINE AND PHARMACEUTICAL COMPOSITION |
US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
PE20121506A1 (en) | 2006-07-14 | 2012-11-26 | Amgen Inc | TRIAZOLOPYRIDINE COMPOUNDS AS C-MET INHIBITORS |
US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
EP1900727A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Aminopyridine derivatives as kinase inhibitors |
CN101516885A (en) | 2006-09-29 | 2009-08-26 | 诺瓦提斯公司 | Pyrazolopyrimidines as PI3K lipid kinase inhibitors |
GB0619342D0 (en) | 2006-09-30 | 2006-11-08 | Vernalis R&D Ltd | New chemical compounds |
RU2454405C2 (en) | 2006-10-04 | 2012-06-27 | Ф.Хоффманн-Ля Рош Аг | 3-pyridine carboxamide and 2-pyrazine carboxamide derivatives as hdl-cholesterol raising agents |
UY30639A1 (en) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | SUBSTITUTED DERIVATIVES OF 2H-FTALAZIN-1-ONA, ITS CRYSTAL FORMS, PREPARATION PROCESS AND APPLICATIONS |
RU2478635C2 (en) | 2006-10-19 | 2013-04-10 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Heteroaryl compounds, compositions containing them and methods of treating with use of such compounds |
JP5244118B2 (en) | 2006-11-10 | 2013-07-24 | ブリストル−マイヤーズ スクイブ カンパニー | Novel kinase inhibitor |
WO2008063671A2 (en) | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic metalloprotease inhibitors |
US20080132698A1 (en) | 2006-11-30 | 2008-06-05 | University Of Ottawa | Use of N-oxide compounds in coupling reactions |
AR064348A1 (en) | 2006-12-15 | 2009-04-01 | Bayer Schering Pharma Ag | 3-H-PIRAZOLOPIRIDINAS AND SALTS OF THESE, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHODS TO PREPARE THEM AND THEIR USES |
EP2125781A2 (en) | 2006-12-20 | 2009-12-02 | Amgen Inc. | Substituted heterocycles and methods of use |
PE20121126A1 (en) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | PIRROLO [2,3-B] PYRIDINES COMPOUNDS AS KINASE MODULATORS |
GB0625659D0 (en) | 2006-12-21 | 2007-01-31 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
EP2109608B1 (en) | 2007-01-10 | 2011-03-23 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
MX2009008531A (en) | 2007-02-16 | 2009-08-26 | Amgen Inc | Nitrogen-containing heterocyclyl ketones and methods of use. |
JP5330274B2 (en) | 2007-03-01 | 2013-10-30 | ノバルティス アーゲー | PIM kinase inhibitor and method of use thereof |
JP2008260691A (en) | 2007-04-10 | 2008-10-30 | Bayer Cropscience Ag | Insecticidal arylisoxazoline derivative |
BRPI0810196A2 (en) | 2007-04-10 | 2011-12-06 | Bayer Cropscience Ag | aryl isoxazoline derivatives insecticides |
US20100234386A1 (en) | 2007-05-10 | 2010-09-16 | Chaudhari Amita | Quinoxaline derivatives as pi3 kinase inhibitors |
PE20090717A1 (en) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS |
RU2009147819A (en) | 2007-05-25 | 2011-06-27 | Астразенека Аб (Se) | Combination of SNK and PARP inhibitors for the treatment of malignant neoplasms |
EP2014661A1 (en) | 2007-06-13 | 2009-01-14 | Bayer CropScience AG | Hererocyclically substituted heterocyclic carboxylic acid derivates |
UY31137A1 (en) | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | DERIVATIVES OF QUINAZOLINE AS INHIBITORS OF THE PI3 QUINASA |
EP2012409A2 (en) | 2007-06-19 | 2009-01-07 | Hitachi, Ltd. | Rotating electrical machine |
JP2009027904A (en) | 2007-06-19 | 2009-02-05 | Hitachi Ltd | Rotating electrical machine |
WO2008156174A1 (en) | 2007-06-21 | 2008-12-24 | Taisho Pharmaceutical Co., Ltd. | Pyrazinamide compound |
JP2010531888A (en) | 2007-06-26 | 2010-09-30 | レクシコン ファーマシューティカルズ インコーポレイテッド | Methods for treating serotonin-mediated diseases and disorders |
JP2010531358A (en) | 2007-06-27 | 2010-09-24 | メルク・シャープ・エンド・ドーム・コーポレイション | Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors |
US20090012103A1 (en) | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
WO2009006580A1 (en) | 2007-07-05 | 2009-01-08 | Cv Therapeutics, Inc. | Optionally condensed dihydropyridine, dihydropyrimidine and dihydropyrane derivatives acting as late sodium channel blockers |
GB0713259D0 (en) | 2007-07-09 | 2007-08-15 | Astrazeneca Ab | Pyrazine derivatives 954 |
ES2551095T3 (en) | 2007-07-19 | 2015-11-16 | Lundbeck, H., A/S | 5-membered heterocyclic amides and related compounds |
BRPI0814441A2 (en) | 2007-07-19 | 2015-07-14 | Schering Corp | Heterocyclic Amide Compounds as Protein Kinase Inhibitors |
CN101815712A (en) | 2007-08-01 | 2010-08-25 | 辉瑞有限公司 | Pyrazole compound and as the purposes of RAF inhibitor |
WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
WO2009024825A1 (en) | 2007-08-21 | 2009-02-26 | Astrazeneca Ab | 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors |
US8415358B2 (en) | 2007-09-17 | 2013-04-09 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
CA2703653A1 (en) | 2007-10-25 | 2009-04-30 | Astrazeneca Ab | Pyridine and pyrazine derivatives -083 |
MX2010005950A (en) | 2007-11-28 | 2010-06-17 | Schering Corp | 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors. |
WO2009075790A1 (en) | 2007-12-07 | 2009-06-18 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors for intra-articular application |
RU2010129928A (en) | 2007-12-19 | 2012-01-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Pyrazole [1, 5-A] Pyrimidines USED AS JAK2 INHIBITORS |
AU2009204483B2 (en) | 2008-01-04 | 2014-03-13 | Intellikine, Llc | Certain chemical entities, compositions and methods |
KR101653548B1 (en) | 2008-01-08 | 2016-09-02 | 머크 샤프 앤드 돔 리미티드 | 2-4-3--3--2--7- Pharmaceutically acceptable salts of 2-4-3-piperidin-3-ylphenyl-2H-indazole-7-carboxamide |
EP2085398A1 (en) | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
WO2009099982A1 (en) | 2008-02-04 | 2009-08-13 | Osi Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
ATE522536T1 (en) | 2008-02-25 | 2011-09-15 | Hoffmann La Roche | PYRROLOPYRAZINE KINASE INHIBITORS |
BRPI0907928A2 (en) | 2008-02-25 | 2015-07-28 | Hoffmann La Roche | Pyrrolopyrazine kinase inhibitors. |
ATE517107T1 (en) | 2008-02-25 | 2011-08-15 | Hoffmann La Roche | PYRROLOPYRAZINE KINASE INHIBITORS |
JP5368485B2 (en) | 2008-02-25 | 2013-12-18 | エフ.ホフマン−ラ ロシュ アーゲー | Pyrrolopyrazine kinase inhibitor |
TW200940537A (en) | 2008-02-26 | 2009-10-01 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
US20110003859A1 (en) | 2008-02-29 | 2011-01-06 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
US8404694B2 (en) | 2008-03-20 | 2013-03-26 | Amgen Inc. | Aurora kinase modulators and method of use |
EP2283012A1 (en) | 2008-04-28 | 2011-02-16 | AstraZeneca AB | Methods of preparing substituted heterocycles |
WO2009152087A1 (en) | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | Bicyclic heteroaryl compounds and methods for kinase modulation, and indications therefor |
BRPI0915231A2 (en) | 2008-07-08 | 2018-06-12 | Intellikine Inc | kinase inhibitor compounds and methods of use |
GB0814364D0 (en) | 2008-08-05 | 2008-09-10 | Eisai London Res Lab Ltd | Diazaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase |
JP2011530511A (en) | 2008-08-05 | 2011-12-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Therapeutic compounds |
PT2326650E (en) | 2008-08-06 | 2014-05-06 | Biomarin Pharm Inc | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
WO2010016005A1 (en) | 2008-08-06 | 2010-02-11 | Pfizer Inc. | 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors |
ES2710701T3 (en) | 2008-09-24 | 2019-04-26 | Basf Se | Pyrazole compounds for the control of invertebrate pests |
JP2010077286A (en) | 2008-09-26 | 2010-04-08 | Aica Kogyo Co Ltd | Silicone resin composition and adhesive film |
EP2350045A1 (en) | 2008-10-21 | 2011-08-03 | Vertex Pharmaceuticals Incorporated | C-met protein kinase inhibitors |
PE20110828A1 (en) | 2008-10-31 | 2011-11-22 | Genentech Inc | PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS |
WO2010054398A1 (en) | 2008-11-10 | 2010-05-14 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2010059836A1 (en) | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Substituted aza-bridged bicyclics for cardiovascular and cns disease |
EP2379561B1 (en) | 2008-11-25 | 2015-11-04 | University Of Rochester | Mlk inhibitors and methods of use |
CA2744507A1 (en) | 2008-12-05 | 2010-06-10 | F.Hoffmann-La Roche Ag | Pyrrolopyrazinyl urea kinase inhibitors |
RU2016141566A (en) | 2008-12-19 | 2018-12-20 | Вертекс Фармасьютикалз Инкорпорейтед | PYRASINE DERIVATIVES USED AS ATR KINASE INHIBITORS |
CN102325767B (en) | 2008-12-22 | 2014-05-14 | 阵列生物制药公司 | 7-phenoxychroman carboxylic acid derivatives |
US20110053923A1 (en) | 2008-12-22 | 2011-03-03 | Astrazeneca | Chemical compounds 610 |
EP2367824B1 (en) | 2008-12-23 | 2016-03-23 | AbbVie Inc. | Anti-viral derivatives of pyrimidine |
WO2010086040A1 (en) | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy |
CA2750452A1 (en) | 2009-01-30 | 2010-08-05 | Toyama Chemical Co., Ltd. | N-acyl anthranilic acid derivative or salt thereof |
JP5353279B2 (en) | 2009-02-06 | 2013-11-27 | Jnc株式会社 | Method for producing coelenteramide or an analog thereof |
US20100204265A1 (en) | 2009-02-09 | 2010-08-12 | Genelabs Technologies, Inc. | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections |
SG173639A1 (en) | 2009-02-11 | 2011-09-29 | Sunovion Pharmaceuticals Inc | Histamine h3 inverse agonists and antagonists and methods of use thereof |
CN101537007A (en) | 2009-03-18 | 2009-09-23 | 中国医学科学院血液病医院(血液学研究所) | Application of N-(thiofuran-2) pyrazolo (1, 5-a) pyridine-3-formanides compounds for preparing antineoplastic |
WO2010111653A2 (en) | 2009-03-27 | 2010-09-30 | The Uab Research Foundation | Modulating ires-mediated translation |
UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
AR077468A1 (en) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS |
KR101325828B1 (en) | 2009-07-13 | 2013-11-05 | 비덱스 에이/에스 | A hearing aid adapted for detecting brain waves and a method for adapting such a hearing aid |
JP2012533551A (en) | 2009-07-15 | 2012-12-27 | アボット・ラボラトリーズ | Pyrrolopyrazine kinase inhibitor |
JP5771207B2 (en) | 2009-08-07 | 2015-08-26 | ダウ アグロサイエンシィズ エルエルシー | Pest control composition |
AU2010284254B2 (en) | 2009-08-17 | 2015-09-17 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
JP2011042639A (en) | 2009-08-24 | 2011-03-03 | Kowa Co | Biphenylpyrazine compound, and erythropoietin production promoter containing the same as active ingredient |
EP2470183B1 (en) | 2009-08-26 | 2015-09-16 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
CN101671336B (en) | 2009-09-23 | 2013-11-13 | 辽宁利锋科技开发有限公司 | Aromatic heterocyclic pyridine derivatives and analogs and preparation method and application thereof |
DE102009043260A1 (en) | 2009-09-28 | 2011-04-28 | Merck Patent Gmbh | Pyridinyl-imidazolone derivatives |
DK3070077T3 (en) | 2009-10-06 | 2019-04-01 | Millennium Pharm Inc | HETEROCYCLIC COMPOUNDS USING PDK1 INHIBITORS |
AU2010319398B2 (en) | 2009-11-13 | 2014-06-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer |
CN102762208A (en) | 2009-12-04 | 2012-10-31 | 赛林药物股份有限公司 | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors |
DK2526090T3 (en) | 2010-01-18 | 2015-10-19 | Medicines For Malaria Venture Mmv | New antimalarials |
CA2793086C (en) | 2010-03-18 | 2018-08-21 | Institut Pasteur Korea | Substituted imidazo[1,2-a]pyridine compounds and their use in the treatment of bacterial infections |
US8518945B2 (en) | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
WO2011121096A1 (en) | 2010-03-31 | 2011-10-06 | Dkfz Deutsches Krebsforschungszentrum | PYRAZOL[1,5-a]PYRIMIDINE DERIVATIVES AS WNT PATHWAY ANTAGONISTS |
JP2013523805A (en) | 2010-04-08 | 2013-06-17 | ゾエティス・エルエルシー | Substituted 3,5-diphenyl-isoxazoline derivatives as insecticides and acaricides |
WO2011130689A1 (en) | 2010-04-15 | 2011-10-20 | Tracon Pharmaceuticals, Inc. | Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors |
WO2011138751A2 (en) | 2010-05-04 | 2011-11-10 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
MX2012013081A (en) | 2010-05-12 | 2013-05-09 | Vertex Pharma | Compounds useful as inhibitors of atr kinase. |
US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2011143425A2 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2011143423A2 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2011143399A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US9096584B2 (en) | 2010-05-12 | 2015-08-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
CA2799904A1 (en) | 2010-05-20 | 2011-11-24 | F. Hoffmann-La Roche Ag | Pyrrolo [2, 3 - b] pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors |
MX2012013194A (en) | 2010-05-20 | 2013-01-22 | Hoffmann La Roche | Pyrrolopyrazine derivatives as syk and jak inhibitors. |
SA111320519B1 (en) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | Pyrimidinyl Compounds for Use as ATR Inhibitors |
JP2013529643A (en) | 2010-06-23 | 2013-07-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | Pyrrolopyrazine derivatives useful as ATR kinase inhibitors |
KR101970837B1 (en) | 2010-06-24 | 2019-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Pyrazolo[1,5-a]pyrimidines as antiviral agents |
EP3252054A1 (en) | 2010-07-13 | 2017-12-06 | F. Hoffmann-La Roche AG | Pyrazolo[1,5a]pyrimidine derivatives as irak4 modulators |
EP2407478A1 (en) | 2010-07-14 | 2012-01-18 | GENETADI Biotech, S.L. | New cyclotetrapeptides with pro-angiogenic properties |
JP5782238B2 (en) | 2010-07-30 | 2015-09-24 | ルネサスエレクトロニクス株式会社 | Voltage detection circuit and control method thereof |
WO2012022045A1 (en) | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
BR112013011918A2 (en) | 2010-11-16 | 2020-08-25 | Array Biopharma, Inc | chk1 inhibitor, pharmaceutical composition and kit comprising said inhibitor |
US8609669B2 (en) | 2010-11-16 | 2013-12-17 | Abbvie Inc. | Potassium channel modulators |
WO2012078855A1 (en) | 2010-12-08 | 2012-06-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Substituted pyrazolopyrimidines as glucocerebrosidase activators |
WO2012100342A1 (en) | 2011-01-27 | 2012-08-02 | Université de Montréal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
SG193293A1 (en) | 2011-03-04 | 2013-10-30 | Lexicon Pharmaceuticals Inc | Mst1 kinase inhibitors and methods of their use |
JP5970003B2 (en) | 2011-03-04 | 2016-08-17 | ローカス ファーマシューティカルズ インコーポレイテッド | Aminopyrazine compounds |
KR20140027974A (en) | 2011-04-05 | 2014-03-07 | 버텍스 파마슈티칼스 인코포레이티드 | Aminopyrazine compounds useful as inhibitors of tra kinase |
KR102104125B1 (en) | 2011-04-21 | 2020-05-29 | 재단법인 한국파스퇴르연구소 | Anti-inflammation compounds |
CN103619845B (en) | 2011-04-21 | 2016-08-17 | 拜耳知识产权有限责任公司 | Substituted Pyrazolopyridine of fluoroalkyl and application thereof |
EP2710006A1 (en) | 2011-05-17 | 2014-03-26 | Principia Biopharma Inc. | Azaindole derivatives as tyrosine kinase inhibitors |
EP2723745A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
WO2012178124A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
JP2014517079A (en) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Compounds useful as ATR kinase inhibitors |
WO2012177997A1 (en) | 2011-06-22 | 2012-12-27 | The General Hospital Corporation | Treatment of proteinopathies |
EA201490265A1 (en) | 2011-07-13 | 2014-12-30 | Фармасайкликс, Инк. | BLUTON TYROSINKINASE INHIBITORS |
WO2013052263A2 (en) | 2011-09-16 | 2013-04-11 | Microbiotix, Inc. | Antifungal compounds |
WO2013049719A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013049720A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2751099B1 (en) | 2011-09-30 | 2017-06-14 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
BR112014007721B1 (en) | 2011-09-30 | 2022-11-01 | Vertex Pharmaceuticals Incorporated | PROCESSES FOR PREPARING COMPOUNDS USEFUL AS ATR KINASE INHIBITORS |
MX2014003785A (en) * | 2011-09-30 | 2014-07-24 | Vertex Phamaceuticals Inc | Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors. |
RU2014120166A (en) | 2011-10-20 | 2015-11-27 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | SUBSTITUTED Bicyclic AZA-HETEROCYCLES AND THEIR ANALOGUES AS SIRTUIN MODULATORS |
WO2013071094A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
JP2015502925A (en) | 2011-11-09 | 2015-01-29 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of ATR kinase |
EP2776420A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
EP2776421A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US9193725B2 (en) | 2012-03-14 | 2015-11-24 | Bristol-Meyers Squibb Company | Cyclic hydrazine derivatives as HIV attachment inhibitors |
SG10201701101YA (en) | 2012-04-02 | 2017-04-27 | Cytokinetics Inc | Methods for improving diaphragm function |
AR090548A1 (en) | 2012-04-02 | 2014-11-19 | Incyte Corp | BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS |
CA2869309C (en) * | 2012-04-05 | 2021-02-09 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN103373996A (en) | 2012-04-20 | 2013-10-30 | 山东亨利医药科技有限责任公司 | Bicyclic derivatives serving as CRTH2 receptor antagonist |
KR102341637B1 (en) | 2012-05-15 | 2021-12-21 | 캔써 리서치 테크놀로지 리미티드 | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof |
WO2013174931A1 (en) | 2012-05-23 | 2013-11-28 | Savira Pharmaceuticals Gmbh | 7-oxo-4,7 -dihydro- pyrazolo [1, 5 -a] pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease |
BR112014029016A8 (en) | 2012-05-23 | 2018-01-09 | European Molecular Biology Laboratory | 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
US20140018361A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
WO2014015523A1 (en) | 2012-07-27 | 2014-01-30 | Hutchison Medipharma Limited | Novel heteroaryl and heterocycle compounds, compositions and methods |
US8921388B2 (en) | 2012-08-06 | 2014-12-30 | European Molecular Biology Laboratory | Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
EP2895471B1 (en) | 2012-08-09 | 2016-11-23 | VIIV Healthcare UK (No.5) Limited | Piperidine amide derivatives as hiv attachment inhibitors |
WO2014025850A1 (en) | 2012-08-09 | 2014-02-13 | Bristol-Myers Squibb Company | Tricyclic amidine derivatives as hiv attachment inhibitors |
EP2895472B1 (en) | 2012-08-09 | 2016-11-23 | VIIV Healthcare UK (No.5) Limited | Tricyclic alkene derivatives as HIV attachment inhibitors |
AU2013304133B2 (en) | 2012-08-17 | 2017-02-23 | Bayer Cropscience Ag | Azaindole carboxylic acid amides and azaindole thiocarboxylic acid amides for use as insecticides and acaricides |
CA2873295A1 (en) | 2012-08-24 | 2014-02-27 | F. Hoffmann-La Roche Ag | New bicyclicpyridine derivatives |
WO2014035140A2 (en) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
WO2014039831A1 (en) | 2012-09-07 | 2014-03-13 | Takeda Pharmaceutical Company Limited | SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES |
WO2014042433A2 (en) | 2012-09-14 | 2014-03-20 | Kainos Medicine, Inc. | Compounds and compositions for modulating adenosine a3 receptor activity |
TW201412740A (en) | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | Substituted pyrrolopyrimidinylamino-benzothiazolones |
WO2014047648A1 (en) | 2012-09-24 | 2014-03-27 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
US8999632B2 (en) * | 2012-10-04 | 2015-04-07 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
WO2014062604A1 (en) | 2012-10-16 | 2014-04-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2909214B1 (en) | 2012-10-22 | 2020-07-22 | City of Hope | Etp derivatives |
ES2628529T3 (en) | 2012-10-24 | 2017-08-03 | Cyanine-azaindoline dyes substituted with hydroxamate, and bioconjugates thereof | |
RS62174B1 (en) | 2012-12-07 | 2021-08-31 | Vertex Pharma | 2-amino-n-(piperidin-1-yl-pyridin-3-yl) pyrazolo[1,5alpha]pyrimidine-3-carboxamid as inhibitor of atr kinase |
JP6096005B2 (en) | 2013-02-26 | 2017-03-15 | リンテック株式会社 | Sheet peeling apparatus and peeling method |
US8957078B2 (en) | 2013-03-15 | 2015-02-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9663519B2 (en) | 2013-03-15 | 2017-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
JP2016512816A (en) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
JP2016540773A (en) | 2013-12-06 | 2016-12-28 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
PT3077397T (en) | 2013-12-06 | 2020-01-22 | Vertex Pharma | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof |
US20150158868A1 (en) | 2013-12-06 | 2015-06-11 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US9670215B2 (en) | 2014-06-05 | 2017-06-06 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
PT3157566T (en) | 2014-06-17 | 2019-07-11 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
-
2016
- 2016-09-30 AU AU2016331955A patent/AU2016331955B2/en not_active Ceased
- 2016-09-30 KR KR1020187009223A patent/KR20180054657A/en active IP Right Grant
- 2016-09-30 WO PCT/US2016/054996 patent/WO2017059357A1/en active Application Filing
- 2016-09-30 EP EP16852781.0A patent/EP3355926A4/en active Pending
- 2016-09-30 RU RU2018115841A patent/RU2768621C1/en active
- 2016-09-30 JP JP2018516150A patent/JP7187308B2/en active Active
- 2016-09-30 CA CA3000684A patent/CA3000684A1/en active Pending
- 2016-09-30 MX MX2018003657A patent/MX2018003657A/en unknown
- 2016-09-30 US US15/763,366 patent/US11464774B2/en active Active
-
2018
- 2018-03-27 IL IL258410A patent/IL258410A/en unknown
-
2019
- 2019-01-18 HK HK19100925.9A patent/HK1258570A1/en unknown
-
2022
- 2022-08-18 US US17/820,773 patent/US20230106592A1/en active Pending
- 2022-10-20 AU AU2022256154A patent/AU2022256154A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2022256154A1 (en) | 2022-11-24 |
AU2016331955B2 (en) | 2022-07-21 |
EP3355926A1 (en) | 2018-08-08 |
US20180303829A1 (en) | 2018-10-25 |
WO2017059357A1 (en) | 2017-04-06 |
CA3000684A1 (en) | 2017-04-06 |
JP2018529713A (en) | 2018-10-11 |
US11464774B2 (en) | 2022-10-11 |
JP7187308B2 (en) | 2022-12-12 |
US20230106592A1 (en) | 2023-04-06 |
KR20180054657A (en) | 2018-05-24 |
EP3355926A4 (en) | 2019-08-21 |
IL258410A (en) | 2018-05-31 |
HK1258570A1 (en) | 2019-11-15 |
RU2768621C1 (en) | 2022-03-24 |
MX2018003657A (en) | 2018-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016331955B2 (en) | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors | |
RU2687060C2 (en) | Pharmaceutical compounds | |
CN111201223A (en) | Octahydrocyclopenta [ c ] pyrrole allosteric inhibitors of SHP2 | |
JP2023521633A (en) | Compounds, Pharmaceutical Compositions, and Methods of Preparing and Using Compounds | |
US20220088043A1 (en) | Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors | |
US11529350B2 (en) | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | |
TW201922709A (en) | Epidermal growth factor receptor inhibitors | |
WO2022232391A1 (en) | Phthalimido cereblon complex binders and transcription factor degraders and methods of use | |
JP2023553979A (en) | ALK-5 inhibitors and their uses | |
JP2024514844A (en) | Combination therapy including MYT1 inhibitors | |
TW202304925A (en) | (furopyrimidin-4-yl)piperazine compounds and uses thereof | |
CN116113406A (en) | GAS41 inhibitors and methods of use thereof | |
WO2023010102A1 (en) | Imidazo[1,2-b]pyridazinyl compounds and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |